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SUMMARY 
Breast carcinoma is one of the most common malignancies among women 
worldwide and accounts for the leading cause of cancer-related deaths among 
Singaporean women. Among the subtypes of breast cancer, the triple negative 
breast cancers are poorly differentiated and are the more invasive and metastatic 
than the other subgroups. Therefore, finding a feasible strategy for the treatment 
of TNBC is of utmost importance.  
Clinical screening of breast cancer patients revealed a high level of Manganese 
Superoxide Dismutase (MnSOD) in the aggressive breast cancers and a 
microarray analysis of breast cancer cell lines detected high levels of MnSOD in 
the TNBC cell lines. We showed earlier that Peroxisome Proliferator-activated 
Receptor Gamma (PPARγ) is one possible approach for the selective targeting of 
MnSOD. PPARγ is highly expressed in tumor cells, which confers a selective 
advantage for the use of PPARγ agonists to target cancer cells. PPARγ activation 
downregulated MnSOD expression levels, which corresponded to an 
accumulation of mitochondria ROS levels. This mitochondria influx contributed 
to formation of cytotoxic RNS peroxynitrite, a key molecule that enhanced 
chemo-sensitivity of tumor cells to ROS-inducing chemotherapeutic drugs such as 
docetaxel and doxorubicin, demonstrating a unique anti-tumor strategy coined as 
“oxidative stress therapy”. This strategy warrants serious clinical considerations 
against a subtype of cancer with limited treatment options.  
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Furthermore, we showed that PPARγ is under epigenetic regulation in breast 
cancer and that treatment with histone deacetyase inhibitors (HDACi) increases 
PPARγ acetylation status, activity and expression levels. This strongly increases 
the sensitivity of breast tumor cells to low concentrations of PPARγ agonists, 
largely amplifying their cytotoxicity. Combination treatment of HDACi and 
PPARγ ligands led to increased apoptosis, decreased cell proliferation and 
angiogenesis, and also overcame tumor cells resistant to endocrine therapy. This 
combination therapy that allows for lower doses of PPARγ ligands will lessen the 
toxicity and risk of adverse events, and avoid failures met with using PPARγ 
ligands as monotherapy. Therefore, we propose this combination treatment as a 
potential strategy that exhibits strong clinical benefits in the treatment of breast 
cancer.  
Finally, we observed a strong and positive correlation between MnSOD gene 
expression and EMT score in breast cancer patient samples. Suppression of 
MnSOD levels not only led to a decrease in migration and invasion of aggressive 
breast tumor cells, but also promoted EMT reversal. The inverse was validated by 
MnSOD overexpression studies. Taken together, these data suggest that MnSOD 
could be an important target in the search for a viable treatment strategy against 
invasive breast carcinoma. 
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CHAPTER 1 INTRODUCTION 
 
 
1.1 Breast Carcinoma  
 
1.1.1 Trends of breast carcinoma in worldwide and Asia 
Breast carcinoma is a heterogeneous disease that originates from mammary 
tissues and most commonly forms in the ducts and lobules, leading to ductal and 
lobular carcinomas respectively. It is the most frequently diagnosed malignancy 
among women worldwide and remains one of the top public health burdens. 
According to the American Cancer Society, there will be approximately 229,060 
new incidences of invasive breast cancer being diagnosed in United States in 2012. 
Of these, an estimated 226,870 cases will be diagnosed in women while the 
number is markedly lesser at 2190 cases in men [1]. It is also the second leading 
cause of cancer-related deaths in women in the US, accounting for 39,920 deaths 
in 2012 [2]. Risks of developing breast cancer have been associated with early age 
of menarche, family history, inherited gene mutations, hormone therapy, lack of 
exercise and obesity.  
 
In Asia, breast cancer incidence and mortality rates are relatively lower than in 
Western countries but have also been on the rise for the past two decades. Shin et 
al. extracted data from the World Health Organization (WHO) and compared the 
rates of breast cancer mortality across five East Asian populations (Hong Kong, 
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Japan, Korea, Singapore and Taiwan). Singapore had the highest breast cancer 
mortality out of the five countries and Hong Kong was the only country out of the 
five with an overall decreasing tendency for breast cancer mortality from 1979 to 
2005 [3].  
 
In Singapore, breast cancer is the most common malignancy among Singaporean 
women, accounting for 29.4% of all cancers from 2008 to 2012. Age-standardized 
incidence rates of breast cancers have increased significantly over the years, from 
22.0 per 100,000 in 1973-77 to 62.4 per 100,000 in 2008-2012. Comparing breast 
cancer incidences among different ethnic groups in Singapore, breast cancer was 
most commonly diagnosed in Chinese females. Over the past four decades, age-
standardized mortality rates for breast cancer have also been constantly on the rise. 
It is the top cause of mortality due to cancers among women, contributing to 17.9% 
of cancer deaths between 2008-2012 [4, 5].  
 
 
1.1.2 Classifications of breast carcinoma 
Breast cancer is a heterogeneous disease that comprises of multiple entities with a 
variety of clinical characteristics, disease courses and differential responses to 
specific treatments. As such, breast cancers can be classified according to 
different schemata described below: 
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Histopathology 
Histopathologic classification is based upon the morphological and cytological 
patterns of tumors identified by pathologists. Carcinoma in situ refers to cancer 
cells that proliferate within the epithelial tissue without invading the surrounding 
tissue. For invasive breast cancer, the two most common types are ductal and 
lobular carcinoma, which are derived from the epithelium lining the ducts or 
lobules. Invasive ductal carcinoma makes up 75% of all breast cancers, while 
invasive lobular carcinoma is the next most common histologic type of breast 
cancer at 15% [6, 7]. The remaining rarer types of breast cancers include 
mucinous, neuroendocrine, tubular, comedo, medullary, inflammatory and 
micropapillary carcinomas, which have unique biological features but lack useful 
information for tailoring therapy due to their relatively low prevalence [8].  
 
Histological grading 
Grading is based on the degree of differentiation and proliferative activity of 
tumor tissue with reference to normal tissue, reflecting the aggressiveness of the 
tumor [7]. Bloom and Richardson first derived a method of histological grading of 
breast cancer based on histological factors including degree of structural 
differentiation, variations in size, shape and staining of nuclei, and the frequency 
of hyperchromatic and mitotic figures. Tumors are then categorized into three 
grades: low (Grade I), intermediate (Grade II) and high (Grade III) [9]. Their 
model was then modified into the internationally recognized Nottingham Grading 
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System (NGS), which is based on the assessment of three morphological features: 
degree of tubule or gland formation, nuclear pleomorphism and mitotic index, 
each given a score of 1 to 3 points. The total score then corresponds to a tumor 
grade [10, 11]. The NGS is one of the most simple and cost-effective methods of 
tumor biology assessment used today.  
 
Staging 
Staging of cancer is based on the size of the primary tumor and the degree of 
spreading to secondary sites in the body. It determines the selection of therapy 
and assessment of prognosis. The most widely used staging system is the TNM, 
which was developed by the American Joint Committee on Cancer (AJCC) and 
the International Union for Cancer Control (UICC). It defines the extent of the 
tumor (T), the extent of spread to lymph nodes (N), and the presence of distant 
metastases (M) [12, 13]. Carcinoma in situ is classified under stage 0, while 
tumors that are larger in size and/or have spread within the breast or regional 
lymph nodes but not other parts of the body are classified from stage 1 to 3, and 
metastatic cancer is classified under stage 4. The TNM system undergoes revision 
periodically to maintain relevance to clinical practice as a globally recognized 
standard.  
 
Hormone receptor status 
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Staining of molecular markers such as estrogen receptor (ER), progesterone 
receptor (PR), HER2, EGFR and CK5/6, has been used as a diagnostic tool to 
check the gene expression profiles of breast cancer patients [14]. ER, PR and 
HER2 are used to categorize breast cancers into hormone-receptor (HR)-positive 
and Triple Negative (TN) subgroups. Breast cancers that are HR-positive (ER 
and/or PR –positive) and HER2 -positive, account for approximately 75% and 15% 
of all breast cancers respectively [15, 16]. The remaining 10% of breast cancers 
are classified as Triple Negative Breast Cancer (TNBC). TNBC lacks well-
defined therapeutic molecular targets and has a poorer prognosis compared to HR 
and HER2 –positive subgroups. Breast cancers can also be classified into the 
basal-like and non-basal-like phenotypes based on CK5/6 and EGFR expressions. 
TNBC comprises of approximately 80% of all basal-like tumors [17] and these 
are reported to be more aggressive with increased risk of death and distant 
recurrence [18].  
 
Molecular subtype 
Modern advances in gene expression analyses have revealed a classification 
scheme for breast cancers based on their distinct molecular profiles. It divides 
breast cancers into six intrinsic molecular subtypes: luminal A, luminal B, HER2-
enriched, basal-like, normal breast-like and claudin-low [19], which contribute to 
differential survival rates, clinical outcomes, responses to adjuvant therapy and 
patterns of metastatic recurrence [20].  
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Luminal A subtype has the best prognosis and responds to selective estrogen 
receptor modulators and aromatase inhibitors. Luminal B subtype has an 
intermediate prognosis and responds better to neo-adjuvant chemotherapy. HER2-
enriched tumors have poor prognosis but higher chemo-sensitivity compared to 
luminal A and B tumors. Basal-like breast tumors have poorer prognosis 
compared to luminal subtypes and are much more likely to recur despite their 
high response to chemotherapy. Normal-like breast subtype is considered rare and 
is poorly characterized with similar features as normal breast tissues. Claudin-low 
subtype is the most recently identified and features cancers with a low expression 
of genes involved in cell adhesion and high expression of epithelial-mesenchymal 
transition (EMT) markers. This group generally faces poor prognosis with 
mediocre response rates to chemotherapy [21].  
 
 
1.1.3 Treatment of HR-positive breast carcinoma  
Treatment of breast cancers depends largely on the presence of specific hormone 
receptors, namely ER, PR and HER2. Considerable progress has been made in the 
detection, diagnosis and treatment of HR-positive breast cancer, thus leading to 
much improved patient survival and decreases in mortality rates.  
 
ER status determines usage of anti-estrogen (endocrine) therapy in breast cancer 
patients, which reduces the effect of estrogen on the body so as to slow down the 
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growth of ER-positive breast cancer cells. Endocrine therapy involves drugs that 
block or eliminate hormone receptors or lower estrogen levels in the body. 
Tamoxifen is an example of an ERα modulator that is commonly used in breast 
cancer treatment. It acts as an antagonist that induces differential conformational 
changes of ERα and also interacts with co-repressors to decrease transcription of 
ERα -regulated genes [22]. Fulvestrant is an anti-estrogen that acts as an ERα 
antagonist and promotes degradation of the receptor, thus reducing ERα activity 
[23, 24]. Aromatase inhibitors are another class of anti-estrogen agents that block 
estrogen production by inhibiting the estrogen-producing enzyme aromatase. 
They are often used in initial adjuvant therapy or in sequential therapy with 
Tamoxifen [25, 26]. The use of anti-estrogens has limited long-term efficacy 
largely due to the development of drug resistance and metastasis of secondary 
tumors, which often fail to respond to first-line endocrine treatment [27].  
 
HER2-positive breast cancer patients are treated with targeted therapies of 
monoclonal antibodies trastuzumab and pertuzumab, which bind to HER2 and 
inhibit downstream signaling. A clinical trial conducted using trastuzumab and 
adjuvant chemotherapy significantly increased disease-free survival rates and 
lowered the rates of recurrence [28]. HER2-overexpressing tumors have intrinsic 
resistance to endocrine therapy, thus patients with both ER and HER2 –positive 
tumors have to be given a combination of anti-HER2 and anti-estrogen therapies. 
A Phase III trial combining trastuzumab and an aromatase inhibitor showed better 
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clinical outcomes for patients with both ER and HER2 –positive breast cancers 
[29].  
 
Resistance to hormonal therapy has been attributed to the crosstalk between ER 
and HER2 receptors, thus combination of chemotherapy with anti-HER2 agents 
has been recommended as first-line treatment for patients with fast-progressing 
ER and HER2 –positive tumors [30].  
 
 
1.1.4 Treatment of HR-negative/ triple negative breast carcinoma 
The HR-negative breast cancer, in particular the basal subtype tumors, are 
associated with poorer prognosis due in part to a relative lack of target-specific 
therapeutic options. The only systemic therapy available for patients with HR-
negative breast cancer is chemotherapy other than surgery and radiation therapy 
[31, 32]. A commonly used chemotherapeutic agent used against TNBC is 
antracycline, an inhibitor of topoisomerase II that causes DNA strand breaks in 
tumor cells. Clinical data revealed that patients with TNBC had higher rates of 
complete pathologic response upon receiving anthracycline or anthracycline and 
taxane-based regimens compared to patients with luminal subtypes of breast 
cancer [33]. However, the use of anthracyclines has been associated with 
increased risks of cardiotoxicity and secondary leukemia [34].  
 
	   9	  
Germline mutations in BRCA1 have been frequently reported in TNBC, leading 
to defects in the DNA repair machinery and thus increased sensitivity to platinum-
based drugs such as cisplatin, carboplatin and oxaliplatin. These drugs bind to 
DNA directly to form adducts that delay or block cell division [35]. A neo-
adjuvant trial of patients with TNBC and BRCA1 mutations yielded 90% 
complete pathological responses to cisplatin [36].  
 
Another class of drugs used to treat TNBC with BRCA1/2 mutations is PARP 
inhibitors, which prevent the repair of DNA single strand breaks upon damage. 
Inhibition of PARP in a tumor that is already deficient in DNA repair, leads to 
substantial genomic instability and subsequently induces “chemical synthetic 
lethality”. In a study of 54 patients with advanced breast cancers and BRCA1/2 
mutations, a PARP inhibitor olaparib, was given and a 41% overall response rate 
was obtained [37]. A Phase II trial where patients with TNBC were treated with 
PARP inhibitor iniparib, in combination with carboplatin and gemcitabine, 
achieved an overall response rate of 52%. Progression-free and overall survivals 
were also increased [38]. However, other studies showed limited benefits of 
PARP inhibitors or platinum-based drugs in TNBC [39], indicating that there is a 
high level of heterogeneity present among this subgroup of breast cancer.  
 
In an analysis of over 500 TNBC cases from 21 breast cancer databases, TNBC 
was sub-divided into six subtypes [40]. The first two are basal-like subtypes, 
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which are best targeted with taxane-based chemotherapy such as docetaxel and 
paclitaxel. The immunomodulatory (IM) subtype has constitutive activation of 
genes involved in immune processes, such as TNF, NF-kB and JAK. The 
mesenchymal (M) and mesenchymal-like (MSL) subtypes have high expressions 
of genes involved in growth factor signaling and cell motility. In vitro data have 
shown efficacy of PI3K/mTOR inhibitors against these subtypes [41, 42]. The last 
subtype is luminal androgen receptor subtype (LAR), which show high levels of 
steroid synthesis and androgen metabolism, and thus may be better targeted with 
statins or anti-androgens [43].  
 
Therefore, it may be beneficial to rely on “genome-first approaches” to determine 
the gene expression profiles of breast cancer patients before embarking on 
treatment. Using such methods enable the identification of subtype specific 
signaling networks and/or molecular mechanisms in order to design and develop 
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1.2 Manganese Superoxide Dismutase (MnSOD) 
 
1.2.1 Dysregulated ROS levels in breast carcinoma 
Among the many aberrations in the regulation of cell growth and cell fate 
signaling associated with the process of carcinogenesis or cancer progression is a 
significant change in the overall cellular metabolism [44-46].  Growth-promoting 
signals leading to unrestricted cell proliferation also largely inflates the energy 
demand of tumor cells. The increases in metabolic activity and energy demand 
result in a change in cellular redox milieu, which is further compounded by 
alterations in the anti-oxidant defense capacity [47, 48]. Increased redox signaling 
is involved in providing proliferation signals to tumor cells, helping cells evade 
apoptosis and promote angiogenesis, eventually contributing to cancer 
progression [49-51]. In particular, redox activation of tyrosine kinase c-Src has 
been employed by tumors to avoid anoikis [52], while redox-sensitive HIF-1 
transcription factor is responsible for downstream pro-angiogenic effects of 
oxidative stress in cancers [53], further supporting the accumulating evidence 
pointing to ROS as promoters of cell invasion and tumor progression. Intrinsic 
oxidative stress originated from an upregulation of NOX4 or HER2/ERBB2, or 
due to Jun-D nuclear exclusion has been reported to result in increased invasion 
and metastasis [54, 55]. 
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Previous studies have reported the dysregulation of redox buffering systems such 
as thioredoxin, glutathione, catalase and superoxide dismutase in tumors [56]. 
While reported evidence implicates a reduced anti-oxidant capacity in the 
initiation of carcinogenesis, in the settings of an established tumor the high 
metabolic flux often result in a robust induction of cellular anti-oxidant enzymes 
to cope with the increase in oxidative stress. A study by Kim et al. revealed an 
increased expression of MnSOD, catalase, thioredoxin reductase and thioredoxin 
interacting protein with worsening histologic grade [57]. Along these lines, our 
lab’s work has unraveled distinct redox signaling in cancer cell fate decisions [58-




1.2.2 Structure and function of MnSOD 
MnSOD is one of the major antioxidant enzymes that catalyses the dismutation of 
superoxide radical to hydrogen peroxide, which is then converted to oxygen and 
water by glutathione peroxidase and catalase [64]. The human MnSOD protein is 
an 88 kDa homotetrametric enzyme encoded by a nuclear gene located on 
chromosome 6q25. The 5’-proximal promoter in the MnSOD gene is 
characterized by an enrichment of GC boxes, with enhancer elements in the 
second intron [65, 66]. There are various transcription factor binding motifs in the 
promoter and enhancer regions of the MnSOD gene which regulate its 
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transcription (Fig.1). Factors that regulate MnSOD transcription include NF-kB, 
Sp1, activating protein-1 (AP1), p53, CCAAT binding protein (C/EBP), Nrf2 and 
FoxO [67]. The MnSOD protein contains a mitochondrial leader sequence in the 
N-terminal region that localizes it to the mitochondria, where the sequence is then 
cleaved [68].  
 
Figure 1. Genomic structure of the MnSOD gene. The 5’-proximal promoter 
contains many GC boxes, while the promoter and second intron contains many 
transcription factor binding motifs that regulate MnSOD transcription. (Adapted 
from Dhar et al., 2012 [67]) 
 
MnSOD is cytoprotective and has an anti-apoptotic role against oxidative stress, 
inflammatory cytokines and ionizing radiations [69]. In normal physiology, O2.- is 
produced largely by the mitochondrial electron transport chain during oxidative 
phosphorylation, and also by electron reduction of oxygen by enzymes such as 
NADPH oxidase and cyclooxygenase [70]. As much of O2.- generation in the cells 
comes from mitochondrial respiration, MnSOD plays an important role in 
maintaining redox balance and mitochondrial integrity [71].  
 
	   14	  
The importance of this antioxidant enzyme is illustrated by MnSOD knockout 
mice that die just after birth [72] Genetic knockout studies in mice also indicate 
that MnSOD, but not other SODs, is essential for cell survival [73, 74], again 
showing the importance of this enzyme in normal cell physiology.  
 
 
1.2.3 MnSOD in human cancers 
There is compelling evidence that cancer cells are heavily reliant on the activity 
of the various SODs [75] to deal with the acquired oxidative stress [76]. While an 
earlier body of work demonstrated a tumor suppressor function of MnSOD [73, 
77, 78], other reports have demonstrated significantly higher expression of 
MnSOD in human tumors than their normal counterparts [79-82]. Not only has 
MnSOD overexpression been reported in cancers of the thyroid, brain, gastric, 
breast, prostate and colon [80, 83, 84], but more importantly, recent data indicate 
that in lung, gastric and liver cancer patients, high MnSOD gene expression 
correlates with poorer prognosis and lower overall survival rates and relapse-free 
survival [85-87].   
 
Interestingly, more recent studies provide a plausible explanation for the high 
variability in MnSOD gene expression in cancers. The authors show that MnSOD 
gene expression decreases in vivo as cells transit to early-stage cancer, reiterating 
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its tumor suppressor function.  However, MnSOD gene expression increases when 
cells acquire a more aggressive and invasive phenotype, conferring protection 
against mitochondrial injury and oxidative stress, which is typically observed in 
the triple negative breast tumors [67, 88-90]. Relevant to this study, studies have 
also reported higher levels of MnSOD expression in invasive triple negative 
breast cancer cell lines (MDA-MB-231 and BT-549), compared to the non-
invasive (MCF-7 and T47D) or non-tumorigenic cell lines (MCF-12A and MCF-
12F) [69, 91]. This could be due to MnSOD-dependent upregulation of FoxM1 
transcription activity, which will drive the expression of matrix 
metallopreoteinase 2 (MMP2), a key player in stromal degradation associated 
with tumor invasion [92]. Overexpression of MnSOD in MCF7 breast tumor cell 
line has also been demonstrated by Oberley and colleagues to stimulate the 
activation of MMP2 [93]. In addition, upregulated MnSOD has been shown in 
breast cancer metastases, contributing to resistance to anoikis and tumor 
metastasis [94].  
 
 
1.2.4 Targeting MnSOD in breast cancer 
Murias et al. have shown that downregulation of MnSOD in MDA-MB-231 leads 
to accumulation of mitochondrial O2.-, resulting in free radical-mediated damage 
of mitochondrial membranes and induction of apoptosis [95]. Furthermore, 
silencing studies have reported that suppression of MnSOD expression leads to a 
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decrease in breast cancer cells’ invasive property [69] and an increase in 
sensitization to anti-cancer drugs doxorubicin and paclitaxel [96]. Conversely, 
MnSOD over-expression has been shown to suppress apoptosis induced by anti-
cancer drugs in various cell types [97]. The cytotoxic effect of chemotherapeutic 
drugs is reported to be offset by increased MnSOD which dismutates O2.- to less 
harmful hydrogen peroxide [98], suggesting MnSOD to be a potential therapeutic 
target. In an in vivo MnSOD knockout animal model, mouse epidermis tissues 
lacking MnSOD were more susceptible to apoptosis after treatment with a tumor 
promoter, suggesting a protective role of MnSOD in tumor cells [99]. A clinical 
study also showed a strong association between MnSOD promoter (C>T) 
polymorphism leading to decreased MnSOD levels, to improved relapse-free 
breast cancer survival in a cohort of 291 women [100].  
 
These data provide testimony that targeting MnSOD could be an attractive 
therapeutic strategy against breast cancer, which would render cells more 
susceptible to oxidative stress-induced cell death. To that end, increased 
mitochondrial ROS generation has been proposed as an effective anti-cancer 
strategy [101, 102]. Studies targeting MnSOD in cancers have utilized RNAi as a 
means to decrease MnSOD levels in cell line models. A recent paper described 
using siRNA-delivering nanoparticles (NPs) to bring MnSOD siRNA into mouse 
xenograft models injected with MCF7 TAM-resistant breast cancer cells, 
increasing the possibility for gene silencing to be utilized in clinical translation for 
the treatment of breast cancer [98]. However, there are no known 
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pharmacological repressors or inhibitors of MnSOD gene expression to date. 
Interestingly, our lab has recently identified MnSOD to be a target gene of nuclear 
hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ) 
[62].   
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1.3 Peroxisome Proliferator-Activator Receptor Gamma 
 
1.3.1 Peroxisome Proliferator-Activated Receptors (PPARs) 
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear 
hormone receptor superfamily of ligand-activated transcription factors. Other 
members in this family include receptors for steroids, thyroid hormone, vitamin D, 
and retinoic acid [103]. Upon ligand activation, PPAR heterodimerizes with 
retinoic X receptor (RXR) and translocates from the cytoplasm into the nucleus to 
regulate gene transcription. PPARs can be classified into three subtypes (α, β and 
γ) that have differential expressions in various tissues and tumors. Among the 
three PPAR isoforms, PPARγ is the best characterized and appears to play an 
important role in diverse physiological and pathophysiological events.  
 
PPARγ exists in three isoforms (PPARγ-1/2/3) generated by alternative splicing 
and alternate transcription-starting sites [104]. PPARγ1 mRNA is found in all 
types of tissues while PPARγ2 is less abundant than PPARγ1 and is mainly 
expressed in adipose tissue. PPARγ3 mRNA is found in white adipose tissue, 
large intestine and macrophages [62, 105]. The highest levels of PPARγ mRNA 
are found in adipose tissues and large intestines, while low levels are detected in 
the kidney, liver, and small intestines and levels are barely detectable in muscles 
[105]. 
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Early studies on PPARγ established its involvement in adipocyte differentiation 
[106], growth regulatory pathways (regenerating gene IA), and immune 
modulation (neutrophil-gelatinase-associated lipocalin) [107]. Drg-1, a putative 
tumor suppressor gene in human colorectal cancer [108], and PTEN, a tumor 
suppressor gene that modulates several cellular functions, were found to be 
controlled by PPARγ agonists in colon cancer cell lines [109]. In hepatocellular 
carcinoma cell lines, PPARγ agonists elicited growth inhibition through up-
regulation of cyclin-dependent kinase inhibitors, p21 and p27 proteins [110].  
 
In addition to activating gene transcription, the ligands of PPARγ also repress 
gene transcription. For example, in monocytes and macrophages, PPARs lower 
the expression of cytokines such as IL-4 as well as pro-inflammatory products, 
including TNF, IL-1, as well as inducible nitric oxide synthetase [111]. The pro-
inflammatory transcription factors such as AP1, Stat, and NF-κB have also been 
shown to be inhibited. However, the mechanism by which PPARs repress gene 
expression is still not clear. Possible mechanisms may be via interactions with co-
repressors, such as nuclear receptor co-repressor (N-CoR) and silencing mediator 
for retinoid and thyroid hormone receptors (SMRT) [112].  
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1.3.2 Functional domains of PPARγ  
Similar to other members of the nuclear receptor superfamily, PPARγ has a 
characteristic molecular structure with four distinct structural domains. The N-
terminal domain has a ligand-independent transcriptional activation function (AF-
1) and is also a site for functional regulation by phosphorylation. The next region 
is the DNA binding domain (DBD), which contains two zinc fingers. It allows the 
receptor to target specific DNA sequences. The hinge region is essential for 
docking of co-factors. The C-terminal region is a multifunctional complex 
containing the ligand binding domain (LBD), a dimerization interface and ligand-
dependent activation domain (AF-2) (Fig.2) [113-115]. 
 
Figure 2. PPARγ structure and its corresponding binding response element. 
DNA binding domain (DBD) allows for specific targeting of PPARγ to DNA 
sequences in the response element (PPRE). Ligand binding domain (LBD) is the 
docking site for the PPARγ agonist which brings about a conformational change 
in ligand-dependent activation domain (AF-2). (Adapted from Venkatachalam et 
al., 2009 [116]). 
 
Activation of PPAR involves ligand binding, which causes a conformational 
change in the AF-2 domain found in the ligand-binding domain. The PPAR α, β 
and γ subtypes share a highly conserved DNA binding domain that matches with 
	   21	  
specific DNA sequences known as Peroxisome Proliferator Response Elements 
(PPREs) [117, 118]. PPAR DNA-binding activity is modulated by the isotype of 
the Retinoic-X-Receptor (RXR) heterodimeric partner. The bound PPAR/RXR 
complex then binds to PPREs on the target DNA. These PPREs consist of a DNA 
recognition motif composed of a Direct Repeat (DR) usually spaced by one 
nucleotide (DR-1), with a consensus sequence of AGGTCA-A-AGGTCA [119]. 
PPARs are also able to recognize and bind to DR-2 motifs, which are preferably 
spaced by two nucleotides [62, 120-122]. Various co-activators and co-repressors 
also bind to PPARγ and exert effects on the receptor’s binding and ability to 
promote or repress gene transcription. They could either cause chromatin 
remodeling and/or act as adaptor molecules that link the receptor complex to the 
PPRE on the target DNA (Fig.3) [123-125].  
 
 
Figure 3. Schematic diagram of PPARγ activation. PPARγ functions as 
heterodimer with its obligate partner, RXRα. The dimer interacts with 
coregulators and binds to the PPRE that is present in the promoters of target genes 
and regulate their transcription. (Adapted from Venkatachalam et al., 2009 [111])  
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1.3.3 PPARγ ligands 
Putative endogenous ligands for the PPARγ receptor include polyunsaturated fatty 
acids, the eicosanoids 15-deoxyΔ12,14-PGJ2 (15d-PGJ2) [126, 127], 13-
hydroxyoctadecadienoic acid and 15-hydroxyeicosatetraenoic acid [128] but their 
respective roles in PPARγ signaling or PPARγ target gene(s) in antitumor activity 
is yet to be determined. 15d-PGJ2 is a naturally occurring cyclopentenone, an 
arachidonic acid metabolite from cyclooxygenase and lipoxygenase pathways. It 
is derived from the human albumin-catalyzed transformation of prostaglandin D2, 
downstream of the biosynthesis of eicosanoids from arachidonic acid [129]. 
Lipophilic ligands such as polyunsaturated fatty acids and oxidized low density 
lipoproteins derived from fatty acids, have also been reported to bind PPARγ 
receptors [130].  
 
Synthetic thiazolidinedione (TZD) ligands include troglitazone, rosiglitazone, and 
pioglitazone, also known in the clinical setting as Rezulin, Avandia and Actos, 
respectively. Some non-steroidal anti-inflammatory drugs (NSAIDs), such as 
indomethacin, ibuprofen and fenoprofen, can also function as synthetic ligands for 
PPARγ [117]. In addition, non-TZD tyrosines, such as CDDO, GW7845, KPR297, 
have also been classified as PPARγ synthetic ligands [131]. Recently, an organic 
compound thymoquinone, the main component in the essential oil extracted from 
Nigella sativa, commonly known as the black cumin seed, was reported to be a 
PPARγ ligand. Molecular docking analysis revealed interaction sites between 
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thymoquinone and the ligand-binding domain of PPARγ and anti-tumor effects 
were exerted through the PPARγ pathway [132].  
 
 
1.3.4 Effects of PPARγ in human cancers 
PPARγ activation has been reported to inhibit proliferation of malignant cells 
from different lineages such as liposarcoma [133], breast adenocarcinoma [62, 
122, 132, 134, 135], prostate carcinoma [136-138], gastric carcinoma [139, 140], 
hepatocarcinoma [141, 142] and colorectal carcinoma [143]. We and others have 
previously shown that breast cancer cells express higher levels of PPARγ 
compared to normal breast epithelial cells lining the mammary ducts [122, 134, 
144], thus suggesting a possible role for ligand-activated PPARγ as an anti-tumor 
agent in differentiation-based breast cancer therapy. In the recent decade, 
numerous studies have been made on the anti-tumor effects of PPARγ ligands in 
various human cancers [130, 145]. 
 
Use of PPARγ synthetic TZDs ligands have been reported to inhibit proliferation 
and induce differentiation-like changes in breast cancer cell lines both in vitro and 
in vivo [122, 132, 146]. Similar inhibitions in proliferation of colon cancer cell 
lines have been observed, with evidence that effects are PPARγ-dependent as pre-
incubation with the PPARγ antagonist GW9662 was able to reverse the anti-
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proliferative effects [147, 148]. Furthermore, it was reported that PPARγ ligands 
were able to inhibit tumor angiogenesis and invasion of breast cancer [149, 150].  
 
Effects of PPARγ activation were also investigated in various in vivo studies 
using animal models. Mouse xenograft models of colon cancer showed that 
PPARγ agonists effectively inhibited tumor growth and colon carcinogenesis [151, 
152]. In a rat model of experimental mammary carcinogenesis, a PPARγ ligand 
GW7845 was able to significantly inhibit tumor formation upon exposure to 
nitrosomethylurea [153]. In triple-immunodeficient mice injected with MCF7 
breast cancer cells, a combined treatment of troglitazone and tretinoin was 
reported to block subcutaneous tumor growth and induced apoptosis of tumor 
cells [134].  
 
 
1.3.5 PPARγ target genes 
Several independent studies have identified some PPARγ target genes in breast 
cancer cell lines. The inhibition of cell growth observed in human breast cancer 
cells was accompanied by a profound decrease in Bcl-2 gene expression and a 
marked increase in apoptosis [134]. PPARγ ligands were also found to inhibit 
proliferation of breast cancer cells by repressing cyclin D1 expression [154] and 
enhance tumor suppressor genes BRCA1 [155] and PTEN gene expressions [109]. 
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Our group has also shown recently that PPARγ activation by both the natural and 
synthetic ligands represses gene expressions of sodium hydrogen exchanger-1 
(NHE1) and MnSOD in human breast cancer cell lines while PRKCZ and PGK1, 
genes that are highly associated with prostate cancer progression, were 
experimentally shown to be repressed upon PPARγ activation by 15d-PGJ2 [62]. 
Our group also showed isorhamnetin (IH), a 3’-O-methylated metabolite of 
quercetin, to be able to inhibit proliferation and invasion of gastric cancer via the 
activation of PPARγ pathway [139]. However, despite the identification of several 
PPARγ-target genes, none of these genes have been conclusively shown to have a 
direct role in antitumor activity via PPARγ activation.  
 
 
1.3.6 ROS production via PPARγ activation  
On another note, ligand-activation of PPARγ produces ROS that play critical roles 
in regulating cell proliferation, apoptosis and transformation (Table 1). Thus, 
upsetting the intracellular ROS balance to activate apoptotic pathways is closely 
associated with PPARγ-induced cytotoxicity. However, the mechanism(s) by 
which PPARγ agonism induces ROS production were never clearly elucidated. 
Several possible mechanisms were suggested in Table 1 but none of these was 
experimentally proven.  
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Table 1. ROS production induced by PPARγ ligands in human cell lines 
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1.3.7 PPARγ ligands in clinical trials  
While animal model studies have shown the effectiveness of PPARγ agonists in 
inhibiting tumor growth, there is limited data from clinical studies on breast 
cancer patients showing similar efficacies. A Phase II clinical trial conducted by 
Burstein et al. published the only study in the last decade using troglitazone in 
breast cancer patients. However, no clinical benefits were obtained from 
troglitazone treatment on patients with metastatic breast cancer and it was later 
withdrawn and replaced with rosiglitazone and pioglitazone due to instances of 
hepatotoxicity [164, 165]. A pilot trial on 38 women with early-stage breast 
cancer was conducted using short-term treatment with rosiglitazone. When tumor 
cell proliferation was assessed in terms of Ki-67 expression, there were no 
significant anti-proliferative effects [166]. Efatutazone, CS-7017, is a new class of 
novel PPARγ ligands belonging to the TZD family. When used in a Phase I trial, 
it exhibited anti-tumor activity in patients with advanced malignancies [167]. 
Taken together, these suggest that usage of PPARγ agonists as anti-tumor 
treatment in breast cancer has to undergo further study with better-binding ligands 
or include selection of patients with high expressions of PPARγ as important 
considerations. Some studies have also suggested that there are factors interfering 
with ligand activation of PPARγ, such as histone deacetylases (HDAC) [168].  
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1.4 Effects of Histone Deacetylase on PPARγ signaling pathway 
 
1.4.1 Histone acetylation and deacetylation 
Epigenetic regulation modifies DNA and histone structure by processes such as 
DNA methylation, histone modification and remodeling, and gene silencing by 
small RNAs [169]. Histone acetylation plays a crucial role in gene expression and 
is tightly controlled by the balance of histone acetyltransferase (HAT) and histone 
deacetylase (HDAC) activities. Acetylation of histone tails by HAT maintains an 
extended chromatin structure that facilitates binding of transcriptional regulators 
to gene promoter regions, increasing gene transcription [170]. Conversely, 
deacetylation of histone tails by HDAC induces DNA to adopt a closed 
conformation with histones, thereby leading to transcriptionally inactive DNA. 
 
HDACs can be divided into four families: class I (HDAC1, 2, 3 and 8), class II 
(HDAC4, 5, 6, 7, 9 and 10), class III (sirtuins) and class IV (HDAC11). These 
four classes of HDACs can be classified into two groups: zinc-dependent (Class I, 
II, and IV) and zinc independent (Class III) [171]. Inhibition of HDAC enzymes 
by HDACi would increase the acetylation levels of histone, leading to a relaxed 
chromatin conformation and thus enhanced transcription levels (Fig.4).  
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Figure 4. Effect of histone acetylation and deacetylation on gene 
transcription. Acetylation of histone tails promotes a relaxed chromatin 
confirmation which facilitates binding of transcription factors that lead to 
increased transcription. (Adapted from Kazantsev et al., 2008 [172] ).  
 
Individual HDACs have distinct cellular localization, tissue distribution and 
distinct interacting partners. HDAC enzymes are differentially overexpressed in 
various human cancer types, conferring a selective advantage by targeting them in 
cancer therapy. In breast cancer cells, HDAC2 and HDAC3 have been identified 
on the promoter regions of ERα target genes [173] and are strongly expressed in 
tumor subtypes that are highly aggressive [174]. All Class I HDACs other than 
HDAC8, have been implicated as mediators of estrogen signaling in both ERα+ 
and ERα- breast cancer. Inhibition of HDAC2 by siRNA reduced ERα levels in 
ERα+ cells [175] while inhibition of HDAC6 has also been reported to 
downregulate ERα levels [173]. 
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1.4.2 Histone deacetylase inhibitors (HDACi) in cancer therapy 
In recent years, there has been growing evidence showing that HDACs are 
promising targets for the development of new cancer therapeutic interventions, 
leading to the design of many HDAC inhibitors. Based on their chemical structure, 
HDACi can be classified into four main groups: hydroxamic acids (Trichostatin A, 
panobinostat, vorinostat), cyclic peptides (trapoxin and depsipeptide), benzamides 
(MS-27-275) and short chain fatty acids (butyric acid, valproic acid) [176]. 
Despite their heterogeneous structure, they share a common mechanism of action 
of sequestering zinc ions at the bottom of the HDAC’s catalytic pocket, thus 
blocking the recognition of acetylated lysine by HDAC enzymes [177]. 
 
Among them, hydroxamic acids have been the most widely studied and vorinostat 
or SAHA (suberoylanilide hydroxamic acid) is one of the earliest HDACi 
validated for treatment of cutaneous T cell lymphoma. SAHA inhibits multiple 
Zn2+-dependent HDAC enzymes, particularly HDAC1, 2, 3 and 6 [178, 179]. It 
has been used in clinical studies involving a wide range of human cancers 
including leukemia, gastric, breast and colorectal cancer [180-182]. Panobinostat 
(LBH589) is a potent inhibitor with activity against Class I, II, and IV HDAC 
enzymes, suggesting true pan-HDAC activity. LBH589 has demonstrated anti-
tumor properties both in vitro as well as in several clinical trials that have yielded 
favorable responses with minimal toxicity. Clinical trials involving panobinostat 
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included both hematological and solid malignancies such as non-Hodgkin’s 
lymphoma, acute myeloid leukemia, breast, colorectal, brain and renal carcinoma 
[183, 184]. 
 
The effects of HDACi in cancers have been diverse and extensively studied. 
Clinical studies showed a lack of activity of HDACi as a single agent and much 
more promising clinical benefit has been noted in combinations of HDACi with 
other agents [185]. Daud et al. conducted a Phase I/II trial of valproic acid and 
topoisomerase I inhibitor Karenitecin in patients with stage IV melanoma [186]. 
Results showed that HDACi increased the efficacy of anti-tumor therapy with 
increased objective response rates (ORR). In 2010, a Phase III trial in cervical 
cancer patients showed that a combination of hydralazine valproate and cisplatin 
topotecan demonstrated significant advantage in progression-free survival versus 
placebo [187]. In ENCORE 301, a randomized Phase II study of locally recurrent 
or metastatic ERα+ breast cancer, treatment of entinostat in combination with 
anti-hormone therapy showed positive clinical benefit [188].  
 
 
Another possible combination is HDACi and PPARγ agonists. It has been 
reported that HDAC3 is complexed with PPARγ in the promoters of PPARγ 
target genes, thereby possibly affecting their transcription [189, 190]. Guan et al. 
reported that HDAC3 and co-repressors NCoR / SMRT are bound to PPARγ, 
repressing its transcriptional activity [191]. HDAC3 has also been found to be 
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interacting with PPARγ and retinoblastoma protein (RB), with direct effects on 
cell cycle progression and apoptosis [168]. The synergistic use of HDACi with 
PPARγ agonists in various tumor cell types has resulted in cell cycle arrest, 
induction of apoptosis and decrease in invasion potential [168, 190, 192]. Thus, 
HDACi is hypothesized to be more effective in suppressing growth of tumor cells 
when used in combination with PPARγ agonists. However, the mechanism behind 
the efficacy of the drug combination remains elusive.  
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1.5   Involvement of Epithelial Mesenchymal Transition (EMT) in Breast 
Carcinoma 
 
1.5.1 EMT in cancer progression 
ERα+ breast cancer cell lines such as MCF7 and T47D have been associated with 
low invasiveness while TNBC cell lines such as MDA-MB-231 and BT549 are 
highly metastatic and invasive [193]. The progression from non-invasive to 
invasive tumors has been proposed to involve EMT. The process of tumor 
pathogenesis involves multiple steps that facilitate tumor progression towards 
metastasis: carcinogenesis, sustained proliferative signaling, generation of 
hypoxic environment, sustained angiogenesis, cross-talk with the new 
microenvironment, migration through the ECM and invasion, intravasation into 
the bloodstream, survival in the blood and lymphatic vessels, extravasation from 
circulation into tissues, preparation of the metastatic niche and finally growth in 
new microenvironment [194]. EMT has been implicated in the progression from a 
carcinoma in situ to invasive carcinoma as well as intravasation into lymph or 
blood vessels. At secondary sites, MET is involved in the conversion of 
micrometastasis into macrometastasis (Fig.5) [195].  
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Figure 5. Role of EMT and MET in tumor progression. EMT program is 
involved in the progression of carcinoma in situ to invasive carcinoma, as well as 
during intravasation into lymph or blood vessels. Conversely, MET occurs when 
micrometastasis is transformed to macrometastasis, forming tumors at secondary 
sites. (Adapted from Gunasinghe et al., 2012 [196]).  
 
EMT is the process where epithelial cells undergo changes that enhance their 
migratory ability, invasiveness, production of extracellular matrix (ECM) proteins 
and resistance to stresses and apoptotic death [197, 198]. It is characterized by 
cellular marker alterations, such as reduction of epithelial marker E-cadherin, and 
an elevation of mesenchymal markers such as ECM components fibronectin and 
intermediate filament protein vimentin [199]. E-cadherin molecules establish 
contacts in epithelial cells known as adherens junctions and also promote the 
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formation of desmosomes [200]. Vimentin overexpression is essential for EMT-




Figure 6. Changes in expression of cellular markers during EMT. Markers 
that have been cited in previous studies to regulate EMT in breast cancer are 
underlined. (Adapted from Giannoni et al., 2012 [194]).  
 
 
In breast carcinoma, cancers with a basal-like phenotype have been found to have 
high levels of mesenchymal markers (Vimentin, N-cadherin, α-SMA) and ECM 
remodeling proteins (laminin, fascin) and reduction of E-cadherin and 
cytokeratins (Fig.2). These basal-like tumors are often more aggressive and 
invasive, confirming the association between EMT and cancer progression [203]. 
A 68% correlation was reported between elevated Twist and Akt2 in late stage 
breast cancer patients compared to 13% in early stage breast cancer [204]. Blanco 
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et al. analyzed a series of breast cancer specimens and showed that level of Snail 
expression was correlated with metastatic potential [205]. Relapse-free survival 
and risk of relapse were also lower in women with high Snail levels, 
demonstrating that Snail could be a potential clinical prognostic indicator [206]. 
Therefore, finding ways to inhibit or reverse EMT could be a favorable approach 
against basal-like breast cancer.  
 
 
1.5.2 Regulators and mediators of EMT 
EMT is tightly regulated by various processes: activation of transcription factors 
(TFs), de novo expression of cytoskeletal and surface proteins, reorganization of 
cytoskeleton assembly, change in integrin expression pattern, producing of ECM-
degrading enzymes such as metalloproteinases (MMPs), cathepsins, urokinase-
type plasminogen activator (uPA) protease, and expression of specific 
microRNAs [194, 207]. Some master transcription factors regulating EMT 
include Snail, Slug, Twist, FoxC1, HIF-1A, TCF3, Sox4 and Prrx1 [208, 209]. 
Hypoxia inducible factors (HIFs) are strong inducers of EMT-TFs such as Snail, 
Slug, Zeb1 and Zeb2, as well as metastasis-associated genes such as VEGF, 
cathepsin D and MMP2 [210, 211]. There has also been a recent link between 
Slug and Twist in EMT induction and metastasis formation in breast cancer 
tumors [212]. Prrx1 is a homeobox TF that has been shown to induce EMT-TFs 
Slug, Zeb1/2, and Twist1, and upregulate tenascin C, an ECM protein which 
increases migration capacity of tumor cells [213].  
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Several signal-transduction pathways have been identified for EMT, such as 
activation of receptor tyrosine kinases and transforming growth factor-β receptors. 
These signaling pathways activate downstream genes such as Snail, Slug, Zeb1 
and Zeb2, which are transcriptional repressors of E-cadherin, thus resulting in the 
loss of the epithelial phenotype in tumor cells [214, 215]. TGF-β is one of the best 
studied inducers of EMT through both Smad-dependent and/or Smad-independent 
transcriptional pathways [216, 217]. Smads orchestrate the loss of epithelial 
markers and activates transcription of mesenchymal markers such as Snail, Slug, 
Twist and Zeb1/2 [218, 219]. TGF-β also activates receptor tyrosine kinases such 
as Ras/Erk, phosphatidylinositol-3 kinase (PI3K)/Akt, and Rho GTPases [219], 
stimulating pathways to promote EMT. TGF-β can also mediate dissolution of 
tight junctions and increase invasiveness by phosphorylating PAR6 (cell polarity 
protein) [220, 221]. TGF-β is also found to induce MMP-9 via Akt-dependent Erk 
pathway to achieve metastasis [222]. 
 
Growth factors such as human growth factor (HGF), fibroblast growth factor 
(FGF) and ERBB have also been reported to induce EMT in vivo and in vitro. 
These soluble factors activate downstream signaling pathways such as PI3K, Ras-
MAPK and Stat3, which are involved in promoting cell scattering and motility 
during EMT [223, 224]. Of note, PI3K/Akt inactivates the glycogen synthase 
kinase-3β (GSK-3β), which promotes β-catenin subcellular localization. 
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Subsequent association of β-catenin with TCF/LEF increases the transcription of 
various master transcription factors of EMT such as Snail [225-227]. 
 
miRNAs are also emerging as important regulators of EMT. They are a family of 
noncoding RNAs that bind to various mRNA targets and affect translation 
expression or mRNA degradation [228]. miR-200 and miR-205 are repressors of 
Zeb1 and Zeb2, miR-124 represses Slug expression, while miR-30a has been 
identified as a repressor of Snail, and inhibition of these miRNAs have been 
reported to lead to acquisition of mesenchymal-like features [229-231]. 
Conversely, miR-155, miR-21, miR-29a and miR-103/107 have been associated 
with TGF-β-induced EMT and metastasis [232-234]. 
 
Recently, a study conducted by Meng et al. in 2013 proposed that suppressing 
miRNA-212 by siRNA knock down in colorectal cancer led to a decrease in 
MnSOD levels. They observed a corresponding reduction of mesenchymal 
markers in line with an inhibition of the EMT program in colorectal cancer cell 
lines [235]. Conversely, treatment of estradiol or 27-hydroxycholesterol in MCF7 
breast tumor cells upregulated MnSOD levels and promoted EMT [236]. 
Therefore, preliminary evidence exists to propose MnSOD as a potential regulator 
of EMT in breast carcinoma but additional studies need to be conducted to 
provide further validation.  
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1.5.3 Targeting EMT in breast cancer 
Since EMT plays crucial roles in cancer progression, it would be of paramount 
importance to inhibit or repress EMT in the targeting of cancer. EMT is a 
reversible phenomenon that can be exploited for therapeutic applications. 
Targeting of critical signaling pathways of EMT such as Akt/mTOR, NF-kB, 
MAPK, AP1/Smad, are possible strategies [237, 238]. Indeed, preclinical research 
and clinical trials using small molecule inhibitors of EMT signaling pathways are 
currently ongoing [239, 240]. These small molecule inhibitors include those 
targeting cell adhesion receptors, tyrosine kinases and their receptors (integrins, 
Src, EGF-R, IGF-R) and also G-protein coupled receptors [241]. MAPK pathway 
inhibitors AS-703026 and PD-0325901 have been used in Phase I/II clinical trials 
for advanced breast carcinomas [242].  
 
In addition, monoclonal antibodies against EMT receptors and ligands that are 
overexpressed or constitutively active have also been used in clinical trials. Such 
antibodies include: Herceptin (used to target the HER2 receptor in breast cancer 
patients), Avastin (targets VEGF-A), Erbitux (blocks EGFR dimerization) and 
Dasatinib (dual-specific inhibitor of Src and Abl) [243]. Herceptin has been 
approved for the treatment of HER2-overexpressing breast cancer [244] while 
Avastin was approved for treatment of metastatic breast cancer in combination 
with paclitaxel [49]. Dasatinib was used in Phase II clinical trials for TNBC and 
HER2 breast cancers [245].  
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Silencing RNA and adenovirus-based gene transfer of therapeutic miRNAs and 
interfering expression vectors targeting EMT pathways and its associated 
molecules are also potential strategies in cancer treatment [241]. Transduction of 
miR-124 in invasive breast cancer cell lines decreased Slug levels and 
correspondingly reduced migratory and invasive capacities. Mouse xenograft 
models injected with breast tumor cells with ectopic expression of miR-124 
showed reduced lung metastases [246].  
 
In perspective, emerging genome-wide analysis of gene profiles of cancer patients 
would identify corresponding EMT signatures and master regulators of EMT. 
These would improve the diagnosis and tailoring of treatment for cancer patients 
by efficient targeting of specific pathways or molecules. If MnSOD is indeed an 
EMT regulator, targeting MnSOD would reap therapeutic benefits against 
invasive breast cancer.   
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1.6 Project objectives and hypothesis 
MnSOD has been reported to be upregulated in triple negative breast cancers 
compared to the ERα positive subtypes. Various lines of evidence highlight the 
therapeutic benefits of targeting MnSOD in these aggressive breast tumors, 
resulting in accumulation of cytotoxic ROS that could be exploited for its anti-
tumor properties. We hypothesized that repression of MnSOD could hence 
increase the chemo-sensitivity of TNBC cells to other ROS-inducing 
chemotherapeutic drugs in a unique antitumor strategy coined “tumor-specific 
oxidative stress therapy”. We recently reported that the human MnSOD promoter 
region contains PPRE binding motifs and that PPARγ activation in TNBC cell 
lines (MDA-MB-231 and BT549) resulted in significant decreases in MnSOD 
levels. Therefore, using molecular and PPARγ-dependent approaches to repress 
MnSOD, we aim to assess the therapeutic potential of targeting MnSOD in the 
treatment of aggressive TNBC tumors. We would also seek to identify the species 
of cytotoxic ROS induced upon MnSOD repression. 
 
Furthermore, evidence shows that PPARγ activity might be affected by epigenetic 
modifications such as acetylation. Therefore, we aim to explore if HDAC 
inhibition would alter the acetylation status of PPARγ and render it more 
permissive for ligand activation in breast cancer cell line models. This will allow 
us to amplify the effects of PPARγ signaling pathway in cell lines which have low 
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levels of PPARγ and allow for lower doses of PPARγ agonists to be used in cell 
lines with higher levels of PPARγ.  
 
Lastly, EMT has been implicated in the invasion and metastasis of aggressive 
breast tumors. We aim to investigate if MnSOD is a regulator of EMT and 
whether it plays a role in mediating tumor progression in breast cancer. 
Henceforth, this provides further support for the targeting of MnSOD to inhibit 
EMT and reduce tumor metastasis.  
 
  
	   43	  
CHAPTER 2 MATERIALS AND METHODS 
2.1 General buffer preparation 
• Phosphate buffered saline (PBS) (137mM NaCl, 2.7mM KCl, 
4.3mM, Na2HPO4, 1.4mM KH2PO4, pH 7.4) 
• TE Buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0) 
• SDS-PAGE and Western Blotting 
o Tris, pH 8.8 (1.5M Tris base, 0.4% (w/v) SDS, pH adjusted to 
8.8 with concentrated HCl) 
o Tris, pH 6.8 (0.5M Tris base, 0.4% (w/v) SDS, pH adjusted to 6.8 with 
concentrated HCl) 
o 10X SDS-PAGE Running buffer (0.25M Tris base, 1.92M 
Glycine, 1% (w/v) SDS) 
o 1X Transfer buffer (0.025M Tris base, 0.192M Glycine, 20% 
Methanol) 
o Blocking buffer (5% skim milk powder in 1X TBS-T) 
o 1X TBS-T (50 mM Tris.HCl, pH 7.4 and 150 mM NaCl, 0.1% 
Tween-20) 
o 5X Loading Dye (0.25M, pH 6.8 Tris-HCl, 0.5M DTT, 0.25% 
Bromophenol blue, 50% glycerol, 10% SDS) 
o SDS-PAGE gel: 12% Resolving gel (30% Acrylamide, 1.5M Tris (pH 
8.8), 10% SDS, 10% APS, TEMED, dH2O), 5% Stacking gel (30% 
Acrylamide, 1.0M Tris (pH 6.8), 10% SDS, 10% APS, TEMED) 
o 1X RIPA buffer: 50mM Tris at pH 7.5, 150mM NaCl, 1% v/v NP-40, 
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1% v/v deoxycholic acid, 0.1% v/v SDS and 1mM EDTA. 1mM PMSF, 
leupeptin, pepstatin A, aprotinin and Na3VO4 were added freshly before 
use. 
o Crystal Violet Solution (0.75% crystal violet, 50% ethanol, 1.75% 
formaldehyde, 0.25% NaCl) 
 
 
2.2 Cell lines and culture conditions 
ER-negative MDA-MB-231, MDA-MB-468, BT-549, MCF7, T47D, MCF-12A, 
MCF-10A and 184A1 breast cancer cells (American Type Culture Collection, 
MD, USA) were used. Cells lines were routinely maintained in RPMI 1640 for 
tumor cell lines and MEGM (Mammary Epithelial Growth Medium) for normal 
epithelial cell lines supplemented with 10% FBS, 2mM L-glutamine and a growth 
factor kit containing bovine pituitary extract (BPE), hydrocortisone, hEGF, 
insulin and gentamicin (Lonza, MD, USA) in a 37°C incubator with 5% CO2. 
Breast cancer cell lines T47D A18 and T47D A18 4OHT, WS8 and MCF7 ICI 
resistant cell lines were obtained from Jordan V. Craig [247, 248]. Cells lines 
were routinely maintained in RPMI 1640 supplemented with 10% FBS, 2mM L-
glutamine and 0.05mg/ml gentamicin in a 37°C incubator with 5% CO2. HUVEC 
endothelial cells were obtained from Lobie P.E. (CSI, NUS, Singapore). Cells 
lines were routinely maintained in EBM (Endothelial Basal Medium) 
supplemented with 10% FBS, 2mM L-glutamine and a growth factor kit 
containing hEGF, hydrocortisone, ascorbic acid, VEGF, hFGF-B, IGF-1 and 
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gentamicin (Lonza, MD, USA) in a 37°C incubator with 5% CO2. Cell lines were 
subcultured in 75cm2 flasks (NUNC, NY, USA) every three days at a ratio of 1:3. 
 
 
2.3 Drug treatments on cell lines 
 
2.3.1 Treatment of Cells with PPARγ  ligands and antagonist 
For use in experiments, cells were trypsinised and seeded in 6-well plates (Falcon, 
NJ, USA) at 1.4 x 105 cells per well and grown overnight on RPMI medium with 
10% FBS. The cells were then deprived to fresh RPMI with 2% FBS for another 
24 hours before the start of treatment. This is to reduce effects of growth factors 
on PPARγ-activation [106]. A stock concentration of 1mg/ml 15d-PGJ2 was 
diluted with complete medium to attain final concentrations of 3, 5 and 10µM. 
Stock solutions of 50mM troglitazone, 20mM ciglitazone and 80mM rosiglitazone 
(BIOMOL, USA) were prepared in DMSO. For GW9662, a stock solution of 
20mM GW9662 (Cayman, USA) was prepared in DMSO. A final concentration 
of 10µM was used. Various concentrations of drugs were then prepared by 
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2.3.2 Treatment of cells with Docetaxel and Doxorubicin  
Cells were trypsinised and seeded as described in section 2.3.1 before treatment 
with Docetaxel (DOC) and Doxorubicin (DOX). DOC and DOX were purchased 
from Sigma (Sigma-Aldrich, MO, USA). Stock solutions of 100µM DOC were 
prepared in DMSO. Stock solutions of 200µM DOX were prepared in DMSO. 
Various concentrations of drugs were then prepared by diluting the stock solution 
with complete medium to attain the desired final concentrations. Doses of DOC 
used were 30nM and 60nM. Doses of DOX used were 200nM and 400nM.  
 
 
2.3.3 Treatment of cells with ROS scavengers 
Cells were trypsinised and seeded as described in section 2.3.1 before treatment 
with the various ROS scavengers. N-acetyl cysteine (NAC), Sodium 4,5-
dihydroxybenzene-1,3-disulfonate (Tiron), 5,10,15,20-Tetrakis(4-
sulfonatophenyl)porphyrinato Iron (III), Chloride (FeTPPS), N5-
[imino(methylamino)methyl]-L-ornithine, citrate (L-NMMA) were purchased 
from Sigma (Sigma-Aldrich, MO, USA). Stock solutions of 1M NAC and Tiron 
were prepared in DMSO. Stock solutions of 50mM FeTPPS were prepared in 
DMSO. Stock solutions of 10mM L-NMMA were prepared in DMSO. Various 
concentrations of drugs were then prepared by diluting the stock solution with 
complete medium to attain the desired final concentrations of 10mM for NAC and 
Tiron, 10µM L-NMMA and 50µM FeTPPS.  
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2.3.4 Treatment of cells with LBH589  
Cells were trypsinised and seeded as described in section 2.3.1 before treatment 
with LBH589. LBH589 was obtained from Goh B.C. (CSI, NUS. Singapore) at 
stock solutions of 100µM. Various concentrations of LBH589 were then prepared 
by diluting the stock solution with complete medium to attain the desired final 
concentrations of 30nM, 50nM and 100nM.  
 
 
2.4 Western Blot Analysis 
At the time of harvest, cells were washed with ice-cold 1X PBS and harvested 
into a 1.5ml eppendoff tube using a cell scraper. Cells were then centrifuged to 
collect cell pellets, which were resuspended in 1X RIPA lysis buffer, 
supplemented with 1mM sodium orthovanadate (Na3VO4), 1µg/ml leupeptin (N-
acetyl-L-leucyl-L-leucyl-L-argininal), 1µg/ml pepstatin A, 1µg/ml aprotinin and 
1mM PMSF (Phenylmethylsulfonyl fluoride) before use. Protein concentration 
was determined using Coomassie Blue reagent (PIERCE, IL, USA). One 
microlitre of cell lysate was added to 200µl of Coomassie Dye and its absorbance 
at 595nm was read using a Spectrofluoro Plus spectrophotometer (TECAN, 
GmbH, Grödig, Austria). The Coomassie Protein Assay is based on an absorbance 
shift from 465nm to 595nm that occurs when the reagent binds to proteins in an 
acidic solution, resulting in a colour change from brown to blue. Protein standards 
were prepared using bovine serum albumin (PIERCE, IL, USA). For western 
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blotting, 40μg of each protein sample was warmed at 37°C for 5min before being 
subjected to SDS-PAGE (Polyacrylamide Gel Electrophoresis) at 80V for 20min 
followed by 130V for 1.5h using the BioRad Mini- PROTEAN 3 Cell (CA, USA). 
Thereafter, proteins were transferred onto nitrocellulose membrane by wet 
transfer method at 370mA for 1h using the BioRad Mini Trans-Blot 
Electrophoretic Transfer Cell (CA, USA). The membrane was then blocked with 
5% non-fat milk in TBS-T for 1h at room temperature and incubated overnight at 
4oC with the primary antibodies. The membrane was washed with TBS-T to 
remove unbound primary antibodies and then probed with secondary antibodies 
for 1h at room temperature. The membrane was again washed with TBS-T before 
the protein bands were detected using the Supersignal West Pico 
Chemiluminescence (PIERCE, IL, USA) on Kodak Biomax MR X-ray film. β-
actin antibody was used as a loading control. The primary anti-HuMnSOD, anti-
N-Cadherin, anti-E-Cadherin, anti-vimentin, anti-slug, anti-snail, anti-acetylated 
lysine, anti-acetylated H3, anti-total H3, anti-cyclinD1, anti-BIRC5, anti-FLAG, 
and anti-β-catenin monoclonal antibodies were diluted to a factor of 1:1000, 
primary anti-HuPPARγ monoclonal antibody to a factor of 1:500, and primary 
mouse anti-β-actin monoclonal antibody to a factor of 1:5000 dilutions in 5% 
BSA. For HRP-conjugated secondary antibody, goat-anti mouse IgG was used at 
1:5000, and goat-anti rabbit IgG was used at 1:2000. 
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2.5 RNA Isolation  
Total RNA was isolated from cells by TRIZOL reagent (Invitrogen, Carlsbad, CA, 
USA), as described by manufacturer’s instructions. Cells were homogenized with 
TRIZOL incubated at room temperature for 5min to permit complete dissociation 
of nucleoprotein complexes. Chloroform was then added and the mixture was 
vortexed and centrifuged at 13 000rpm for 15min. Following centrifugation, the 
mixture separates into a lower red phenol-chloroform phase, interphase and an 
upper colourless aqueous phase. RNA remains exclusively in the aqueous layer 
whereas DNA and proteins are in the interphase and organic bottom phase 
respectively. The top aqueous layer was transferred to a fresh tube and an equal 
volume of chloroform/isoamyl alcohol (24:1) was added to reduce foaming and 
ensure deactivation of RNase. After centrifugation for another 15min, the top 
aqueous layer was again transferred to a new tube and equal volume of 
isopropanol was added before freezing at -80°C for at least half an hour. The 
samples were then thawed and centrifuged for 45min to precipitate the RNA. The 
supernatant was then discarded and the pellet was washed with 75% ethanol. The 
samples were then centrifuged at 13000rpm for another 15min. Supernatant was 
then removed and the RNA pellet was air-dried. RNA was dissolved in water and 
RNA concentration was measured using NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
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2.6 Reverse Transcription and Real-time Polymerase Chain Reaction  
Each Reverse Transcription reaction contains 2.5µg of total RNA, 1X RT buffer, 
5mM MgCl2, 425µM of each dNTPs, 2µM random hexamers, 0.35U/µl RNase 
inhibitor, 1.1U/µl MultiScribe™ reverse transcriptase and made up to 10µl with 
sterile water. Reverse transcription was carried out at 37oC for 1h in a PCR 
thermal cycler (Mastercycler gradient, Eppendorf, Hamburg) using the following 
steps: The reaction mix is heated at 25°C for 10min, followed by 37°C for 1h and 
finally at 95°C for 5min to terminate the reaction.  
Five microlitres of the 10µl cDNA reaction volume was used in real-time 
quantitative PCR using ABI PRISM 7500 (Applied Biosystems, Foster City, CA, 
USA). Normalization was performed with respect to endogeneous 18S. 
Fluorescence was measured with the Sequence Detection Systems 2.0 software. 
PCR was performed in multiplex (both target and endogenous control co-
amplified in the same reaction) with distinct fluorescent dyes. Primers and probe 
for human 18S, human PPARγ, BIRC5, CyclinD1, VEGFA, Vimentin, PTEN and 
MnSOD were purchased from ABI (Applied Biosystems, Foster City, CA, USA). 
 
 
2.7 Real-time Polymerase Chain Reaction using SYBR Green primers 
Total RNA was extracted and reverse transcription to generate cDNA from RNA 
was carried out as described in section 2.5. Forward and reverse primers used for 
RT-PCR using SYBR Green PCR Master Mix were kindly provided by Lobie P.E 
(CSI, NUS, Singapore): 
	   51	  
β-catenin – Forward (CCCACTGGCCTCTGATAAAGG)  
       Reverse (ACGCAAAGGTGCATGATTTG) 
E-Cadherin – Forward (TGAGTGTCCCCCGGTATCTTC)  
          Reverse (CAGTATCAGCCGCTTTCAGATTTT) 
Fibronectin – Forward (CCCATCAGCAGGAACACCTT) 
           Reverse (GGCTCACTGCAAAGACTTTGAA) 
GAPDH – Forward (TGCACCACCAACTGCTTAGC) 
                  Reverse (GGCATGGACTGTGGTCATGAG) 
N-Cadherin – Forward (CAAGAGCTTGTCAGAATCAGG) 
                       Reverse (CATTTGGATCATCCGCATC) 
Snail – Forward (TGCCCTCAAGATGCACATCC) 
            Reverse (TGTGGTGGTGCCTTATGAGC) 
Twist – Forward (GCAAGCCAGGACCCACCTG) 
                Reverse (GATGTGAACCTGGGTCTCTGTC) 
Vimentin – Forward (CCTTGAACGCAAAGTGGAATC) 
                    Reverse (GACATGCTGTTCCTGAATCTGAG) 
Zeb1 – Forward (GCACCTGAAGAGGACCAGAG) 
              Reverse (TGCATCTGGTGTTCCATTTT) 
Zeb2 – Forward (CCTTCTGCGACATAAATACGAACA) 
              Reverse (AGTACGAGCCCGAGTGTGAGA) 
SYBR Green RT-PCR was performed using 2X SYBR Green PCR Master Mix 
using ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA). 
Fluorescence was measured with the Sequence Detection Systems 2.0 software. 
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2.8 DNA and siMnSOD Transfection 
Plasmid pCMX-mPPARγ, a cDNA clone encoding the mouse PPARγ was a 
generous gift from Dr. Ronald M. Evans, The Salk Institute for Biological Studies, 
San Diego, CA, USA. PPARγ mutant (PPARγC126A/E127A) (PPARγ-DN) 
containing amino acid substitutions in the DNA binding domain that abolish 
binding to PPARγ response elements was kindly provided by Dr. Christopher K. 
Glass, UCSD, San Diego, CA, USA. Plasmid pcDNA flag PPARγ (plasmid 8895) 
was purchased from Addgene. The pcDNA3-MnSOD plasmid was kindly 
provided by Dr. Larry W. Oberley (University of Iowa, Iowa City, IA). Short 
hairpin RNA (shRNA) constructs against PPARγ were purchased from OriGene 
(OriGene Technologies, MD, USA):  
shRNA1: CCTTCACTACTGTTGACTTCTCCAGCATT  
shRNA2: CAGTGGTTGCAGATTACAAGTATGACCTG  
shRNA3: TGAGAAGACTCAGCTCTACAATAAGCCTC  
shRNA4: TGACTTGAACGACCAAGTAACTCTCCTCA  
Negative control shRNA1: GCACTACCAGAGCTAACTCAGATAGTACT 
Negative control shRNA2: GCACTACCAGAGCTAACTCAGATAGTACT  
In vitro transfections were done using LipofectAMINE 2000 (Invitrogen, 
Carlsbad, CA) following manufacturer's protocols. For silencing of MnSOD, 
100nM of MnSOD siRNA (5’-AAAUUGCUGCUUGUCCAAAUC-3’ [249] or 
scrambled control siRNA (5’-AGCUUCAUAAGGCGCAUGCTT-3’ (luciferase 
gene sequence inverted)) was transiently transfected using LipofectAMINE 
RNAiMAX (Invitrogen,Carlsbad, CA) following manufacturer's protocols.  
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2.9 MitoSOX Red Assay 
Intracellular mitochondrial O2.- production was detected via MitoSOX Red 
(Invitrogen, CA, USA) staining, coupled with flow cytometric analysis. MitoSOX 
Red is a fluorescent probe that is highly sensitive to O2.- oxidation. It is 
specifically targeted to the mitochondria, thus allowing the detection of 
mitochondrial specific O2.- production [91]. Cells were pelleted and then 
resuspended with 100µl of plain RPMI containing 10µM MitoSOX Red reagent. 
Resuspended cells were then incubated for 15min at 37oC, washed once with 1X 
PBS, and resuspended again in fresh medium. Stained cells were immediately 
analyzed by flow cytometry (Beckman-Coulter Epics ALTRA flow cytometer) 
with excitation set at 510nm, emission set at 580nm and cell counter set at 10000 
events. Subsequent data analysis was done with WinMDI 2.9 software. 
 
 
2.10 DCFH-DA Assay 
Intracellular H2O2 was monitored by flow cytometry with the fluorescent probe, 
2’,7’-dichlorofluorescein diacetate [DCFH-DA (Molecular Probes, Invitrogen, 
CA, USA)]. DCFH-DA is readily oxidized by H2O2 or other peroxides products 
into a fluorescent product (dichloroflurescein), which emits detectable 
fluorescence that allows the semi-quantitation of intracellular H2O2 [250]. Sample 
preparations for flow cytometry were carried out as mentioned in section 2.8 and 
staining was done with 5µM of DCFH-DA for 15min at 37°C. Stained samples 
were washed once with 1X PBS, resuspended again in fresh medium and then 
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immediately analyzed by flow cytometry (BD FACSCalibur, BD Biosciences, US) 
with excitation set at 495nm, emission set at 529nm and cell counter set at 10000 
events. Subsequent data analysis was done with the WinMDI2.9 software. 
 
 
2.11 DAF-FM Assay 
Intracellular nitric oxide production was detected via DAF-FM (Invitrogen, CA, 
USA). DAF-FM reacts with nitric oxide to form a fluorescent benzotriazole. 
Sample preparations for flow cytometry were carried out as mentioned in section 
2.8 and staining was done with 5µM DAF-FM for 20min at 37°C. Stained 
samples were washed once with 1X PBS, resuspended again in fresh medium and 
then incubated for another 15min to allow complete de-esterification of the intra- 
cellular diacetates. Samples were then analyzed by flow cytometry (BD 
FACSCalibur, BD Biosciences, US) with excitation set at 495 nm, emission set at 
515nm and cell counter set at 10000 events. Subsequent data analysis was with 
using the WinMDI2.9 software. 
 
 
2.12 Superoxide Dismutase Activity Assay 
 SOD activity was measured using OxiSelect Superoxide Dismutase Activity 
Assay (Cell Biolabs, Inc., CA, USA). Briefly, cells were harvested in 1x lysis 
buffer (10mM Tris, pH 7.5, 150mM NaCl, 0.1mM EDTA) and lysed by 
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sonication. MnSOD activity was estimated by incubating the supernatant from 
whole cell lysates with 50mM DDC at room temperature for 1 hour to inhibit 
Copper/Zinc SOD. Samples were then added with 10µl of 1x Xanthine Oxidase 
solution and 5µl chromagen solution and incubated for 1 hour at 37°C. Xanthine 
oxidase generates O2.- which is detected by reacting with the chromagen solution. 
In the presence of SOD, O2.- concentrations will be reduced, yielding lesser 
colorimetric signal. Therefore, the lower the absorbance reading, the higher the 
SOD activity of the sample. Absorbance was read using a Tecan Plate Reader 
(TECAN, GmbH, Grödig, Austria) at 490nm. 
 
 
2.13 Cell viability assays 
 
2.13.1 MTT Assay 
Cell number after drug treatment was assessed by MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay. The assay is based on the ability of 
mitochondrial dehydrogenase enzyme from viable cells to cleave the tetrazolium 
rings of the pale yellow MTT and form dark blue formazan crystals which are 
largely impermeable to cell membranes, thus resulting in its accumulation within 
healthy cells. 5mg/ml MTT was dissolved in PBS and filter-sterilised. Three 
hours before the end of drug incubation, MTT solution was added into each well 
	   56	  
at 1: 10 dilution and incubated at 370C with 5% CO2 for 3h. Medium was then 
removed prior to addition of DMSO to dissolve the formazan crystals. The 
number of viable cells is directly proportional to the amount of formazan crystals 
present in the cell lysate, which was determined by measuring its absorbance at 
550nm using the Spectrofluoro Plus spectrophotometer (TECAN, GmbH, Grödig, 
Austria). 
 
2.13.2 Crystal Violet Assay 
Cell number after drug treatment was assessed by crystal violet uptake assay. 
Medium was removed from the wells and cells were washed with 1X PBS. 
Crystal violet solution (0.75% crystal violet, 50% ethanol, 1.75% formaldehyde 
and 0.25% NaCl) was added and incubated for 10min. Excess crystal violet 
solution was washed away with distilled water and cells were washed several 
times before being left to air-dry. Crystals were dissolved in 1% SDS in 1X PBS 
and absorbance was read at 595nm using a Tecan Plate Reader (TECAN, GmbH, 
Grödig, Austria). The absorbance reflects the quantity of viable cells present.  
 
 
2.14 Luciferase Assay 
The luciferase reporter construct used was pPPRE-tk-Luc, which contains three 
PPREs from rat acyl-CoA oxidase promoter under the control of the Herpes 
simplex virus thymidine kinase promoter (kind gift from Dr. Ronald M. Evans, 
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The Salk Institute for Biological Studies, San Diego, CA, USA). 3X PPRE 
promoter activities were assessed with a dual-luciferase assay kit. Briefly, cells 
were washed once with 1X PBS, and lysed with 100µl of ice-cold reporter lysis 
buffer. Ten microlitres of cell lysate was then added to 50µl of luciferase substrate 
solution, following which 50µl of stop & glow buffer was added for Renilla 
reading. Bioluminescence generated was measured using a Sirius luminometer 
(Berthold, Munich, Germany). The luminescence readings obtained were 
normalized to the protein content of the corresponding cell lysate. 
 
 
2.15 Colony forming assay 
Cells transfected with control scrambled siRNA (ctsi) and siMnSOD were 
subjected to docetaxel and doxorubicin treatment for 48h. After which, cells were 
trysinised and 15 000 cells per treatment were re-seeded into 100mm dishes and 
left to grow for 10 to 15 days with complete medium. At the end of the assay, 
cells were washed with PBS and stained with crystal violet. 
 
 
2.16 Soft agar colony forming assay 
Soft agar colony formation assay in 96-well plates was performed as described by 
Ke et al. with minor modifications [251]. Briefly, 5x103 cells were seeded into 
100 ml 0.35% agarose onto the 0.5% agarose base layer. Serum supplemented 
	   58	  
medium (100 ml) containing drugs was added on the top and changed every 3 
days. After 10 days, total number of colonies per well was counted under 100x 
magnification. Light microscopy images were captured under 100x magnification.  
 
 
2.17 Generation of Doxorubicin- and Docetaxel-resistant cells 
Generation of MDA-MB-231 doxorubicin- and docetaxel- resistant cells were 
carried out as described [252]. Briefly, cells were first exposed to one-tenth of 
IC50 of the respective drug for 24h before replacing with fresh medium. Cells 
were then allowed to proliferate before exposure to stepwise increasing 
concentrations of the drug for 24h each time. The starting dose of doxorubicin 
used was 0.1µM and dose was increased by 0.1µM each time. The starting dose 
of docetaxel used was 10nM and dose was increased by 10nM each time. Cells 
were passaged whenever 80-90% confluency was reached. After 4-6 weeks, cell 
viability assay was carried out on parental (drug sensitive) and drug resistant cell 
lines to measure fold-resistance. 
 
 
2.18 Annexin-V/Propidium Iodide (PI) Staining for Apoptosis detection 
An early indicator of apoptosis is the rapid translocation and accumulation of the 
membrane phospholipid phosphatidylserine from the cytoplasmic interface to the 
extracellular surface. This loss of membrane asymmetry can be detected by 
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utilizing the binding properties of annexin V. To identify apoptosis, staining of 
cells using Annexin V : FITC Apoptosis Detection Kit I (BD Biosciences, San 
Jose, CA) was carried out as per manufacturer’s instructions. Briefly, 5 x 105 cells 
were trypsinised, pelleted and then stained with Annexin V-FITC conjugate. Cells 
were washed in PBS, resuspended in 100 µl of binding buffer containing FITC-
conjugated anti-annexin V antibody, and then analyzed by flow cytometer (BD 




For detection of acetylation of PPARγ, immunoprecipitation with PPARγ was 
performed. Cells were seeded at 0.4 x 105 density and transfected with FLAG 
tagged PPARγ before treatment with LBH589. Cells were harvested and cell 
pellets were lysed in IP lysis buffer (20mM Tris HCl [pH 8], 137mM NaCl, 10% 
glycerol, 1% NP-40, 2mM EDTA). 250µg of proteins were pre-cleared with 
magnetic G beads (Millipore, Bedford, MA) for 1h before rotating with 1µg of 
FLAG antibody or normal rabbit IgG overnight at 4°C. Magnetic G beads were 
added to the mixture the next day and rotated for 1.5h. Magnetic-enriched IP 
samples were washed four times in cold wash buffer (200mM Tris [pH 8.0], 
100mM NaCl, 0.5% NP-40, 2mM DTT, 0.5mM PMSF, 1mM sodium 
orthovanadate, 1µg/ml leupeptin, 1µg/ml aprotinin) at 10min intervals. Samples 
were then boiled in 5x SDS loading buffer and subjected to SDS-PAGE. Proteins 
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2.20 3D-Invasion assay 
In vitro invasion assay was performed using BD Bio-Coat Matrigel invasion assay 
system (BD Biosciences, San Jose, CA) according to the manufacturer’s 
instructions. Briefly, cells were trypsinized 48h post-transfection, 1.5 x 105 cells 
suspended in serum- free medium and seeded into the Matrigel transwell 
chambers consisting of polycarbonate membranes with 8-µm pores. Regular 
medium containing 10% FBS was added to the bottom chamber to act as 
chemoattractant. After incubation for 48h, the media in the transwell chamber was 
removed, and upper surface of the chambers was wiped off with a cotton swab. 
The invading cells were fixed and stained with crystal violet solution. The 
invading cell numbers were counted in five randomly selected microscope fields 
(x200) and their averages were converted to percentage with the control setup 
taken to be at 100%. 
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2.21 Wound healing assay 
MDA-MB-231 and BT549 cells were treated according to experimental design 
and a wound healing assay was carried out as described [253]. Briefly, two 
parallel lines were drawn at the underside of the well before plating the cells. 
These lines serve as fiducial marks for the wound areas to be analysed. Before 
marking the wound, the cells should be 90% confluent. The growth medium was 
aspirated and replaced by calcium-free PBS to prevent killing of cells at the edge 
of the wound by exposure to high calcium concentrations. Two parallel scratch 
wounds were made perpendicular to the marker lines with a 200µl yellow tip. The 
medium was then changed to complete media. After incubation for 24-72h, the 
wounds are observed using bright field microscopy and multiple images were 
taken at areas flanking the intersections of the wound and the marker lines at the 
start and end of the experiment. Three measurements of the gap distance between 
the wound were taken at the start and end of the experiment from the images, and 
their averages are converted to percentages to depict percentage change with the 
control setup taken to be at 100%. 
 
 
2.22 Tube formation assay 
A tube formation assay to assess angiogenesis was performed using endothelial 
cells as described [254]. A total of 50,000 HUVEC cells were seeded onto 
Growth Factor Reduced BD Matrigel™ Matrix (BD Biosciences, San Jose, CA) 
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in complete medium in 24-well plates in triplicate, incubated at 37°C for 30min. 
After cells have settled down and attached to the matrigel, medium containing 
drugs were added into each well. Cells were then allowed to grow for 12h. For 
fluorescence imaging of tubes, cells were incubated with 2ug/ml of calcein for 
30min at 37°C in the dark. Tubules were visualized by fluorescence and light 
microscopy at low magnification (x100) and representative images were captured 
at randomly selected microscope fields. Number of tubes formed and number of 
branching points were counted during analysis.  
 
 
2.23 Immunofluorescence Staining 
For immunofluorescence assay, cells were seeded on cover slips in 24-well plates. 
Cells were fixed with 100% methanol for 30min at room temperature. After 
fixation, cells were washed with 1XPBS twice to remove excess methanol. Cells 
were permeabilized with 0.2% TritonX-100 (Sigma-Aldrich, LO, USA) for 10min 
at room temperature. Cells were then incubated with primary antibody of the 
protein of interest overnight at 4°C. After washing with PBS, cells were incubated 
with Alexa Fluor 568 goat anti-mouse acid IgG (Molecular Probes Inc., Eugene, 
OR, USA) and with DAPI nucleic stain (Molecular Probes Inc., Eugene, OR, 
USA) for 1min. The cells were washed three times with 1XPBS before the cover 
slip was mounted for confocal analysis using Olympus FluoView1000 (FV1000; 
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Olympus, Japan) with identical acquisition parameters for the same image session. 
Pictures are analyzed with Olympus FLUOVIEW Ver1.7a Viewer. 
 
 
2.24 Statistical Analysis 
Statistical analysis was performed using paired Student’s t-test. A p-value of less 
than 0.05 was considered significant.  
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CHAPTER 3 RESULTS 
 
3.1 Analysis of MnSOD expressions in breast carcinoma  
 
3.1.1 MnSOD expression is significantly higher in triple negative breast 
cancer cell lines 
Triple negative breast cancer (TNBC) cell lines have been reported to be more 
invasive and aggressive than the ERα positive breast cancer cell lines. We set out 
to investigate if altered MnSOD levels exist between these subgroups of breast 
cancer and potentially contribute to the differences in aggressiveness. Total RNA 
was extracted from a panel of breast cancer cell lines and relative MnSOD mRNA 
levels were estimated by RT-PCR analysis. Normal breast cell line MCF10A and 
TNBC cell lines such as MDA-MB-231 and BT549 expressed higher levels of 
MnSOD mRNA than ERα positive breast tumor cell lines such as MCF7 and 
T47D (Fig.7). The mRNA levels also correlated with the protein content in the 
breast cell lines. Protein levels analyzed by western blot showed the MnSOD 
protein levels in descending rank order as TNBC cell lines, normal epithelial cell 
lines and ERα positive breast tumor cell lines. (Fig.8).  
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Figure 7. MnSOD mRNA levels across a panel of breast cell lines. Relative 
MnSOD mRNA levels were normalized to 18S mRNA levels. Results are 
expressed as fold changes from MCF10A. Results shown represent mean ± SD, 
n=3. 
                             
Figure 8. Western blot analysis of MnSOD protein levels across a panel of 
breast cell lines. 40µg of protein was used for western blotting and detected for 

























MnSOD mRNA levels 
	   66	  
3.2 Regulation of chemo-sensitivity by MnSOD in triple negative breast 
cancer cells 
 
3.2.1 MnSOD suppression decreases colony forming ability of TNBC cells 
Since the highly invasive and aggressive TNBC cells have been shown to have 
higher MnSOD levels compared to the other subgroups of breast cancer, we 
hypothesize that MnSOD could be an attractive therapeutic target in the 
management of this particular subgroup of breast carcinoma. To test this 
hypothesis, we selected MDA-MB-231 and BT549 as two models of TNBC cell 
lines that express high levels of MnSOD. We then performed silencing of 
MnSOD using specific siRNA and determined long-term effects on colony 
forming ability. We first validated that MnSOD knockdown translated into a 
decrease in MnSOD activity (Fig.9A). Correspondingly, our results showed that 
gene knockdown of MnSOD impaired long-term colony forming ability in the 















Figure 9. Targeted repression of MnSOD inhibits colony forming ability of 
MDA-MB-231 cells. (A) MnSOD activity of MDA-MB-231 cells transfected 
with 100nM control scrambled siRNA (ctsi) and siMnSOD and grown for 48h. (B) 
Top panel: Western blot of MDA-MB-231 cells transfected with 100nM control 
scrambled siRNA (ctsi) and siMnSOD. Bottom panel: Colony forming assay of 
MDA-MB-231 cells transfected with ctsi and siMnSOD and grown for two weeks. 
(C) Number of colonies from (B) were counted. Results shown represent mean ± 
SD, n=3, *P<0.05 vs. control. 
B  





Figure 10. Targeted repression of MnSOD inhibits colony forming ability of 
BT549 cells. (A) Top panel: Western blot of BT549 cells transfected with 100nM 
control scrambled siRNA (ctsi) and siMnSOD. Bottom panel: Colony forming 
assay of BT549 cells transfected with ctsi and siMnSOD and grown for two 
weeks. (B) Number of colonies from (A) were counted. Results shown represent 
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3.2.2 Downregulation of MnSOD enhances chemo-sensitivity of TNBC cell 
lines 
Additionally, we wanted to investigate if suppression of MnSOD would affect the 
sensitivity of breast tumor cells to low doses of chemotherapeutic drugs used in 
the clinical treatment of breast cancer. We showed that silencing of MnSOD in 
both MDA-MB-231 and BT549 significantly increased the sensitivity of both cell 
lines to Docetaxcel (DOC) and Doxorubicin (DOX) (Fig.11 and Fig.12), two 
commonly used drugs in breast cancer patients. Furthermore, long-term colony 
forming ability was significantly decreased in MDA-MB-231 cells that were 
transfected with siMnSOD and exposed to low-sensitizing doses of DOC and 
DOX (Fig.13).  In MDA-MB-231 and BT549, percentage decrease in viability of 
cells to DOC increased from 10% in control cells to ~37.5% in siMnSOD-
transfected cells; percentage decrease in viability of cells to DOX increased from 
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Figure 11.  Targeted repression of MnSOD in combination with DOC or 
DOX decreases cell viability of MDA-MB-231 cells. (A) MDA-MB-231 cells 
were transfected with ctsi and siMnSOD and treated with 30nM and 60nM DOC 
for 48h before cell viability was assessed using crystal violet assay. (B) Cells 
were transfected with ctsi and siMnSOD and treated with 0.2µM and 0.4µM DOX 
for 48h before cell number was assessed using crystal violet assay.  Results shown 
represent mean ± SD, n=3, *P<0.05 vs. ctsi medium. (C) Light microscopy 
images of MDA-MB-231 cells transfected with ctsi and siMnSOD and treated 
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Figure 12.  Targeted repression of MnSOD in combination with DOC or 
DOX decreases cell viability of BT549 cells. (A) BT549 cells were transfected 
with ctsi and siMnSOD and treated with 30nM and 60nM DOC for 48h before 
cell viability was assessed using crystal violet assay. (B) BT549 cells were 
transfected with ctsi and siMnSOD and cells were treated with 0.2µM and 0.4µM 
DOX for 48h before cell number was assessed using crystal violet assay.  Results 
shown represent mean ± SD, n=3, *P<0.05 vs. ctsi medium. (C) Light microscopy 
images of BT549 cells transfected with ctsi and siMnSOD and treated with 60nM 










Figure 13. Targeted repression of MnSOD decreases long term colony 
forming ability of MDA-MB-231 breast cancer cells. (A) Colony forming assay 
of MDA-MB-231 cells transfected with ctsi and siMnSOD and treated with 60nM 
docetaxel or 0.4µM doxorubicin for 48h. Cells were re-seeded into 100mm dishes 
and grown for 2 weeks. (B) Number of colonies from (A) were counted. Results 
shown represent mean ± SD, n=3, *P<0.05 vs. control.   
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3.3 Regulation of chemo-sensitivity by MnSOD in drug-resistant MDA-MB-
231 breast cancer cells 
 
3.3.1 Generation of MDA-MB-231 Doxorubicin and Docetaxel resistant cells  
We next sought to investigate if chemo-resistance is in any way associated with 
MnSOD expression. Acquisition of chemo-resistance remains a major challenge 
in the therapeutic management of breast cancer. Based on our data demonstrating 
that the absence of MnSOD influences chemo-sensitivity of breast cancer cells, 
we set out to generate chemotherapy resistant clones of MDA-MB-231 cell line 
and assessed the role of MnSOD. This was accomplished by exposing cells to 
doxorubicin or docetaxel in a ‘stepwise increase’ method for a period of 4-6 


















Figure 14. Generation of DOC and DOX resistant MDA-MB-231 cell lines. 
(A) MDA-MB-231 wildtype and Doxorubin-resistant (DOX-R) cells were treated 
with 0.2µM, 0.4µM and 1µM of Doxorubicin for 48h before cell viability was 
assessed by crystal violet assay. (B) MDA-MB-231 wildtype and Docetaxel-
resistant (DOC-R) cells were treated with 50nM, 100nM and 200nM docetaxel for 
48h before cell viability was assessed by crystal violet assay. Results shown 
represent mean ± SD, n=3, *P<0.05 vs. control.  
 
 
	   75	  
3.3.2 MDA-MB-231 DOX-R and DOC-R cells have higher MnSOD 
expression levels 
After obtaining the drug-resistant clones of MDA-MB-231, we analysed the 
levels of MnSOD by RT-PCR and western blot. Interestingly, the expression of 
MnSOD (mRNA and protein) was significantly increased in MDA-MB-231 cells 
rendered resistant to both the chemotherapeutic agents compared to the parental 














Figure 15. Drug resistant cell lines have higher MnSOD levels than parental 
cells. (A) Left: Basal MnSOD mRNA levels in MDA-MB-231 wildtype vs DOX-
R cells normalized to 18S mRNA. Right: Basal MnSOD protein levels in MDA-
MB-231 wildtype vs DOX-R cells. (B) Left: Basal MnSOD mRNA levels in 
MDA-MB-231 wildtype vs DOC-R cells normalized to 18S mRNA. Results 
shown represent mean ± SD, n=3, *P<0.05 vs. control. Right: Basal MnSOD 
protein levels in MDA-MB-231 wildtype vs DOC-R cells.  
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3.3.3 Downregulation of MnSOD resensitizes drug-resistant cells to DOC and 
DOX 
Having observed the boost in MnSOD expressions in the drug-resistant clones 
compared to the parental cell line, we sought to examine the impact of crippling 
MnSOD expressions on the chemo-sensitivity of these drug-resistant cells. 
Knockdown of MnSOD using siRNA restored the sensitivity of the doxorubicin- 
and docetaxel- resistant MDA-MB-231 cell lines, showing that MnSOD plays a 
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Figure 16. Downregulation of MnSOD resensitizes DOC-R and DOX-R 
MDA-MB-231 cell lines. (A) MDA-MB-231 DOX-R cells were transfected with 
Control scrambled RNA (ctsi) or 100nM siMnSOD. Forty-eight hours post 
transfection cells were treated with 0.2µM, 0.4 µM and 1µM doxorubicin for 48h 
before cell number was assessed by crystal violet assay. (B) MDA-MB-231 DOC-
R cells were transfected with ctsi or 100nM siMnSOD. Forty-eight hours post 
transfection cells were treated with 30nM and 60nM docetaxel for 48h before cell 
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3.4 Regulation of MnSOD by PPARγ activation in TNBC cell lines 
 
3.4.1 PPARγ activation downregulates MnSOD expression in TNBC cell lines 
Our results so far indicated that targeting MnSOD expression could have potential 
implications in enhancing the chemo-sensitivity of TNBC subgroup of breast 
tumors. However, for this approach to have therapeutic applications there is a 
need to find a clinically relevant protocol to selectively decrease MnSOD 
expression in these cells. Interestingly, we recently showed that human MnSOD 
gene is a target of the Peroxisome Proliferator-Activated Receptor gamma 
(PPARγ). A functional Peroxisome Proliferator Hormone Response Elements 
(PPRE) was identified in the upstream/promoter region of the human MnSOD 
gene. Of note, activation of PPARγ by its endogenous ligand, 15d-PGJ2, 
significantly decreased MnSOD promoter activity and mRNA level in the TNBC 
cell lines MDA-MB-231 and MDA-MB-468 [62]. In the present report these 
results were reproduced using BT549 cells and confirmed in the MDA-MB-231 
cell line.  Exposure of MDA-MB-231 and BT549 cells, but not normal breast cell 
line 184A1 to 15d-PGJ2, induced the activation of PPARγ (Fig.17A) via the DR1-
luciferase reporter assay, which correlated with a dose dependent decrease in 













C      D 
 
Figure 17. Repression of MnSOD upon PPARγ activation in TNBC cells. (A) 
Left: Basal PPARγ activity in MDA-MB-231, BT549 and 184A1 cells. Results 
are expressed as relative light units (RLU) per µg protein. Results shown 
represent mean ± SD, n=3, *P<0.05 vs. 184A1. Right: Western blot of basal 
PPARγ levels.  (B) Comparison of PPARγ activity in MDA-MB-231, BT549 and 
184A1 following 24h treatment with 5µM and 10µM 15d-PGJ2. Results are 
expressed as percentage increases in RLU per µg protein from control. Results 
shown represent mean ± SD, n=4, *P<0.05 vs. control. (C) RT-PCR analysis of 
relative MnSOD mRNA levels normalized to 18S mRNA levels. MDA-MB-231 
cells were subjected to 24h of 5µM and 10µM 15d-PGJ2 treatment with and 
without 4h pre-incubation with 10µM GW9662. Results are expressed as fold 
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changes from control. Results shown represent mean ± SD, n=4, *P<0.05 vs. 
control. (D) Experiment from (C) was repeated in BT549.  
 
 
3.4.2 Downregulation of MnSOD expressions in TNBC cell lines is PPARγ 
receptor-dependent 
Moreover, the downregulation of MnSOD mRNA and protein expressions in 
MDA-MB-231 and BT549 with 15d-PGJ2 treatment was inhibited by the selective 
and irreversible PPARγ antagonist GW9662 (Fig.18A and Fig.19A) or upon 
transfection of the cells with a dominant negative form of PPARγ, 
PPARγC126A/E127A (DN PPARγ) (Fig.18B-C and Fig.19B). The plasmid pcmx-EV 
(Empty Vector) was used as a control for the transfection of pcmx-DN PPARγ. 
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Figure 18. Repression of MnSOD by PPARγ activation in MDA-MB-231 cells 
is PPARγ receptor-dependent. (A) Western blot analysis of MDA-MB-231 
breast cancer cells ± GW9662 pre-incubation and then treated with 5µM and 
10µM 15d-PGJ2 for 24h. (B) MDA-MB-231 cells were transfected with pcMX-
EV (empty vector) and 5µg DNPPARγ (plasmids encoding a dominant negative 
form of PPARγ) and treated with 15d-PGJ2 for 24h. RT-PCR analysis of relative 
MnSOD mRNA levels normalized to 18S mRNA levels. Results are expressed as 
fold changes from control. Results shown represent mean ± SD, n=3, *P<0.05 vs. 
control. (C) Western blot analysis of PPARγ and MnSOD levels. 







Figure 19. Repression of MnSOD by PPARγ activation in BT549 cells is 
PPARγ receptor-dependent. (A) Western blot analysis of BT549 breast cancer 
cells ± GW9662 pre-incubation and then treated with 5µM and 10µM 15d-PGJ2 
for 24h. (B) BT549 cells were transfected with pcMX-EV and 5µg DNPPARγ 
(plasmids encoding a dominant negative form of PPARγ) and treated with 15d-
PGJ2 for 24h. Top panel: Western blot analysis of PPARγ and MnSOD levels. 
Bottom panel: RT-PCR analysis of relative MnSOD mRNA levels normalized to 
18S mRNA levels. Results are expressed as fold changes from control. Results 
shown represent mean ± SD, n=3, *P<0.05 vs. control.  
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3.4.3 Treatment with PPARγ  ligands has no effect on MnSOD expressions in 
normal epithelial breast cell lines 
On the contrary, exposure of the non-tumorigenic breast cell lines 184A1 and 
MCF10A to 15d-PGJ2 neither induced PPARγ activation (Fig.17A) nor decreased 





Figure 20. Normal breast epithelial cells are refractory to treatment with 
PPARγ ligands. (A) 184A1 and MCF 10A were subjected to 24h of 5µM and 10 
µM 15d-PGJ2 treatment. RT-PCR analysis of relative MnSOD mRNA levels 
normalized to 18S mRNA levels in samples treated with 5µM and 10µM 15d-
PGJ2 for 24h. Values are expressed as fold change against control. Results shown 
represent mean ± SD, n=3. (B) Western blot analysis of MnSOD protein levels.  
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3.4.4 Synthetic PPARγ ligands downregulate MnSOD expressions in vitro  
Having demonstrated that activation of PPARγ using its natural ligand 15d-PGJ2, 
specifically decreased MnSOD expression in triple negative breast cancer cell 
lines, we next investigated if these results could be reproduced using synthetic 
PPARγ ligands, such as rosiglitazone and troglitazone. MDA-MB-231 and BT549 
cells were exposed to increasing concentrations of rosiglitazone and troglitazone 
to determine the concentration required to detect an activation of PPARγ. 
Exposure of MDA-MB-231 to 40 to 80µM rosiglitazone and 30 to 50µM 
troglitazone induced significant increases in PPARγ activation that were 
prevented in the presence of the PPARγ antagonist GW9662 (Fig.21A and 
Fig.22A). Moreover, downregulation of MnSOD mRNA levels and protein 
expressions induced by the synthetic PPARγ ligands were inhibited by pre-
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Figure 21. Rosiglitazone downregulates MnSOD expressions in TNBC cells. 
(A) MDA-MB-231 cells were treated with 40µM and 80µM ROSIG for 16h +/- 
4h pre-incubation with GW9662 before PPARγ activity was measured using 
luciferase assay. Results are expressed as percentage increases in relative light 
units (RLU) per µg protein from control. (B) MDA-MB-231 ± GW9662 were 
treated with 40µM and 80µM ROSIG for 24h. RT-PCR analysis of relative 
MnSOD mRNA levels normalized to 18S mRNA levels. Results are expressed as 
fold changes from control. Results shown represent mean ± SD, n=4, *P<0.05 vs. 
control.  (C) Western blot analysis of MDA-MB-231 ± GW9662 and treated with 
40µM and 80µM ROSIG for 24h. 
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Figure 22. Troglitazone downregulates MnSOD expressions in TNBC cells. 
(A) MDA-MB-231 cells were treated with 30µM and 50µM TROG for 16h +/- 4h 
pre-incubation with GW9662 before PPARγ activity was measured using 
luciferase assay. Results are expressed as percentage increases in relative light 
units (RLU) per µg protein from control. (B) MDA-MB-231 ± GW9662 were 
treated with 30µM and 50µM TROG for 24h. RT-PCR analysis of relative 
MnSOD mRNA levels normalized to 18S mRNA levels. Results are expressed as 
fold changes from control. Results shown represent mean ± SD, n=4, *P<0.05 vs. 
control.  (C) Western blot analysis of MDA-MB-231 ± GW9662 and treated with 
30µM and 50µM TROG for 24h. 
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3.5 Effects of PPARγ activation-induced MnSOD repression on chemo-
sensitivity of TNBC cells 
 
3.5.1 PPARγ activation-induced MnSOD repression enhances chemo-
sensitivity of TNBC cells 
Synthetic ligands of PPARγ have been shown to sensitize a variety of human 
cancer cell types to chemotherapy-induced cell death.  Intrigued by our findings 
that gene knockdown of MnSOD enhanced chemo-sensitivity of MDA-MB-231 
and BT549 cells and that activation of PPARγ downregulated MnSOD expression, 
we next questioned if the chemo-sensitizing effect of PPARγ ligands could be 
mediated via their repressive effect on MnSOD. Indeed, exposure of MDA-MB-
231 cells to rosiglitazone alone or in combination with docetaxel or doxorubicin 
resulted in a significant downregulation of MnSOD expression (Fig.23A-B), and 
the combination treatment drastically affected the clonogenic potential of these 
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Figure 23. PPARγ activation-induced MnSOD repression enhances chemo-
sensitivity of MDA-MB-231 breast cancer cells. (A) Top panel: Western blot 
for MnSOD expression in MDA-MB-231 cells treated with 80µM ROSIG, 60nM 
DOC, or in combination for 48h. Bottom panel: Western blot for MnSOD 
expression in MDA-MB-231 cells treated with 80µM ROSIG, 0.4µM DOX, or in 
combination for 48h. (B) Experiment from (A) repeated in BT549. (C) Colony 
MDA-MB-231 BT549 
MDA-MB-231 MDA-MB-231 
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formation in soft agar of MDA-MB-231 cells treated with ROSIG, DOC, DOX, 
combination of ROSIG and DOC or combination of ROSIG and DOX 
respectively. (D) Left: Colonies from (C) were counted for ROSIG, DOC, or in 
combination and presented as a percentage of control cells, n=3, *P<0.05 vs. 
control. Right: Colonies from (C) were counted for ROSIG, DOX, or in 




3.5.2 PPARγ activation-induced MnSOD repression enhances chemo-
sensitivity of MDA-MB-231 DOC-R and DOX-R cells 
Since PPARγ ligand-induced MnSOD repression sensitized MDA-MB-231 cells 
to chemotherapeutic drugs, we wanted to investigate if the same strategy could be 
utilitzed to overcome drug resistance in DOC-R and DOX-R variants of MDA-
MB-231. These cell lines have been shown to exhibit higher levels of MnSOD 
expression than the parental MDA-MB-231 cells (Fig.15). From our results, we 
showed that repression of MnSOD upon ligand-induced activation of PPARγ 
successfully restored chemo-sensitivity in the drug resistant variants of MDA-
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Figure 24. PPARγ  ligand-induced MnSOD repression resensitizes DOC-R 
and DOX-R MDA-MB-231 cell lines. (A) MDA-MB-231 DOX-R cells were 
treated with 0.2µM, 0.4µM and 1µM DOX with and without 6h pre-incubation of 
10µM 15d-PGJ2 for 48h before cell number was assessed by crystal violet assay. 
(B) MDA-MB-231 DOC-R cells were treated with 30nM and 60nM DOC for 48h 
with and without 6h pre-incubation of 10µM 15d-PGJ2 before cell number was 
assessed by crystal violet assay. Results shown represent mean ± SD, n=3, 
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3.5.3 MnSOD regulates PPARγ activation-induced chemo-sensitization of 
MDA-MB-231 cells  
Most importantly, the chemo-sensitizing effect of rosiglitazone in MDA-MB-231 
breast tumor cells was significantly blocked upon overexpression of MnSOD 
(Fig.25), thus providing further testimony for a critical role of MnSOD in 













Figure 25. PPARγ activation-induced chemo-sensitization is MnSOD-
dependent. (A) Western blot for MDA-MB-231 cells transfected with pcDNA3 
or 2ug pcDNA3-MnSOD plasmid and treated with ROSIG+DOC or 
ROSIG+DOX. (B) Left: Transfected MDA-MB-231 cells were treated with 
80µM ROSIG, 60nM DOC or both for 48h. Right: Transfected MDA-MB-231 
cells were treated with 80µM ROSIG, 0.4µM DOX or both for 48h. Cell viability 
was assessed by crystal violet assay. Results shown represent mean ± SD, n=3, 
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3.5.4 No effect of PPARγ ligands on chemo-sensitization of normal breast 
epithelial cell lines 
Since PPARγ activation did not induce PPARγ activity or affect MnSOD mRNA 
and protein levels in normal breast epithelial cells, we sought to investigate if 
treatment of PPARγ ligands would affect their sensitivity towards DOC and DOX. 
We observed that similar treatment of non-tumorigenic cells (MCF10A and 
184A1) with the combination treatment had negligible effects on MnSOD 
expressions and cell viability, thus providing further evidence that this chemo-
sensitization effect is specific to cancer cells (Fig.26 and Fig.27). This provided 
further evidence that downregulation of MnSOD is crucial for the chemo-
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Figure 26. No chemo-sensitization in normal MCF-10A breast epithelial cells. 
(A) Left: MCF-10A cells were treated with 80µM ROSIG, 60nM DOC or in 
combination for 48h before cell number was assessed using MTT assay. Right: 
MCF-10A cells were treated with 80µM ROSIG, 0.4µM DOX or in combination 
for 48h before cell number was assessed using MTT assay. Results shown 
represent mean ± SD, n=3. (B) Light microscopy images of MCF-10A cells from 















Figure 27. No chemo-sensitization in normal 184A1 breast epithelial cells. (A) 
Left: 184A1 cells were treated with 80µM ROSIG, 60nM DOC or in combination 
for 48h before cell number was assessed using MTT assay. Right: 184A1 cells 
were treated with 80µM ROSIG, 0.4µM DOX or in combination for 48h before 
cell number was assessed using MTT assay. Results shown represent mean ± SD, 
n=3. (B) Light microscopy images of 184A1 cells from (A) under 200x 
magnification. (C) Western blot analysis of MnSOD expression from (A). 
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3.6 Effects of targeting MnSOD expression on intracellular ROS 
 
3.6.1 MnSOD downregulation results in an accumulation of mitochondrial 
ROS  
Studies have shown that MnSOD is critical in the regulation of mitochondrial 
ROS. In order to better understand the mechanism involved in the increased 
chemo-sensitivity afforded by downregulation of MnSOD, we measured the effect 
of a gene knockdown of MnSOD or its repression by 15d-PGJ2, on mitochondrial 
ROS levels. Results show that downregulation of MnSOD expression using 
siMnSOD or 15d-PGJ2 in MDA-MB-231 and BT549 produced an increase in 
mitochondrial ROS that was blocked by the antioxidant N-Acetyl Cysteine (NAC) 
(Fig.28). On the other hand, similar treatment in normal epithelial breast cells had 
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 C      D 
	   	  
 
Figure 28. MnSOD downregulation is linked to an increase in intracellular 
ROS in TNBC cells. (A) MDA-MB-231 were transfected with ctsi or 100nM 
MnSOD small-interfering RNA (siRNA). Post transfection cells were incubated 
+/- 10mM NAC for 48h. Top: Western blot analysis of MnSOD protein levels. 
Bottom: Mitochondrial O2.-  production was measured using MitoSOX Red assay. 
(B) Mitochondrial O2.- was measured in MDA-MB-231 +/- pre-incubation of 
10mM NAC for 4h followed by 10µM 15d-PGJ2 treatment for 16h using 
MitoSOX Red assay. Results are expressed as percentage increases in arbitrary 
units (a.u.) from control. (C-D) Experiments from (A-B) were repeated in BT549. 
Results shown represent mean ± SD, n=3, *P<0.05 vs. control.  
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Figure 29. MnSOD downregulation does not affect intracellular ROS in 
normal breast epithelial cells. (A) 184A1 and MCF10A were transfected with 
ctsi or 100nM MnSOD siRNA. Top: Western blot analysis of MnSOD protein 
levels. Bottom: Mitochondrial O2.-  production was measured using MitoSOX Red 
assay. (B) Mitochondrial O2.- was measured in 184A1 and MCF10A followed by 
5µM and 10µM 15d-PGJ2 treatment for 16h using MitoSOX Red assay. Results 
shown represent mean ± SD, n=3. 
 
 
3.6.2 Increase in mitochondrial ROS upon exposure to PPARγ ligands is 
PPARγ receptor-dependent 
Furthermore, we wanted to examine if the induction of mitochondrial ROS is 
dependent on the PPARγ receptor. We observed that the increase in mitochondrial 
O2.-  caused by PPARγ activation via 15d-PGJ2 treatment in MDA-MB-231 and 
BT549 cells could be inhibited by pre-incubation with the PPARγ antagonist 
GW9662 (Fig.30A-B). In addition, use of synthetic ligands rosiglitazone and 
troglitazone in MDA-MB-231 cells showed similar effects on mitochondrial ROS 
(Fig.30C-D).  
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Figure 30. Increase in intracellular ROS upon PPARγ activation is receptor-
dependent. (A) Mitochondrial O2.- production in MDA-MB-231 upon 10µM 15d-
PGJ2 treatment +/- 4h pre-incubation with 10µM GW9662 was measured using 
MitoSOX Red assay. (B) Experiment from (A) was repeated in BT549. (C) 
Mitochondrial O2.- production in MDA-MB-231 upon 40µM and 80µM 
rosiglitazone treatment +/- 4h pre-incubation with 10µM GW9662 was measured 
using MitoSOX Red assay. (D) Mitochondrial O2.- production in MDA-MB-231 
upon 30µM and 50µM troglitazone treatment +/- 4h pre-incubation with 10µM 
GW9662 was measured using MitoSOX Red assay. Results are expressed as 
percentage increases in arbitrary units (a.u.) relative to control. Results shown 
represent mean ± SD, n=3, *P<0.05 vs. control.  
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3.6.3 MnSOD levels regulate mitochondrial ROS upon PPARγ activation  
Next, we wanted to investigate if the increase in mitochondrial ROS upon PPARγ 
activation is dependent on the repression of MnSOD levels. We measured 
mitochondrial ROS levels after overexpressing MnSOD in MDA-MB-231 and 
BT549 cells and observed that the increase in MitoROS induced upon 15d-PGJ2 
treatment could be abrogated by maintaining MnSOD at high levels (Fig.31). Use 
of synthetic ligands rosiglitazone and troglitazone showed similar effects in 
MDA-MB-231 cells, showing that changes to mitochondrial ROS are dependent 
on the reduction of MnSOD levels upon exposure to the TZDs (Fig.32). 
A      B 
	   	  
Figure 31. MnSOD regulates 15d-PGJ2-induced increase in intracellular 
ROS. (A) MDA-MB-231 cells were transfected with 2µg human MnSOD 
plasmid or empty vector pcDNA3. Forty-eight hours post transfection cells were 
treated with 10µM 15d-PGJ2 treatment for 16h. Top panel: Western blot analysis 
of MnSOD protein levels. Bottom panel: Mitochondrial O2.-  production was 
measured using MitoSOX Red assay. (B) Experiment from (A) was repeated in 
BT549. 
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Figure 32. MnSOD regulates synthetic PPARγ ligand-induced increase in 
intracellular ROS. (A) MDA-MB-231 cells were transfected with 2µg human 
MnSOD plasmid or empty vector pcDNA3. Forty-eight hours post transfection 
cells were treated with 80µM ROSIG for 24h. Top panel: Western blot analysis of 
MnSOD protein levels. Bottom panel: Mitochondrial O2.- production was 
measured using MitoSOX Red assay. (B) Top panel: Western blot of MDA-MB-
231 cells transfected with empty vector pcDNA3 or 2µg MnSOD plasmid. Forty-
eight hours post transfection cells were treated with 50µM TROG for 24h. Bottom 
panel: Mitochondrial O2.- production was measured using MitoSOX Red assay. 
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3.6.4 Chemo-sensitization by PPARγ  ligands is dependent on accumulation of 
intracellular ROS 
Intracellular increase in ROS has been implicated in the anti-cancer activity of 
docetaxel or doxorubicin [102, 255]. Thus we next questioned if the increased 
sensitivity of cancer cells to these drugs in combination with PPARγ ligands 
could be due to this accentuated oxidative stress. Indeed, MitoROS levels 
measured by MitoSOX Red assay, as well as levels of reactive nitrogen species 
(RNS) such as nitric oxide (NO) and peroxynitrite (ONOO-), measured by DAF 
assay, were synergistically increased in MDA-MB-231 cells upon combination 
treatment of rosiglitazone and DOC or DOX, compared to single agent treatment 
(Fig.33). DAF-FM is a reagent that detects NO and forms a fluorescent 
benzotriazole. On the other hand, similar treatment of the non-tumorigenic cell 
lines (MCF10A and 184A1) did not significantly alter MitoROS levels (Fig.34). 
Furthermore, ectopic overexpression of MnSOD prevented the synergistic 
increase in MitoROS induced by combination treatment, showing that MnSOD 
repression is instrumental in the buildup of intracellular ROS upon combination 
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Figure 33. Combination treatment contributes to synergistic increase in 
intracellular ROS in TNBC cells. (A) Left: MDA-MB-231 cells were treated 
with 80µM ROSIG, 60nM DOC, or in combination for 24h. Mitochondrial O2.- 
production was measured using MitoSOX Red assay. Right: MDA-MB-231 cells 
were treated with 80µM ROSIG, 0.4µM DOX, or in combination for 24h. 
Mitochondrial O2.- production was measured using MitoSOX Red assay. (B) 
Experiments from (A) was repeated and nitric oxide production was measured 
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Figure 34. Combination treatment does not produce synergistic increase in 
intracellular ROS levels in normal breast epithelial cells. Left: 184A1 and 
MCF-10A cells were treated with 80µM ROSIG, 60nM DOC, or in combination 
for 24h. Mitochondrial O2.- production was measured using MitoSOX Red assay. 
Right: 184A1 and MCF-10A cells were treated with 80µM ROSIG, 0.4µM DOX, 
or in combination for 24h. Mitochondrial O2.- production was measured using 























Figure 35. MnSOD regulates increase in intracellular ROS during chemo-
sensitization treatment. (A) Western blot of MDA-MB-231 cells transfected 
with empty vector pcDNA3 or 2µg pcDNA3-MnSOD plasmid. (B) Left: 
Transfected cells were treated with 80µM ROSIG and 60nM DOC in combination 
for 24h before mitochondrial O2.- production was measured using MitoSOX Red 
assay. Right: Transfected cells were treated with 80µM ROSIG and 0.4µM DOX 
in combination for 24h before mitochondrial O2.- production was measured using 
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3.6.5 Chemo-sensitization by PPARγ  ligands is dependent on peroxynitrite 
We next wanted to identify the species of free radicals induced by MnSOD 
repression. Accumulation of O2.- in the mitochondria was confirmed by showing 
that upon treatment with rosiglitazone and DOC or DOX, NAC and superoxide 
scavenger, Tiron, prevented the increase in mitochondrial ROS production 
(Fig.36). In addition, using DAF-FM to detect NO, our data showed an increase in 
DAF fluorescence upon silencing of MnSOD in MDA-MB-231 cells. The 
increase in RNS production was blocked by NO synthase inhibitor, L-NMMA, 
and peroxynitrite decomposition catalyst, FeTPPS, demonstrating the presence of 
ONOO- (Fig.37). These data led us to hypothesize that upon MnSOD repression, 
mitochondrial O2.- production is induced, which could be quickly sequestered to 
react with NO to form ONOO-. The reaction between O2.-  and NO to form 
ONOO- has been previously demonstrated by Pacher et al. [256]. 
In agreement with this idea, chemo-sensitization to docetaxel or doxorubicin by 
rosiglitazone treatment was blocked by pre-incubation of the cells with NAC, and 
Tiron, showing that O2.-  is involved in the chemo-sensitization process (Fig.38). 
In addition, the decrease in cell viability was blocked by L-NMMA and FeTPPS 
(Fig.39). Taken together these data indicate that ONOO- could be the probable 
species involved in mitigating enhanced chemo-sensitivity of triple negative 
breast carcinoma upon gene knockdown or pharmacological inhibition of MnSOD. 





Figure 36. Chemo-sensitization by PPARγ  ligands involves superoxide 
radicals.  (A) Left: MDA-MB-231 cells +/- pre-incubation of 10mM NAC for 4h 
were treated with 80µM ROSIG and 60nM DOC for 24h before mitochondrial 
O2.-  production was measured by MitoSOX Red assay. Right: MDA-MB-231 
cells +/- pre-incubation of 10mM NAC for 4h were treated with 80µM ROSIG 
and 0.4µM DOX for 24h before mitochondrial O2.-  production was measured by 













Figure 37. Chemo-sensitization by PPARγ  ligands involves peroxynitrite 
formation.  (A) Left: MDA-MB-231 cells +/- pre-incubation of 50µM L-NMMA 
for 4h were treated with 80µM ROSIG and 60nM DOC for 24h before nitric 
oxide production was measured by DAF assay. Right: MDA-MB-231 cells +/- 
pre-incubation of 50µM L-NMMA for 4h were treated with 80µM ROSIG and 
0.4µM DOX for 24h before nitric oxide production was measured by DAF assay. 
(B) Experiments from (A) were repeated with 100µM FeTPPS and nitric oxide 
production was measured by DAF assay. Results shown represent mean ± SD, 
n=3, *P<0.05 vs. control. 
 
 






Figure 38. Chemo-sensitization by PPARγ  ligands involves superoxide 
radicals. (A) Left: MDA-MB-231 cells +/- pre-incubation of 10mM NAC for 4h 
were treated with 80µM ROSIG, 60nM DOC or both for 48h before cell viability 
was assessed by crystal violet assay. Right: MDA-MB-231 cells +/- pre-
incubation of 10mM NAC for 4h were treated with 80µM ROSIG, 0.4µM DOX 
or both for 48h before cell viability was assessed by crystal violet assay. (B) 










Figure 39. Chemosensitization by PPARγ  ligands is dependent on 
peroxynitrite. (A) Left: MDA-MB-231 cells +/- pre-incubation of 50µM L-
NMMA for 4h were treated with 80µM ROSIG, 60nM DOC or both for 48h 
before cell viability was assessed by crystal violet assay. Right: MDA-MB-231 
cells +/- pre-incubation of 50µM L-NMMA for 4h were treated with 80µM 
ROSIG, 0.4µM DOX or both for 48h before cell viability was assessed by crystal 
violet assay. (B) Experiments from (A) were repeated with 100µM FeTPPS. 
Results shown represent mean ± SD, n=3, *P<0.05 vs. control. 
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3.7 Epigenetic regulation of PPARγ in breast carcinoma 
 
3.7.1 Effect of LBH589 on acetylation status of histone protein H3  
Since PPARγ has been reported to be interacting with HDACs and its activity 
influenced by epigenetic regulation in breast cancer cells, we were interested to 
investigate how inhibition of HDACs would affect PPARγ function. We started 
with treatment of HDAC inhibitor, LBH589 (Panobinostat), in MDA-MB-231 
cells to look at its effects on acetylation of histone 3. Firstly, increasing doses of 
HDACi LBH589 showed a marked dose-dependent increase in acetylated histone 
3 (H3) while treatment with 50nM of LBH589 for increasing durations showed a 
time-dependent increase in acetylated H3 (Fig.40). These are in line with 
published studies on HDACi treatment increasing acetylation of histone proteins 








































Figure 40. Increase in acetylation status of H3 upon LBH589 treatment. (A) 
Western blot analysis of MDA-MB-231 cells treated with 0, 10, 20, 50, 80 and 
100nM of LBH589 for 24h. (B) Western blot analysis of MDA-MB-231 cells 
treated with 50nM of LBH589 for 0h, 4h, 8h, 16h and 24h.  
 
 
3.7.2 Increase in acetylation status of PPARγ upon HDACi treatment 
Previous studies have shown that PPARγ activity is affected by acetylation status 
[168, 190]. Hence we sought to investigate if LBH589 treatment will alter the 
acetylation of PPARγ in breast cancer. When MCF7 breast cancer cells were 
treated with 50nM LBH589 for 1h, immunoprecipitation of FLAG tagged PPARγ 
showed an increase in acetylation status of lysine residues on PPARγ (Fig.41). 
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Figure 41. Increase in acetylation status of PPARγ upon LBH589 treatment. 
Immunoprecitation of FLAG tagged PPARγ in MCF7 cells treated with 50nM 
LBH589 for 1h. Immunoprecipitated lysates were blotted for aceylated lysine 
residues on PPARγ. 
 
 
3.7.3 Effects of HDACi in breast cancer cells 
Having shown that HDAC inhibition altered the epigenetic status of PPARγ, we 
were then interested to investigate the resultant effects on PPARγ activity. Firstly, 
treatment of breast tumor cells lines that were ERα positive (MCF7 and T47D) 
with increasing doses of LBH589 showed a marked decrease in ERα protein 
expressions. Concurrently, an increase in PPARγ protein levels was observed. In 
breast tumor cell lines that were ERα negative (MDA-MB-231 and BT549), 
similar increases in PPARγ protein levels were observed with increasing doses of 
LBH589 (Fig.42A). We next analyzed PPARγ mRNA levels in MCF7 and MDA-
MB-231 treated with increasing durations of 50nM LBH589 and observed 
significant up-regulation of PPARγ mRNA levels as early as 3h and persisting up 
to 18h, with the greatest up-regulation observed at 6h of treatment (Fig.42B). 
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PPARγ protein levels increased as early as 6h and continued to increase at 18h in 
MCF7 and MDA-MB-231. Correspondingly, ERα protein levels decreased from 
as early as 3h till 18h of LBH589 treatment (Fig.42C).  
 
In addition, we wanted to determine if PPARγ activity is also increased upon 
LBH589 treatment in line with increased acetylation status of PPARγ. In MCF7, 
T47D, MDA-MB-231 and BT549 breast tumor cell lines, increased PPARγ 




























Figure 42. Increase in PPARγ and decrease in ERα expressions upon 
LBH589 treatment. (A) Western blot analysis of MCF-7, T47D, MDA-MB-231 
and BT549 cells treated with 0, 30, 50 and 100nM of LBH589 for 24h. (B) RT-
PCR analysis of relative PPARγ mRNA levels normalized to 18S mRNA levels. 
MCF7 and MDA-MB-231 cells were subjected to 50nM LBH589 for 0, 3, 6, 9 
and 18h. Results are expressed as fold changes from control. Values represent 
mean ± SD, n=3, *P<0.05 vs. control. (C) Western blot analysis of MCF-7 and 
MDA-MB-231 cells treated with 0, 3, 6, 9 and 18h of 50nM LBH589.  









Figure 43. Increase in PPARγ activity in breast tumor cells upon LBH589 
treatment. PPARγ activity of MCF-7, T47D, MDA-MB-231 and BT549 cells 
treated with 0, 50 and 100nM LBH589 for 16h. Values represent mean ± SD, n=3, 




3.7.4 Induction of PPARγ activity by LBH589 is PPARγ receptor-dependent 
We next investigated if the increase in PPARγ activity upon exposure to LBH589 
in breast tumor cells is dependent on the PPARγ receptor. PPARγ antagonist 
GW9662 was able to block the increase in PPARγ activity upon LBH589 
treatment in MCF7 and MDA-MB-231, indicating that the activation of PPARγ is 
a receptor-dependent effect (Fig.44A). An alternative measure to prove this 
receptor-dependency was via transfection of a mutant dominant-negative form of 
PPARγ receptor into breast tumor cells (Fig.44B). In the empty vector (EV)-
transfected cells, PPARγ activity was increased in MCF7 and MDA-MB-231. 
However, in cells transfected with DN PPARγ, the increase in PPARγ activity 
upon LBH589 treatment was effectively blocked, thus showing that the effect is 
dependent upon PPARγ receptor and is not just a bystander effect (Fig.44B).  



















Figure 44. Increase in PPARγ activity upon LBH589 treatment is PPARγ 
receptor-dependent. (A) PPARγ activity of MCF-7 and MDA-MB-231 cells 
treated with 0, 50 and 100nM LBH589 for 16h +/- 4h pre-incubation of 10µM 
GW9662. (B) Top: Western blot of MCF-7 and MDA-MB-231 cells transfected 
with empty vector pcmx or DN PPARγ mutant. Bottom: PPARγ activity of 
transfected cells treated with 0, 50 and 100nM LBH589 for 16h. Values represent 
mean ± SD, n=3, *P<0.05 vs. control. 
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3.8 Effects of combination therapy of HDACi and PPARγ ligands in breast 
carcinoma cell lines 
 
3.8.1 Combination therapy of HDACi and PPARγ ligands increased PPARγ 
activity 
Since we established that inhibition of HDAC by LBH589 treatment increased 
PPARγ activity and expression levels in breast tumor cells, we next sought to 
exploit the use of LBH589 to potentiate and amplify the effects of PPARγ 
activation in MCF7 breast tumor cell line, which have low expressions of PPARγ 
receptor, and also MDA-MB-231, an aggressive TNBC cell line. Therefore, we 
explored the effects of combination therapy with HDACi LBH589 and PPARγ 
ligands ciglitazone and rosiglitazone. In breast tumor cells MCF7 and MDA-MB-
231, pre-incubation with LBH589 followed by ciglitazone and rosiglitazone 
treatment produced a drastic increase in PPARγ activity compared to each drug 
alone. The increase in PPARγ activity was effectively blocked upon inhibition of 
PPARγ by GW9662, showing that the synergistic activation of PPARγ is 
receptor-dependent (Fig.45A-B). An alternative method of showing receptor 
dependency was via transfection of PPARγ shRNA, effectively repressing PPARγ 
protein expressions in MCF7 and MDA-MB-231 (Fig.45C). Repressing PPARγ 
expressions in MCF7 and MDA-MB-231 cells significantly blocked the 
synergistic increase in PPARγ activity upon combination treatment of LBH589 
and ciglitazone or rosiglitazone (Fig.46). 
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Figure 45. Increase in PPARγ activity upon combination treatment can be 
blocked with GW9662. (A) PPARγ activity of MCF-7 and MDA-MB-231 cells 
treated with 50nM LBH589, 20µM CIG or a combination of both for 16h +/- 4h 
pre-incubation of 10µM GW9662. (B) PPARγ activity of MCF-7 and MDA-MB-
231 cells treated with 50nM LBH589, 60µM ROSIG or a combination of both for 
16h +/- 4h pre-incubation of 10µM GW9662. Values represent mean ± SD, n=3, 



























Figure 46. Increase in PPARγ activity upon combination treatment can be 
blocked by knockdown of PPARγ. (A) Western blot of MCF-7 and MDA-MB-
231 cells transfected with control shRNA or shPPARγ. (B) Transfected cells were 
treated with 50nM LBH589, 20µM CIG or a combination of both for 16h. (C) 
Transfected cells were treated with 50nM LBH589, 60µM ROSIG or a 
combination of both for 16h. Values represent mean ± SD, n=3, *P<0.05 vs. 
control. 
	   121	  
3.8.2 Combination therapy of HDACi and PPARγ ligands decreased cell 
viability 
In the analysis of cell viability, there was a significant decrease in the percentage 
of viable cells after treatment with LBH589 and rosiglitazone / ciglitazone 
compared to each drug alone, reflecting a synergistic effect in increasing the 
cytotoxicity the two drugs when used in combination. Cell death was inhibited 
when pre-incubated with GW9662 or when transfected with PPARγ shRNA, 
indicating that the cytotoxicity of this combination therapy is dependent upon 
PPARγ (Fig.47 and Fig.48). 
A      B 
 
Figure 47. Decrease in cell viability upon combination treatment can be 
blocked with GW9662. (A) Cell viability assay of MCF-7 and MDA-MB-231 
cells treated with 50nM LBH589, 20µM CIG or a combination of both for 24h +/- 
4h pre-incubation of 10µM GW9662. (B) Cell viability assay of MCF-7 and 
MDA-MB-231 cells treated with 50nM LBH589, 60µM ROSIG or a combination 
of both for 24h +/- 4h pre-incubation of 10µM GW9662. Values represent mean ± 




	   122	  
A      B 
 
Figure 48. Decrease in cell viability upon combination treatment can be 
blocked by knockdown of PPARγ. MCF-7 and MDA-MB-231 cells were 
transfected with control shRNA or shPPARγ. (A) Cells were treated with 50nM 
LBH589, 20µM CIG or a combination of both for 24h before cell viability was 
measured using MTT. (B) Cells were treated with 50nM LBH589, 60µM ROSIG 
or a combination of both for 24h before cell viability was measured using MTT. 
Values represent mean ± SD, n=3, *P<0.05 vs. control.  
 
 
3.8.3 Combination therapy of HDACi and PPARγ ligands increased 
apoptosis 
Furthermore, analysis of MCF7 and MDA-MB-231 cells treated with combination 
therapy of LBH589 and rosiglitazone via AnnexinV/PI staining showed a 
significant increase in the percentage of apoptotic cells upon combination 
treatment compared with each drug alone (Fig.49A). Increase in apoptosis of 
MCF7 and MDA-MB-231 cells by combination treatment was blocked by pre-
incubation with PPARγ antagonist GW9662 or transfection with dominant 
negative mutant PPARγ (Fig.50 and Fig.51). Taken together, these data suggest 
that HDACi renders breast cancer cells more susceptible to PPARγ activation by 
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its agonists and combination of HDACi and PPARγ agonists is effective in 




Figure 49. Synergistic increase in apoptosis upon combination treatment.  
Left: Annexin V/PI staining assay of MCF-7 and MDA-MB-231 cells treated with 
50nM LBH589, 20µM CIG, or both for 24h. Right: Annexin V/PI staining assay 
of MCF-7 and MDA-MB-231 cells treated with 50nM LBH589, 60µM ROSIG, 
or both for 24h. Values represent mean ± SD, n=3, *P<0.05 vs. control. 
 





















Figure 50. Synergistic increase in apoptosis upon combination treatment can 
be blocked with GW9662.  (A) Annexin V/PI staining assay of MCF-7 and 
MDA-MB-231 cells treated with 50nM LBH589 and 20µM CIG/60µM ROSIG 
for 24h +/- 4h pre-incubation of 10µM GW9662. (B) Representative graphs from 
(A). Values represent mean ± SD, n=3, *P<0.05 vs. control. 



























Figure 51. Synergistic increase in apoptosis upon combination treatment is 
blocked in cells with DN PPARγ. (A) Annexin V/PI staining assay of MCF-7 
and MDA-MB-231 cells transfected with control pcmx or DN PPARγ and treated 
with 50nM LBH589 and 20µM CIG/60µM ROSIG for 24h. (B) Representative 
graphs from (A). Values represent mean ± SD, n=3, *P<0.05 vs. control. 
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3.8.4 Combination therapy of HDACi and PPARγ ligands decreased 
angiogenesis 
PPARγ activation has been proposed to exhibit anti-angiogenic effects in tumor 
cells [149, 150], hence we hypothesized that HDACi could potentially enhance 
the inhibition of angiogenesis upon combination treatment with PPARγ agonists. 
We therefore sought to validate this effect in vitro using a tube formation assay 
with HUVEC endothelial cells. During angiogenesis, endothelial cells would 
transverse through the basement membrane to form new blood vessels. Formation 
of a well-defined capillary network would signify fully functional angiogenic 
properties. Tube formation ability was significantly decreased upon combination 
treatment of LBH589 and ciglitazone or LBH589 and rosiglitazone compared to 
each drug alone (Fig.52A). Number of tubes formed and number of branching 
points were significantly reduced upon combination treatment compared to each 
drug alone (Fig.52B-C). The inhibitory effect on angiogenesis was shown to be 
receptor-dependent by pre-incubation of GW9662, which was able to attenuate 
the decrease in tube formation upon combination treatment (Fig.53A). Effects on 
number of tubes formed and number of branching points were blocked with 



























Figure 52. Synergistic decrease in angiogenesis upon combination treatment. 
(A) Fluorescence microscopy images of tube formations of HUVEC cells treated 
with 50nM LBH589, 20µM CIG, 60µM ROSIG or a combination of LBH589 and 
CIG/ROSIG for 12h (x100 magnification). (B) Number of tubes from (A) was 
counted and plotted as a percentage from control. (C) Number of branching points 
from (A) was counted and plotted as a percentage from control. Values represent 
mean ± SD, n=3, *P<0.05 vs. control. 




















Figure 53. Decrease in angiogenesis upon combination treatment is PPARγ 
receptor-dependent. (A) Fluorescence microscopy images of tube formations of 
HUVEC cells treated with a combination of LBH589 and CIG/ ROSIG for 12h 
+/- 4h pre-incubation of 10µM GW9662 (x100 magnification). (B) Number of 
tubes from (A) was counted and plotted as a percentage from control. (C) Number 
of branching points from (A) was counted and plotted as a percentage from 
control. Values represent mean ± SD, n=3, *P<0.05 vs. control. 
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3.9 Effects of combination therapy of HDACi and PPARγ ligands in drug 
resistant breast cancer cells 
 
3.9.1 Overcoming Tamoxifen-resistant T47D breast cancer cells 
Development of resistance to endocrine therapy is a common occurrence for 
breast cancer patients, particularly among those with advanced or refractory 
disease. Therefore, we explored the therapeutic potential of combination therapy 
with HDACi and PPARγ ligands to combat drug-resistant breast tumor cells. In 
T47D A18 and 4-hydroxy-tamoxifen- resistant T47D (T47D A18 40HT) cells, 
PPARγ activity was markedly increased upon combination treatment with 
LBH589 and rosiglitazone/ciglitazone compared to each drug alone (Fig.54A). At 
the same time, cell viability was significantly decreased upon combination 
























Figure 54. Combination therapy in Tamoxifen-resistant T47D cells. (A) Left: 
PPARγ activity of T47D A18 and T47D A18 4OHT cells treated with 50nM 
LBH589, 20µM CIG, or both for 24h. Right: PPARγ activity of T47D A18 and 
T47D A18 4OHT cells treated with 50nM LBH589, 60µM ROSIG, or both for 
24h. (B) Left: Cell viability assay of T47D A18 and T47D A18 4OHT cells 
treated with 50nM LBH589, 20µM CIG, or both for 24h. Right: Cell viability 
assay of T47D A18 and T47D A18 4OHT cells treated with 50nM LBH589, 
60µM ROSIG, or both for 24h. (C) Light microscopy images of (B) (x200 
magnification). Values represent mean ± SD, n=3, *P<0.05 vs. control.  
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3.9.2 Overcoming ICI-resistant MCF7 breast cancer cells 
ICI (Fulvestrant) is an anti-estrogen that acts as an ERα antagonist and promotes 
degradation of the receptor, thus reducing ERα activity [23, 24]. In WS8 and 
MCF7 cells that are ICI -resistant (MCF7 ICI-R), PPARγ activity was also 
drastically increased upon combination treatment compared to each drug alone 
(Fig.55A). Percentage of cell viability was also significantly decreased upon 
combination treatment compared to each drug alone (Fig.55B-C). Taken together, 
these data indicate that the combination therapy of HDACi and PPARγ ligands is 
a possible approach to effectively overcome chemo-resistance in endocrine 




















Figure 55. Combination therapy in ICI-resistant MCF7 cells. (A) Left: PPARγ 
activity of WS8 and MCF7 ICI-R cells treated with 50nM LBH589, 20µM CIG, 
or both for 24h. Right: PPARγ activity of WS8 and MCF7 ICI-R cells treated 
with 50nM LBH589, 60µM ROSIG, or both for 24h. (B) Left: Cell viability assay 
of WS8 and MCF7 ICI-R cells treated with 50nM LBH589, 20µM CIG, or both 
for 24h. Right: Cell viability assay of WS8 and MCF7 ICI-R cells treated with 
50nM LBH589, 60µM ROSIG, or both for 24h. (C) Light microscopy images of 
(B) (x200 magnification). Values represent mean ± SD, n=3, *P<0.05 vs. control.  
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3.10 Effects of combination therapy of HDACi and PPARγ ligands in normal 
breast epithelial cells  
 
3.10.1 Normal breast epithelial cells are refractory to combination therapy  
Having observed the anti-tumor effects of combination treatment in breast tumor 
cell lines, we assessed the feasibility of applying this strategy in potential clinical 
applications by analyzing its effects in normal breast epithelial cells. Interestingly, 
treatment of LBH589 in normal breast epithelial cell lines MCF10A and 
MCF12A did not affect PPARγ expressions or activity levels (Fig.56). 
Furthermore, combination therapy with LBH589 and rosiglitazone / ciglitazone 
did not produce a synergistic effect in decreasing cell viability in normal breast 











Figure 56. Normal breast epithelial cells are refractory to LBH589 treatment. 
(A) Western blot analysis of MCF-10A and MCF-12A treated with 0, 50 and 
100nM LBH589 for 24h. (B) PPARγ activity of MCF-10A and MCF-12A cells 
treated with 0, 50 and 100nM LBH589 for 24h. Values represent mean ± SD, n=3.  
 


















Figure 57. Normal breast epithelial cells are refractory to combination 
treatment. (A) Left: Cell viability assay of MCF-10A and MCF-12A cells treated 
with 50nM LBH589, 20µM CIG, or both for 24h. Right: Cell viability assay of 
MCF-10A and MCF-12A cells treated with 50nM LBH589, 60µM ROSIG, or 
both for 24h. (B) Light microscopy images of (A) (x200 magnification). Values 
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3.11 Effects of combination therapy of HDACi and PPARγ ligands on PPARγ 
target genes 
 
3.11.1 Repression of PPARγ target genes 
We next went on to investigate the effect of combination therapy using LBH589 
and PPARγ ligands on the regulation of several reported PPARγ target genes. 
Real-time PCR revealed that relative mRNA levels of cell cycle regulatory genes 
survivin and cyclin D1 were synergistically down-regulated upon combination 
treatment in MDA-MB-231 and T47D cells compared to each drug alone 
(Fig.58A-B and Fig.59A-B). The mRNA levels of an anti-oxidant enzyme 
MnSOD, were also synergistically down-regulated (Fig.58C and Fig.59C). Also, 
there was significant down-regulation in the mRNA levels of VEGFA, a signal 
protein that stimulates angiogenesis (Fig.58D). Furthermore, mRNA levels of a 
tumor suppressor PTEN, were synergistically increased upon combination 
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Figure 58. RT-PCR of PPARγ target genes upon combination treatment in 
MDA-MB-231 cells. MDA-MB-231 cells were subjected to 50nM LBH589, 
20µM CIG, 60µM ROSIG or a combination of LBH589 and CIG/ROSIG for 24h. 
RT-PCR analysis of relative (A) BIRC5 (B) CyclinD1 (C) MnSOD (D) VEGFA 
mRNA levels normalized to 18S mRNA levels. Values represent mean ± SD, n=3, 
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A      B 
 
C      D 
 
 
Figure 59. RT-PCR of PPARγ target genes upon combination treatment in 
T47D cells. T47D cells were subjected to 50nM LBH589, 20µM CIG, 60µM 
ROSIG or a combination of LBH589 and CIG/ROSIG for 24h. RT-PCR analysis 
of relative (A) BIRC (B) CyclinD1 (C) MnSOD (D) PTEN mRNA levels 
normalized to 18S mRNA levels. Values represent mean ± SD, n=3, *P<0.05 vs. 
control. **P<0.01 vs. control. 
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3.11.2 Repression of PPARγ target genes is PPARγ receptor-dependent 
The protein levels were also shown to be down-regulated upon combination 
treatment in MDA-MB-231 cells, which was blocked by pre-incubation of the 
GW9662 inhibitor (Fig.60A). Repression of PPARγ target proteins was also 
shown to be receptor-dependent by transfection of a dominant negative mutant 
PPARγ receptor in MDA-MB-231 cells, which blocked the decrease in protein 




















Figure 60. Downregulation of PPARγ target proteins upon combination 
treatment is receptor-dependent. (A) Western blot of MDA-MB-231 treated 
with 50nM LBH589 and 20µM CIG/60µM ROSIG +/- 4h pre-incubation of 
10µM GW9662 for 24h. (B) Western blot of MDA-MB-231 transfected with 
pcmx or pcmx-DN PPARγ and treated with 50nM LBH589 and 20µM CIG/60µM 
ROSIG for 24h.  
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3.12 Regulation of Epithelial Mesenchymal Transition by MnSOD repression 
in breast cancer 
 
3.12.1 Downregulation of MnSOD promotes formation of tight colonies in 
TNBC cells 
When triple negative breast cancer cells MDA-MB-231 and BT549 were silenced 
with MnSOD siRNA, a long-term cell scattering assay revealed an increased 
tendency of cells to grow in tight colonies compared to highly scattered colonies 
in control cells. Close looks at the morphology showed that MDA-MB-231 and 
BT549 cells that are originally fibroblastic and elongated underwent 
morphological changes such that cells were more epithelial-like and polygonal in 
shape after MnSOD silencing. The percentage distribution of scattered colonies 
significantly decreased in cells after knockdown of MnSOD compared to the 
control cells (Fig.61 and Fig.62). These suggested the promotion of MET upon 
downregulation of MnSOD in MDA-MB-231 and BT549 cells, which originally 














Figure 61.  Cell scattering assay upon MnSOD suppression in MDA-MB-231 
breast cancer cells. MDA-MB-231 cells were transfected with ctsi or 100nM 
siMnSOD. Forty-eight hours post transfection 1000 cells were reseeded into 6-
well plates and grown for 2 weeks. (A) Top: Western blot to shown efficient 
knockdown of MnSOD. Bottom: Colonies were classified into 3 groups (tight, 
loose, scattered) based on intercellular distance between cells in a colony. 
Representative images (x10 and x20 magnification) were shown. (B) Numbers of 
colonies were counted and expressed as percentages of the total number of 
colonies formed. Results shown represent mean ± SD, n=3, *P<0.05 vs. control.  






Figure 62.  Cell scattering assay upon MnSOD suppression in BT549 breast 
cancer cells. BT549 cells were transfected with ctsi or 100nM siMnSOD. Forty-
eight hours post transfection 1000 cells were reseeded into 6-well plates and 
grown for 2 weeks. (A) Top: Western blot to shown efficient knockdown of 
MnSOD. Bottom: Colonies were classified into 3 groups (tight, loose, scattered) 
based on intercellular distance between cells in a colony. Representative images 
(x100 and x200 magnification) were shown. (B) Numbers of tight, loose and 
scattered colonies were counted and expressed as percentages of the total number 
of colonies formed. Results shown represent mean ± SD, n=3, *P<0.05 vs. control.  
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3.12.2 Downregulation of MnSOD promotes MET in mesenchymal-like 
breast cancer cells 
Based on the change in cell phenotype from a mesenchymal-like to an epithelial-
like phenotype in the triple negative breast cancer cell lines, we hypothesized that 
MnSOD has a role in regulating EMT. We then embarked on validating the 
change in EMT markers upon manipulation of MnSOD via siRNA silencing and 
plasmid overexpression studies. When MnSOD was suppressed in MDA-MB-231, 
RT-PCR revealed a downregulation in mRNA levels of mesenchymal markers 
such as Vimentin, Fibronectin and N-Cadherin compared to control cells. 
Transcription factors such as Snail, Twist, Zeb1 and Zeb2, were also significantly 
downregulated upon silencing of MnSOD (Fig.63). When western blot analysis 
was conducted in MDA-MB-231 and BT549, protein levels of mesenchymal 
markers such as N-Cadherin, Vimentin, Snail and Slug were decreased upon 
MnSOD suppression. In addition, levels of active β-catenin, involved in the Wnt 
signaling pathway to promote EMT [260], were also lowered. E-Cadherin protein 
levels were increased upon MnSOD silencing only in BT549 cells (Fig.64). 
Immunofluorescence staining also revealed lower expression levels of 
mesenchymal markers N-Cadherin and Vimentin after knockdown of MnSOD in 
MDA-MB-231 and BT549 (Fig.65 and Fig.66). 
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Figure 63. Real-time PCR of EMT-related genes upon MnSOD suppression 
in MDA-MB-231. MDA-MB-231 cells were transfected with control scrambled 
RNA (ctsi) or 100nM siMnSOD. Forty-eight hours post transfection cells were 
harvested and analysed by RT-PCR for relative mRNA levels of EMT-related 
genes normalized to GAPDH mRNA levels. Results are expressed as fold change 
against ctsi. Results shown represent mean ± SD, n=3, *P<0.05 vs. control. Note 
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Figure 64. Western blot analysis of EMT-related proteins upon MnSOD 
suppression in mesenchymal-like breast tumor cells. (A) MDA-MB-231 cells 
were transfected with control scrambled RNA (ctsi) or 100nM siMnSOD. Forty-
eight hours post transfection cells were harvested and analysed by western blot for 
β-catenin, Slug, N-Cadherin and Vimentin. Protein expressions of E-Cadherin 
were undetected. (B) BT549 cells were transfected with control scrambled RNA 
(ctsi) or 100nM siMnSOD. Forty-eight hours post transfection cells were 
harvested and analysed by western blot for β-catenin, Snail, and N-Cadherin, E-
Cadherin. β-actin was used as an endogenous control. 
MDA-MB-231 
BT 549 














Figure 65. Immunofluorescence staining of EMT-related genes upon MnSOD 
suppression in MDA-MB-231 cells. MDA-MB-231 cells were transfected with 
control scrambled RNA (ctsi) or 100nM siMnSOD. Forty-eight hours post 
transfection cells were reseeded on glass slides for immunofluorescence staining. 
(A) Red Vimentin staining and blue DAPI staining were viewed under confocal 
microscope. (B) Red N-Cadherin staining and blue DAPI staining were viewed 
under confocal microscope. Immunofluorescence images are representative of 
two independent experiments. 





Figure 66. Immunofluorescence staining of EMT-related genes upon MnSOD 
suppression in BT549 cells. BT549 cells were transfected with control scrambled 
RNA (ctsi) or 100nM siMnSOD. Forty-eight hours post transfection cells were 
reseeded on glass slides for immunofluorescence staining. (A) Red Vimentin 
staining and blue DAPI staining were viewed under confocal microscope. (B) Red 
N-Cadherin staining and blue DAPI staining were viewed under confocal 
microscope. Immunofluorescence images are representative of two independent 
experiments.  
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3.12.3 Downregulation of MnSOD inhibits migration in mesenchymal-like 
breast cancer cells  
EMT has long been associated with metastasis and studies have shown how 
reversal of EMT leads to a well-differentiated and epithelial-like phenotype in 
breast tumor cells, which reduces migration and hence metastasis [261]. Since we 
observed decreases in mesenchymal gene expression upon silencing of MnSOD in 
mesenchymal-like breast tumor cells, we hypothesized that cells undergoing MET 
would have crippled migratory abilities. We used a wound healing assay to 
examine the migration of the mesenchymal-like cells upon gene knockdown of 
MnSOD. A decrease in migratory ability was observed in MDA-MB-231 and 





















Figure 67. Migration assay upon MnSOD suppression in MDA-MB-231 
breast cancer cells. MDA-MB-231 cells were transfected with control scrambled 
RNA (ctsi) or 100nM siMnSOD. Forty-eight hours post transfection cells were 
reseeded in 60mm dishes and grown to 90% confluency. (A) Top: Western blot to 
show efficient knockdown of MnSOD. Bottom: A wound was made and images 
were taken at 0h, 24h, 48h and 72h to depict wound healing ability. (B) The gap 
distances between cells were measured at 3 separate regions. Results shown 
represent mean ± SD, n=3, *P<0.05 vs. control. 






Figure 68. Migration assay upon MnSOD suppression in BT549 breast 
cancer cells. BT549 cells were transfected with control scrambled RNA (ctsi) or 
100nM siMnSOD. Forty-eight hours post transfection cells were reseeded in 
60mm dishes and grown to 90% confluency. (A) Top: Western blot to show 
efficient knockdown of MnSOD. Bottom: A wound was made and images were 
taken at 0h, 24h, 48h and 72h to depict wound healing ability. (B) The gap 
distances between cells were measured at 3 separate regions. Results shown 
represent mean ± SD, n=3, *P<0.05 vs. control. 
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3.12.4 Downregulation of MnSOD inhibits invasion in mesenchymal-like 
breast cancer cells 
It has been reported that breast tumor cells that have undergone EMT would have 
enhanced invasive capacities such that cells would be able to invade through the 
extracellular matrix and enter the blood stream, achieving metastasis [262]. 
Therefore, we sought to determine the invasive abilities of mesenchymal-like 
breast tumor cells upon gene knockdown of MnSOD using an invasion chamber 
where cells seeded in the top chamber were prompted to invade to the lower 
chamber by using fetal bovine serum as an attractant. Results showed that 
suppression of MnSOD levels decreased invasion of MDA-MB-231 and BT549 






















Figure 69. Invasion assay upon MnSOD suppression in MDA-MB-231 breast 
cancer cells. MDA-MB-231 cells were transfected with control scrambled RNA 
(ctsi) or 100nM siMnSOD. Forty-eight hours post transfection cells were reseeded 
in into the upper chamber of a transwell invasion chamber with serum free media 
and grown for 48h. The membranes of the chambers were then stained with 
crystal violet solution and mounted on glass slides. (A) Top: Western blot 
analysis to show efficient knockdown of MnSOD. Bottom: Representative light 
microscopy images (x100) were shown. (B) The number of cells that invaded 
through the transwell invasion chambers were counted in five randomly selected 
microscope fields. Results shown represent mean ± SD, n=3, *P<0.05 vs. control. 






Figure 70. Invasion assay upon MnSOD suppression in BT549 breast cancer 
cells. BT549 cells were transfected with control scrambled RNA (ctsi) or 100nM 
siMnSOD. Forty-eight hours post transfection cells were reseeded in into the 
upper chamber of a transwell invasion chamber with serum free media and grown 
for 48h. The membranes of the chambers were then stained with crystal violet 
solution and mounted on glass slides. (A) Top: Western blot analysis to show 
efficient knockdown of MnSOD. Bottom: Representative light microscopy 
images (x100) were shown. (B) The number of cells that invaded through the 
transwell invasion chambers were counted in five randomly selected microscope 
fields. Results shown represent mean ± SD, n=3, *P<0.05 vs. control. 
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3.13 Regulation of Epithelial Mesenchymal Transition by increased MnSOD 
levels in breast cancer  
 
3.13.1 Overexpression of MnSOD promotes formation of scattered colonies 
in MCF7 cells 
Next, we went on to look at the cell morphology and phenotype after 
overexpression of MnSOD in epithelial-like MCF7 breast cancer cells that 
express low levels of the protein [259]. We sought to investigate if ectopic 
overexpression of MnSOD would promote the EMT program in epithelial-like 
breast tumor cells. In a long-term cell scattering assay that analyzes cell 
morphology and type of colony formation, MCF7 cells overexpressing MnSOD 
became more irregularly shaped, fibroblastic and elongated compared to the 
control MCF7 cells that are uniformly shaped and polygonal. Cell to cell distance 
was greatly lengthened with minimal cell contact points in cells with 
overexpressed MnSOD compared to tightly clustered control MCF7 cells. 
Percentage distribution of scattered colonies formed by cells upon MnSOD 














Figure 71. Cell scattering assay upon MnSOD overexpression in MCF7 
breast cancer cells. MCF7 cells were transfected with pcDNA3 vector or 
pcDNA3-MnSOD plasmid. Forty-eight hours post transfection 1000 cells were 
reseeded into 6-well plates and grown for 2 weeks. (A) Top: Western blot to 
shown efficient overexpression of MnSOD. Bottom: Colonies were classified into 
3 groups (tight, loose, scattered) based on intercellular distance between cells in a 
colony. Representative images (x100 and x200 magnification) were shown. (B) 
Numbers of colonies were counted and expressed as percentages of the total 
number of colonies formed. Results shown represent mean ± SD, n=3, *P<0.05 vs. 
control. 
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3.13.2 Overexpression of MnSOD promotes EMT in epithelial-like breast 
cancer cells 
Based on the observed changes in cell morphology from an epithelial-like to a 
mesenchymal-like phenotype in MCF7 cells after overexpression of MnSOD, we 
then went on to validate if MnSOD promotes EMT via an enhancement of EMT 
markers. Using RT-PCR to measure relative mRNA levels, overexpression of 
MnSOD in MCF7 downregulated epithelial marker E-Cadherin mRNA, 
upregulated mRNA levels of mesenchymal markers N-Cadherin, Fibronectin, 
Vimentin and active β-catenin, and also increased mRNA levels of transcription 
factors Snail, Zeb1 and Zeb2 (Fig.72). Western blot analysis also showed similar 
increases in protein levels of mesenchymal markers N-Cadherin, vimentin, active 
β-catenin, Snail and Slug (Fig.73). Immunoflurorescence staining showed reduced 
levels of E-Cadherin, increased expressions of mesenchymal genes N-Cadherin 
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Figure 72.  Real-time PCR of EMT-related genes upon MnSOD 
overexpression in MCF7 breast cancer cells. MCF7 cells were transfected with 
pcDNA3 vector or pcDNA3-MnSOD plasmid. Forty eight hours post transfection 
cells were harvested and analysed by RT-PCR for relative mRNA levels of EMT-
related genes normalized to GAPDH mRNA levels. Results are expressed as fold 
change against pcDNA3. Results shown represent mean ± SD, n=3, *P<0.05 vs. 
control. 
 
             
    
Figure 73. Western blot analysis of EMT-related proteins upon MnSOD 
overexpression in MCF7 breast cancer cells. MCF7 cells were transfected with 
pcDNA3 vector or pcDNA3-MnSOD plasmid. Forty-eight hours post transfection 
cells were harvested and analysed by western blot for β-catenin, Slug, Snail, N-
Cadherin and Vimentin. β-actin was used as an endogenous control. 














Figure 74. Immunofluorescence staining of EMT-related genes upon MnSOD 
overexpression in MCF7 breast cancer cells. MCF7 cells were transfected with 
pcDNA3 vector or pcDNA3-MnSOD plasmid. Forty-eight hours post transfection 
cells were reseeded on glass slides for immunofluorescence staining. (A) Red E-
Cadherin staining and blue DAPI staining were viewed under confocal 
microscope. (B) Red β-catenin staining and blue DAPI staining were viewed 
under confocal microscope. (C) Red N-Cadherin staining and blue DAPI staining 
were viewed under confocal microscope. (D) Red Vimentin staining and blue 
DAPI staining were viewed under confocal microscope. 
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3.13.3 Overexpression of MnSOD increases invasion of epithelial-like breast 
cancer cells  
Corresponding to a switch to a mesenchymal-like phenotype accompanied by an 
enhancement of mesenchymal genes and EMT transcription factors, we went on 
to validate an increased induction of the EMT program by measuring invasive 
abilities of MCF7 cells. Results showed that there was an increase in the number 
of cells that invaded through the invasion chamber after MCF7 cells were 
overexpressed with MnSOD (Fig.75). 







Figure 75. Invasion assay upon MnSOD overexpression in MCF7 breast 
cancer cells. MCF7 cells were transfected with pcDNA3 vector or pcDNA3-
MnSOD plasmid. Seventy-two hours post transfection cells were reseeded into 
the upper chamber of a transwell invasion chamber with serum free media and 
grown for 72h. The membranes of the chambers were then stained with crystal 
violet solution and mounted on glass slides. (A) Top: Western blot analysis to 
show efficient overexpression of MnSOD. Bottom: Representative light 
microscopy images (x100) were shown. (B) The number of cells that invaded 
through the transwell invasion chambers were counted in five randomly selected 
microscope fields. Results shown represent mean ± SD, n=3, *P<0.05 vs. control. 
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3.13.4 MDA-MB-231 DOX-R cells have upregulated mesenchymal genes 
compared to wild type cells 
Having validated that ectopic overexpression of MnSOD promotes EMT in MCF7 
breast tumor cells, we were interested to investigate if MDA-MB-231 cells that 
were rendered resistant to DOX and exhibit upregulated basal MnSOD levels 
have an enhanced mesenchymal gene signature. Using RT-PCR, we showed that 
mRNA levels of mesenchymal genes such as vimentin, fibronectin, N-Cadherin 
and active β-catenin, and transcription factors such as Twist, Zeb1 and Zeb2, were 
further enhanced in MDA-MB-231 DOX-R cells compared to wild type cells. 
Protein levels also corresponded to the changes in mRNA levels (Fig.76 and 
Fig.77). 
 
Figure 76. Real-time PCR of EMT-related genes in MDA-MB-231 wild type 
versus DOX-R cells. Relative mRNA levels of EMT-related genes were 
normalized to GAPDH mRNA levels. Results are expressed as fold change 
against wild type cells. Results shown represent mean ± SD, n=3, *P<0.05 vs. 
control. 
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Figure 77. Western blot analysis of EMT-related proteins in MDA-MB-231 
wild type versus DOX-R cells. Western blot analysis for β-catenin, Snail, Slug, 
N-Cadherin and Vimentin. β-actin was used as an endogenous control.	  
 
 
3.13.5 MDA-MB-231 DOX-R cells have higher migration ability compared to 
wild type cells 
Since MDA-MB-231 DOX-R cells exhibit increased levels of EMT-related genes 
compared to wild type cells, we went on to determine if DOX-R cells would 
migrate faster than wild type cells.  Using a wound healing assay to measure 
migration ability, DOX-R cells were indeed more migratory than their parental 
cells, with a significant shortening of the gap caused by the “wound” between 
DOX-R cells compared to parental MDA-MB-231 cells (Fig.78). 
 
 






Figure 78. Migration assay of MDA-MB-231 wild type versus DOX-R cells. 
Cells were seeded in 60mm dishes and grown to 90% confluency. (A) Top: 
Western blot to show protein levels of MnSOD. Bottom: A wound was made and 
images were taken at 0h, 24h, and 36h to depict wound healing ability. (B) The 
gap distances between cells were measured at 3 separate regions. Results shown 
represent mean ± SD, n=3, *P<0.05 vs. control. 
	   164	  
3.13.6 MDA-MB-231 DOX-R cells have higher invasive ability compared to 
wild type cells 
Besides increased migratory ability, cells that have an enhanced EMT program 
would be expected to have high invasive capacities as well. We then investigated 
if MDA-MB-231 DOX-R cells, which have higher expressions of EMT-related 
genes compared to the parental MDA-MB-231 cells, are also more invasive. 
Results showed that number of cells that invaded through the invasion chamber 
was significantly higher for MDA-MB-231 DOX-R cells than wild type MDA-
























Figure 79. Invasion assay of MDA-MB-231 wild type versus DOX-R cells.	  
Cells were seeded into the upper chamber of a transwell invasion chamber with 
serum free media and grown for 24h. The membranes of the chambers were then 
stained with crystal violet solution and mounted on glass slides. (A) Top: Western 
blot analysis to show protein levels of MnSOD. Bottom: Representative light 
microscopy images (x100) were shown. (B) The number of cells that invaded 
through the transwell invasion chambers were counted in five randomly selected 
microscope fields. Results shown represent mean ± SD, n=3, *P<0.05 vs. control.	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CHAPTER 4 DISCUSSION 
 
4.1 MnSOD expression is associated with more aggressive sub-type of breast 
cancer 
Across a panel of breast epithelial cell lines, we observed higher levels of 
MnSOD mRNA and protein in the triple negative breast cancer cell lines such as 
MDA-MB-231 and BT549, compared to ERα+ cell lines MCF7 and T47D. The 
triple negative cell lines have been shown to closely resemble basal-like 
molecular subtype of breast cancer while the ERα+ cell lines are associated with 
luminal A or B molecular subtypes [263]. In line with the in vitro data, 
hierarchical clustering of microarray data also revealed that MnSOD expression 
was significantly different in the various subtypes of breast carcinoma. The basal-
like / claudin-low breast carcinoma subtypes often associated with the more 
aggressive triple negative breast cancer tumors had a significantly higher MnSOD 
expression than the luminal breast carcinoma subtypes (Supp.Fig.1).  
 
Evidence from a host of earlier studies suggested a tumor suppressor role for 
MnSOD [264-266]; however, the fact that MnSOD is overexpressed in a variety 
of cancers such as thyroid tumors, neuroblastomas, gastric and colorectal 
carcinomas [80, 83, 84] argues in favor of a complex functional biology of this 
protein in the various stages of cancer development and progression. Moreover, 
we as well as others have reported elevated levels of MnSOD in basal breast 
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cancer cell lines, MDA-MB-231 and BT-549, compared to luminal cell lines 
MCF-7 and T47D, and non-tumorigenic cell lines, MCF-12A and MCF-10A [69, 
91]. Hence, the correlation between MnSOD expression and tumor aggressiveness 
suggests the possibility of distinctly different expression patterns and anti-oxidant 
functions depending on the stage of the tumor. This dual role of MnSOD was 
recently demonstrated in a model of skin carcinogenesis where MnSOD 
expression was suppressed at very early stage but increased at the late stage of the 
skin carcinoma [88]. Activation of p53-mediated transcriptional repression of 
MnSOD, increased NFkB binding and decreased Sp1 (Specificity protein 1) 
binding to the MnSOD promoter, have been proposed as mechanisms responsible 
for low MnSOD levels during early tumorigenesis [67, 267, 268]. In advanced 
stage tumors, p53 is usually reduced or mutated [269, 270], thus allowing for Sp1 
binding to MnSOD promoter and increasing its levels. It is plausible that, similar 
to the development of skin carcinoma, MnSOD may be involved in the 
suppression of the early development of breast cancer but an increase in MnSOD 
expression is required for the acquisition of a more aggressive phenotype. A 
higher MnSOD expression would confer tumor cells with greater antioxidant 
capacity to cope with higher levels of oxidative stress [102, 271], a pre-dominant 
feature associated with higher tumor aggression.  
 
Therefore, therapeutic strategies targeting MnSOD may need to be tailored in a 
subtype-specific manner. For example, the ERα+ breast cancer might not be 
responsive to changes in MnSOD expression while the basal-like breast cancer 
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could be more vulnerable to a decrease in MnSOD expression. This is further 
reinforced by the clinical outcomes data obtained from the TCGA database 
demonstrating that within the basal-like subtype, patients with lower expressions 
of MnSOD have a better survival than patients with higher expressions of 
MnSOD (Supp.Fig.2). This trend is also observed in patients with lung 
adenocarcinomas, where patients with MnSOD-negative tumors had better overall 
survival and relapse-free survival [92]. These data provide impetus to the idea that 
within the basal-like breast carcinoma subtype, high MnSOD expression could be 
a prognostic marker for poor survival.  
 
 
4.2 MnSOD expression is associated with chemo-sensitivity in triple negative 
breast cancer 
Indeed, supporting the critical role of MnSOD expression in the survival of 
TNBC cells and in agreement with a previous report [69], silencing of MnSOD 
using gene-specific siRNA was associated with a decrease in the colony forming 
ability of MBA-MD-231 and BT549 cell lines. Interestingly, a previous study 
showed that the expression of MnSOD was an important factor in the response of 
gastric cancer cells to 5-flurouracil [255].  In line with this study, we observed a 
significant increase in sensitivity to docetaxel and doxorubicin when MnSOD was 
suppressed in TNBC cells. Also, in breast cancer cells rendered resistant to 
docetaxel and doxorubicin, we observed increases in the basal MnSOD 
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expressions. A study by Suresh et al. showed using the inverse approach where 
overexpression of MnSOD increased resistance of melanoma and lymphoma cell 
lines to doxorubicin treatment [272]. Our results are also in line with a study 
where overexpression of cyclin E is associated with increased MnSOD 
expressions and elevated resistance to doxorubicin [273]. More importantly, upon 
repression of MnSOD via siRNA silencing or pharmacological reduction, chemo-
sensitivity was restored in the drug-resistant cells. This suggests a vital role of 
MnSOD expression as a prognostic marker of response to chemotherapy and 
reveals MnSOD as a promising target in the treatment of TNBC. Hence, this 
propels the search for viable modes of targeting MnSOD in breast carcinoma.  
 
 
4.3 PPARγ activation: a promising approach to downregulate MnSOD 
expression in triple negative breast cancer 
Intrigued by our findings linking MnSOD expression to chemo-resistance, we set 
out to search for a clinically relevant approach to specifically decrease MnSOD 
expression in our model cell lines of TNBC.  To that end, we recently reported the 
presence of three putative Peroxisome Proliferator Response Elements (PPREs) in 
the human MnSOD promoter and provided experimental evidence that human 
MnSOD was, indeed, a PPARγ target gene [62]. Of note, among the three PPAR 
isoforms, PPARγ activation has been shown to inhibit the proliferation of 
malignant cells from different lineages such as liposarcoma [133], breast 
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adenocarcinoma [122, 134, 274], prostate carcinoma [136] and colorectal 
carcinoma [143]. Herein we present evidence that activation of PPARγ, either via 
its physiological ligand or upon exposure to the synthetic ligands, resulted in 
repression of MnSOD in the basal type breast cancer cell lines (MDA-MB-231 
and BT-549) in vitro. This result was further supported by the work of our 
collaborators in a MDA-MB-231 xenograft model (Supp.Fig.3). When MDA-
MB-231 mice xenografts were treated with 15d-PGJ2, tumor size and weight 
decreased and immumohistochemical analysis of tumor tissues stained for 
MnSOD antigens showed reduced MnSOD expressions in 15d-PGJ2-treated mice 
compared to control mice. These data provide physiological evidence suggesting 
that reduction in MnSOD parallels the antitumor activity of 15d-PGJ2 and that 
MnSOD repression could be crucial to the killing mechanism induced upon 
PPARγ activation. 
 
We went on to show that the decrease in MnSOD levels was dependent on PPARγ 
receptor and is not just an off-target effect. Synthetic ligands ciglitazone and 
rosiglitazone were tested and downregulated MnSOD expressions in a similar 
receptor-dependent fashion. Moreover as a “proof of concept” using a cohort of 
diabetic breast cancer patients treated with rosiglitazone, a study done by our 
collaborators validated that patients on rosiglitazone treatment expressed reduced 
levels of MnSOD in their breast tumor tissues compared to their normal tissues 
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(Supp.Fig.4). These data provide strong evidence that the repression of MnSOD 
by PPARγ activation occurs not only in vitro, but also in vivo.  
 
In addition, it is interesting to note that MnSOD levels remained unchanged in 
normal cells upon PPARγ, possibly due to low PPARγ activity and expression 
levels that were detected. This suggests a selective advantage of using PPARγ 
ligands to target tumor cells as repression of MnSOD occurs specifically in tumor 
cells and not normal cells. It also highlights the fact that PPARγ ligands should 
only be used in breast cancer patients with a high level of functional PPARγ 
receptor so as to ensure that PPARγ-induced MnSOD repression will occur.  
 
 
4.4 Repression of MnSOD upon PPARγ activation enhances chemo-
sensitivity of triple negative breast cancer 
When a decrease in MnSOD was induced upon PPARγ activation, the sensitivity 
of TNBC cell lines to docetaxel and doxorubicin was significantly enhanced. In 
DOC- and DOX- resistant cell lines, repression of MnSOD by PPARγ activation 
was able to overcome the chemo-resistance. Interestingly, a previous report had 
demonstrated synergism between PPARγ activation and carboplatin in lung 
cancer cells; however, the target and exact mechanism of the increased chemo-
sensitivity remained elusive [275, 276]. We then showed that MnSOD repression 
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is instrumental to the effectiveness of the chemo-sensitization as overexpression 
of MnSOD blocked the synergistic decrease in cell viability. Importantly, we 
demonstrated that chemo-sensitization to docetaxel and doxorubicin does not 
occur in normal breast epithelial cells. At the same time, we observed that 
MnSOD levels remained unchanged, which suggests the presence of an 
unwavering antioxidant defense system to cope with the oxidative insults. 
Therefore, our results not only implicate MnSOD repression in the anti-tumor 
activity of PPARγ activation in basal-like breast cancer, but also provide evidence 
that the repression of this important anti-oxidant protein is instrumental to this 
chemo-sensitization therapy. The next mystery then lies in the mechanism behind 
suppressing MnSOD levels and its impact on chemo-sensitivity.  
 
 
4.5 Repression of MnSOD enhances chemo-sensitivity via mitochondrial 
ROS generation 
As MnSOD is an important anti-oxidant protein expressed in the mitochondria, a 
logical explanation for these effects could be that an altered expression of 
MnSOD changes the redox milieu of cells, which could account for the varied 
responses to drug treatment.  Indeed, repression of MnSOD by small-interfering 
RNA (siRNA) was accompanied by an increase in mitochondrial O2.- production 
in tumor cells. This accumulation of O2.- could be due to decreased MnSOD levels 
as cells are less able to get rid of O2.- generated by sources such as mitochondrial 
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respiratory chain, glucose autoxidation, NAD(P)H oxidase and cyclooxygenase 
enzymes [70]. Interestingly, there was no increase in O2.- observed in normal cells 
after suppression of MnSOD. This result was also reported in a study by Yeung et 
al. [96]. This difference could be due to the Warburg effect as cancer cells are 
under intrinsic oxidative stress and possess a significantly higher antioxidant 
capacity than their normal counterparts [277]. Coupled to this is the observation 
that the cellular levels of other antioxidant enzymes such as glutathione 
peroxidase, are significantly lower in tumor cells compared to normal cells [69]. 
Thus, the intrinsic vulnerability of tumor cells provides a window for potential 
therapeutic exploitation.    
 
It has been well established that PPARγ ligands can inhibit cell growth and induce 
the differentiation or death of tumor cells [278]. However, the mechanism of cell 
death is still unclear. Studies have reported that production of ROS is closely 
associated to PPARγ-induced cytotoxicity, but the species of ROS is not well 
defined. It is also not entirely clear whether the effect on intracellular ROS is 
linked to the transcriptional activity of the active nuclear receptor or a bystander 
effect. A number of possible mechanisms of PPARγ-induced increase in 
intracellular ROS have been proposed (Table 1), suggesting that altering redox 
homeostasis to activate apoptotic pathways is closely associated with PPARγ-
induced cytotoxicity.  In this study, we looked at the ROS production in human 
breast carcinoma cell lines when exposed to PPARγ activation. Our results 
showed a marked increase in mitochondrial O2.- production in tumor cells 
	   174	  
corresponding to an increase in PPARγ activity following exposure to the PPARγ 
ligands. This result, as well as a study by Martinez et al. also confirmed the site of 
ROS production induced by 15d-PGJ2 as the mitochondrion [279]. Conversely, 
mitochondrial O2.- levels did not change significantly in normal breast cells 
treated with 15d-PGJ2 . This could be due to the significantly lower expression of 
PPARγ in the non-transformed cells, thereby rendering them insensitive to low 
concentrations of 15d-PGJ2, unlike tumor cells. This is further supported by the 
insignificant change in PPARγ activity when non-transformed cells were exposed 
to increasing doses of 15d-PGJ2, thus strengthening the therapeutic potential of 
specifically targeting tumor cells with PPARγ ligands. These data also suggest 
that MnSOD repression upon PPARγ activation could be responsible for 
mediating the ROS induction.  
 
Furthermore, we investigated if 15d-PGJ2’s effects on increase in O2.- and 
MnSOD repression in tumor cells are PPARγ-dependent by using GW9662. 
GW9662 is a potent and selective antagonist of PPARγ by covalent modification 
of the cysteine (285) residue in the PPARγ ligand binding domain [280]. Results 
showed that increase in mitochondrial O2.- production was abrogated upon pre-
incubation with GW9662. To provide further evidence, overexpression of a 
dominant-negative form of PPARγ prevented the downregulation of MnSOD in 
response to 15d-PGJ2. Therefore, these results show that production of O2.- and 
MnSOD repression by 15d-PGJ2 in tumor cells are PPARγ-dependent. Moreover, 
MnSOD overexpression blocked the intracellular ROS influx induced by PPARγ 
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activation. Therefore, these results support the correlation between MnSOD 
repression upon PPARγ activation, and increased oxidative stress in tumor cells. 
It also provides an explanation for other studies that associated MnSOD 
deficiencies to an increase in mitochondria ROS production [100, 281, 282]. 
 
Most importantly, this increase in mitochondrial ROS via repression of MnSOD 
appears to be an effector mechanism in the significant synergism observed in the 
combined use of PPARγ ligands and chemotherapeutic agents doxorubicin and 
docetaxel. We observed not only an increase in sensitivity towards cell death, but 
also an amplification of mitochondria ROS, knowing that MnSOD is repressed 
and docetaxel and doxorubicin are known inducers of oxidative stress. A similar 
mechanism might explain the observed synergy between rosiglitazone and 
carboplatin in lung carcinoma, considering that carboplatin and other platinum-
based compounds trigger an increase in mitochondrial ROS [283]. 
Overexpression of MnSOD overcame the increase in mitochondrial ROS, 
indicating the importance of this key antioxidant protein in the effectiveness of 
this “oxidative stress therapy”.  
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4.6 Repression of MnSOD enhances chemo-sensitivity via formation of RNS 
peroxynitrite 
Besides an increase in mitochondrial O2.- induced by repression of MnSOD levels 
in MDA-MB-231 cells, we also detected an influx of reactive nitrogen species 
upon combination treatment. This led us to suspect the involvement of 
peroxynitrite, formed by the reaction between mitochondria-derived O2.- and NO. 
The presence of ONOO- was validated by the use of RNS scavenger L-NMMA 
and peroxynitrite decomposition catalyst FeTPPS, which effectively attenuated 
the chemo-sensitization. Similar reports of peroxynitrite being an effector 
molecule in inducing oxidative damage and cancer cell cytotoxicity [284-286] 
might explain the mechanism behind the combination treatment of PPARγ ligands 
and docetaxel or doxorubicin. ONOO- was demonstrated to activate the caspase 
cascade by induction of p53 and MAPK-mediated pathways. Disruption of 
mitochondrial membrane stability by ONOO- inducing the opening of 
mitochondrial pores has also been reported. These independent studies provide 
precedence to the possible involvement of ONOO- in the enhanced chemo-
sensitivity of basal-like breast carcinoma upon targeting MnSOD expression by 
PPARγ ligands. Therefore, we show for the first time, a mechanism that accounts 
for the induction of mitochondrial ROS and ultimately leads to the formation of a 
potent RNS ONOO-.  
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In conclusion, the first part of our study provides evidence for the tumor-specific 
repression of MnSOD upon PPARγ activation in vitro and in vivo. We have 
shown the novel association between repression of MnSOD and increase in 
intracellular ROS. This study shows for the first time, that MnSOD repression is 
linked to the production of mitochondria O2.-, which combines with nitric oxide to 
form a highly cytotoxic RNS peroxynitrite. ONOO- could in turn play a key 
contributing factor to the cytotoxic effects of PPARγ ligands and enhancing 
chemo-sensitivity to ROS-inducing drugs [144]. Thus we propose this potential 
therapeutic strategy to eliminate cancer cells through the exploitation of PPARγ 
agonists to target MnSOD and increase intracellular ROS, a unique strategy also 
termed as “tumor-specific oxidative stress therapy” (Fig.80).  
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Figure 80. Model of “tumor-specific oxidative stress therapy” against triple 
negative breast carcinoma. Use of PPARγ ligands lead to downregulation of 
MnSOD, which induces mitochondrial O2.-. O2.- combines with NO to form 
ONOO-, which works synergistically with DOC and DOX to induce cell death 
and inhibit proliferation in breast cancer cells.  
 
The challenge to the application of this “oxidative stress therapy” in the clinical 
treatment of breast cancer lies in the lack of a safe and efficacious PPARγ ligand. 
Troglitazone and rosiglitazone have been associated with increased risk of 
myocardial infarction and congestive heart failure in the treatment of Type 2 
diabetes mellitus, thus leading to their withdrawal by the European Medicines 
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Agency and FDA [287]. This leaves pioglitazone as the only TZD available for 
clinical use [288]. Therefore, the search for safer and more potent PPARγ agonists 
is of paramount importance. Recently, a novel PPARγ ligand efatutazone, has 
been introduced in Phase I trials for the treatment of patients with thyroid cancer 
and advanced solid malignancies and it has demonstrated biologic anti-tumor 
activity with acceptable tolerability [167, 289].  Ohashi et al. have also developed 
a series of PPARγ partial agonists that are structurally derived from pioglitazone 
and exhibit higher potencies against human gastric cancer cells compared to 
troglitazone [290]. These indicate that the despite the withdrawal of many TZDs 
for treatment of Type 2 diabetes mellitus, the era of PPARγ agonists as anti-
tumors agents is still ongoing and much potential still remains to be uncovered.  
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4.7 Epigenetic regulation via HDACs in breast cancer 
Histone deacetylases play a complex role in the epigenetic control of tumor cells. 
Deregulated or aberrant expressions of various HDACs have been reported in 
many cancers, thus making them important targets for cancer therapy [291]. In an 
analysis of breast carcinoma patient samples performed by a collaborating 
laboratory, HDAC1 and HDAC2 are significantly expressed in the basal subtype; 
HDAC1, HDAC3 and HDAC8 are highly expressed in the luminal-A subtype; 
and luminal-B subtype has high expressions of HDAC1 (Supp.Fig.5A-E). This is 
in line with published data that HDAC1 and HDAC2 are overexpressed in breast 
cancer [292] and HDAC1 expression correlates with estrogen and progesterone 
receptor expressions, making it a potential prognostic marker [293, 294]. HDAC2 
was also identified as a key contributor to tumor pathogenesis due to high 
expressions among malignant and slightly mesenchymal tumors [295]. In cell line 
studies, overexpression of HDAC1, HDAC6 or HDAC8 has been reported to 
increase cell invasion and MMP9 expression in breast cancer [296], further 
demonstrating HDACs to be potential targets for breast cancer therapy. 
 
HDAC inhibitors have been widely utilized in cell line and animal models of solid 
tumors. HDACi was shown to promote hyperacetylation of non-histone targets 
such as transcription factors and other proteins involved in cell cycle progression. 
HDACi was also reported to induce growth arrest, differentiation, and/or 
apoptosis, inhibit angiogenesis and decrease invasion and metastasis in tumor cell 
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lines, both singly as well as in combination with chemotherapeutic drugs, 
autophagy inhibitors, radiation and other agents [297-300]. Use of valproic acid in 
human ovarian carcinoma exhibited growth inhibitory effects via perturbations of 
cell cycle and also induced apoptosis via activation of caspase 9 and caspase 3 
[301]. Furthermore, the unique distinction from other cancer therapeutic agents is 
that HDACi can induce tumor cell death in both the proliferative and non-
proliferative phases of the cell cycle [302]. HDACi has also been used to inhibit 
tumor development by attenuation of angiogenesis and tumor cell proliferation in 
rodents [303-305]. Carew et al. showed that vorinostat induced cell death and 
autophagy in imatinib-resistant chronic myelogenous leukemia (CML) via 
superoxide generation [306].  
 
This led to the introduction of HDACi in clinical studies for cancer therapy across 
a wide range of cancer types. Vorinostat was the first HDACi to be approved by 
FDA for clinical treatment of cutaneous T-cell lymphoma. At present, there are 
over a 100 ongoing clinical trials involving HDACi in hematologic malignancies 
and solid tumors. However, the superior antitumor activity in in vitro cancer 
models could only be moderately translated as monotherapy of HDACi in clinical 
trials. Studies carried out for various human cancers such as renal cell cancer, 
ovarian cancer and mesothelioma have showed conflicting results with limited 
efficacy [307-309].  
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There have been several reasons proposed for the discrepancy between preclinical 
and clinical outcomes. One reason is that HDACi have been shown to increase 
transcription of both pro- as well as anti-apoptotic genes, therefore the overall 
efficacy of HDACi would be compromised depending on the final balance of 
transcribed genes [310]. Resistance to HDACi has also been suggested due to 
drug efflux, epigenetic alterations, increase in antioxidant enzymes and induction 
of anti-apoptotic and pro-survival mechanisms [311, 312]. Another reason could 
be due to a lack of specificity for a HDAC isoform that could be a causative factor 
in a particular cancer as available HDACi are at best only class-specific [313]. 
The class of HDACs that is dysregulated also varies across cancer types, thus the 
HDACi used in cancer treatment is also an important consideration as some 
HDACi are specific for a class of HDACs while some are pan-HDAC inhibitors. 
It is still unclear if selective targeting of a particular HDAC is more efficacious 
compared to a pan-HDACi such as panobinostat [171].  
 
 
4.8 PPARγ is epigenetically regulated by HDACs in breast tumor cells  
HDACs have likewise been implicated in epigenetic regulation of PPARγ. Gene 
analysis in breast cancer patient samples showed that PPARγ had a significant 
inverse correlation with HDAC1 and HDAC2 (Supp.Fig.5F-J). We also 
demonstrated that HDACi LBH589 treatment in breast cancer cells increased the 
acetylation status of PPARγ, corresponding to dose-dependent increases in 
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PPARγ activity. This is in line with a recent paper showing that a Class III HDAC 
Sirtuin I, is able to deacetylate PPARγ, thus affecting its activity [314]. Studies 
also revealed that transcriptional co-repressors such as HDAC1 and HDAC3 
modulate PPARγ activity in adipose cells [191, 315]. In neurons, HDAC4 has 
also been identified as a co-repressor of PPARγ [316]. Furthermore, LBH589 
induced dose and time dependent increases in PPARγ mRNA and protein 
expressions in a series of breast cancer cell lines, suggesting a possible strategy of 
targeting breast cancer cells with a combination of HDACi and PPARγ ligands.  
The increase in PPARγ activity by LBH589 treatment was receptor-dependent, 
showing that the induction is not an off-target effect of the HDAC inhibitor.  
 
ERα receptor has been suggested to interfere with PPARγ activation due to ERα 
binding at the promoters of PPARγ target genes [317], thus making PPARγ 
ligands less effective against ERα-positive breast cancer cells. However, ERα 
receptor expression was decreased upon LBH589 treatment in ERα-positive 
breast cancer cells, thus rendering them “receptor-negative” and their PPARγ 
receptors available for targeting using PPARγ agonists. Decreases in ERα mRNA 
and subsequently protein levels have been reported in several studies, affirming 
the observed results [318, 319].  
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4.9 Combination treatment of HDACi and PPARγ ligands in breast cancer 
Combination of HDACi with other agents has yielded much more favorable 
outcomes. This could be due to the multiple protein targets of HDACs, and 
therefore, a synergistic activity when used in combination with other anticancer 
agents. It is also suggested that HDACi modulate epigenetic alterations that are 
transient and subtle, thus anti-tumor efficacy is only observed in combination 
therapy [302]. Indeed, a recent trial published by Munster et al. demonstrated that 
vorinostat and tamoxifen achieved tumor regression in 40% of breast cancer 
patients who had earlier progressed on despite hormonal and chemotherapy [320]. 
HDACi magnesium valproate was also combined with chemotherapy in clinical 
studies, which achieved good response and disease stabilization rates [187, 321]. 
These could be attributed to an increased sensitivity to chemotherapy after 
overcoming epigenetic modifications with HDACi. These studies therefore 
indicated that use of HDACi in combination therapies might produce better 
results in clinical studies.  
 
The combination of HDACi and PPARγ ligands has been utilized in several 
studies [190, 322, 323]. In prostate cancer, HDAC3 was shown to be complexed 
with PPARγ in the promoters of target genes, inhibiting PPARγ from ligand 
activation. It was hypothesized that HDACs are fully active in prostate cancer 
cells and thus, PPARγ activity was repressed even in the presence of ligands [190]. 
Therefore, we set out to test this hypothesis in breast cancer based on a 
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bioinformatics prediction study done by our collaborators showing that 
combination treatment decreased tumor volume, proliferation, cell viability and 
angiogenesis (Supp.Fig.6A). We validated these predictions using in vitro cell 
line work by showing that the combination treatment induced synergistic 
increases in PPARγ activity and apoptosis, decreased cell viability, and inhibited 
angiogenesis in breast cancer cell lines. In ERα+ breast cancer models, HDACi 
increased the activity and expression levels of PPARγ such that when exposed to 
PPARγ agonists, the effects of PPARγ signaling pathway were synergistically 
amplified. In ERα- breast cancer cell lines that already express high levels of 
PPARγ, HDACi treatment further accentuated the activity and expressions of 
PPARγ. Therefore, lower doses of PPARγ ligands could be used to produce 
potent anti-tumor effects in combination, thus enhancing the safety profile of this 
strategy. This combination overcomes problems with the ineffectiveness of using 
HDACi or PPARγ ligands as monotherapy and also reduces the likelihood of 
adverse events associated with the use of high doses of PPARγ agonists. The 
synergistic effects of the combination therapy were also proven to be PPARγ-
dependent effects via various approaches, suggesting that the strategy might be 
effective only in breast cancer patients with functional PPARγ receptors. If we 
were to take this regimen one step forward into a clinical study, initial selection of 
patients via screening of PPARγ expression would be an indispensible step.  
 
These data are supported by previous studies showing that treatment of HDACi 
and PPARγ ligands was able to synergistically inhibit proliferation and induce 
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cell death in cancer cells [324-327]. Inhibition of angiogenesis upon PPARγ 
activation was also evident in a study by Keshamouni et al. whereby inhibition of 
angiogenic chemokines was mediated by antagonizing NF-kB activation [328]. 
Hence, the amplification of PPARγ-induced anti-angiogenic property by HDACi 
treatment is expected to have a pronounced effect on inhibition of angiogenesis.  
 
The combination therapy also provided an alternative route to overcome drug 
resistance in breast carcinoma. Tamoxifen and ICI are standard treatment options 
for ERα-positive breast cancer patients, but a substantial population of patients, 
especially those with advanced disease, will develop de novo or acquired 
resistance [329, 330]. Our results showed that in Tamoxifen-resistant T47D cells 
and ICI-resistant MCF7 cells, combination treatment of HDACi LBH589 and 
PPARγ ligands was able to decrease cell viability significantly and was as 
effective in the drug-resistant cells as in their parental cells. This is in line with a 
previous study by Fiskus et al. who demonstrated degradation of ERα and 
acetylation of Hsp90 by HDACi hydroxamic acid, which abolished phospho-
ERK1/2 and Akt-mediated resistance to tamoxifen in breast cancer cells [331]. 
Results from our study also suggest that combination of HDACi and nuclear 
receptor-targeted agents could be extended to other nuclear receptor-related 
cancers such as prostate cancer, where HDACi attenuated Androgen receptor (AR) 
synthesis and signaling, and induced apoptosis upon combination with anti-
androgens [332]. Another study in retinoic acid-resistant melanoma cell lines also 
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validated the reversal of epigenetic repression of retinoic acid receptor beta 
(RARβ) by HDACi and restored sensitivity to retinoids [333]. 
 
Importantly, normal epithelial breast cell lines were refractory to the effects of 
combination treatment of HDACi and PPARγ ligands. There were no increases in 
PPARγ activity or expression levels upon LBH589 treatment in MCF10A and 
MCF12A cells. In addition, there were no synergistic decreases in cell viability 
upon combination treatment with PPARγ ligands. This result is supported by 
previous studies, which also reported a lack of sensitivity of normal cells to 
HDACi treatment [334, 335]. This showed that the combination strategy is 
specific for breast tumor cells and did not affect the normal breast epithelial cells, 
which is crucial for a clinically relevant treatment option.  
 
 
4.10 Repression of PPARγ target genes upon combination treatment of 
HDACi and PPARγ agonists 
Upon closer examination of a list of downstream PPARγ target genes, predictive 
proteomics analysis carried out by our collaborators using a virtual epithelial 
tumor cell platform revealed that combination of HDACi LBH589 and PPARγ 
ligand showed reductions in biomarkers such as Cyclin D1, Akt, BCL2, VEGFA 
and Survivin (Supp.Fig.6B). Upon validation in breast cancer cells, there were 
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synergistic downregulation of Survivin and CyclinD1 mRNA levels upon 
combination of HDACi and PPARγ ligands compared to each drug alone, 
contributing to inhibitory effects on cell proliferation and induction of apoptosis. 
Levels of tumor suppressor PTEN, a dual phosphatase that antagonizes PI3K and 
decreases Akt activity, were increased synergistically by HDACi and PPARγ 
ligand treatment. This contributes to the inhibition of cell proliferation via the 
PI3K/Akt signaling pathway. MnSOD mRNA levels were also downregulated, 
which would contribute to a drastic crippling of antioxidant defense capacities 
and enormous increases in oxidative stress in tumor cells. Relative mRNA levels 
of VEGFA, a key stimulant of angiogenesis, were also downregulated upon 
combination treatment, contributing to the inhibitory effects on angiogenesis. This 
would have severe repercussions on metastasis of tumor cells and cancer 
progression. These results are supported by various studies [190, 322]. The 
protein levels of the downstream PPARγ target genes were also validated to be 
decreased upon combination treatment of HDACi and PPARγ ligands. These 
decreases were proven to be receptor-dependent using various approaches. The 
synergistic reduction of these PPARγ target genes support the hypothesis that 
HDAC inhibition indeed amplified the downstream transcriptional activity of 
PPARγ upon its activation by PPARγ agonists.  
 
Other genes reported in previous studies to be synergistically regulated via 
combination therapy of HDACi and PPARγ ligands include MMP2 [336], death 
receptors TNFR1, Fas/CD95, and DR5 [325] and pro-apoptotic genes caspase 3, 
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caspase 8 and PARP [326]. Other genes that are worthy to examine would be 
EMT-related genes such as Vimentin, Snail, Twist and Zeb1/2. HDACi have been 
reported to inhibit EMT and Shan et al. showed that HDAC6 is a key regulator of 
TGFβ-induced EMT in lung adenocarcinoma, suggesting the possibility of using 
HDAC6 inhibitors to inhibit EMT in lung cancer [337]. PPARγ ligands 
rosiglitazone and ciglitazone were demonstrated to inhibit TGFβ-induced 
elevations of N-Cadherin and Collagen 1 alpha 1 [338]. Reka et al. also reported 
that PPARγ activation inhibited mesenchymal markers such as vimentin, N-
Cadherin and fibronectin via antagonization of Smad3 in lung carcinoma [339]. 
Therefore, combination treatment of HDACi and PPARγ ligands in breast cancer 
cell lines would most likely have synergistic effects in downregulating EMT-
related genes.  
 
A more thorough approach would be to use gene expression profiling to identify 
genes that are significantly altered in terms of expression levels upon drug 
treatment. A study with HDACi treated human esophageal cancer cell lines was 
published based on microarray analysis that identified 15 genes that were 
significantly up- or down- regulated upon HDACi treatment. Analysis of these 
genes was postulated to reveal novel information on the anti-tumor mechanism of 
HDACi [340]. Likewise, it would be advantageous to perform a microarray to 
obtain a list of genes that are significantly regulated upon combination treatment 
of HDACi and PPARγ ligands in breast tumor cells. Gene clustering and 
categorization by gene function, which can be carried out with Gene OntologyTM, 
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would then identify signaling pathways or specific groups of genes that are altered 
by combination treatment. This would shed light on critical genes or pathways 
that should be targeted in developing novel breast cancer treatment regimens.  
 
Therefore, the second part of our study is illustrated in a hypothesized model of 
the treatment regimen for HDACi and PPARγ ligands in Figure 81. LBH589 
treatment increases PPARγ acetylation status, activity and expression levels, thus 
causing breast tumor cells to be more susceptible to PPARγ activation. HDACi 
also leads to possible degradation of ERα receptor, removing ERα interference 
from PPARγ-regulated transcription. When PPARγ heterodimerizes with RXR 
and co-localizes into the nucleus, acetylated histones promote an extended 
chromatin structure that facilitates the binding of the PPARγ complex and other 
transcription factors or co-repressors to the PPRE. This promotes PPARγ-induced 
gene regulation, which leads to the deregulation of downstream target genes such 
as MnSOD, VEGFA, CyclinD1, Survivin, PTEN and other genes crucial in 
regulating cell proliferation, apoptosis, angiogenesis and chemo-sensitivity of 
breast tumor cells.  
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Figure 81. Model of combination therapy of HDACi and PPARγ ligands in 
breast carcinoma. Activation of PPARγ signaling pathway leads to downstream 
effects of increasing chemo-sensitivity and apoptosis, decreasing angiogenesis 
and cell proliferation.   
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4.11 MnSOD repression is associated with promotion of MET in breast 
carcinoma 
EMT is an important process driving epithelial cells to undergo alterations to 
achieve a mesenchymal phenotype that is highly migratory, invasive and resistant 
to stresses, ultimately culminating in tumor metastasis and cancer progression. 
Identification of key biomarkers of EMT would shed light on cancer prognosis 
and improvement in treatment strategies. When silencing of MnSOD was carried 
out in aggressive basal-like breast cancer cell lines MDA-MB-231 and BT549, a 
cell scattering assay revealed a marked change from a mesenchymal-like to an 
epithelial-like phenotype. There was an increased tendency to form tightly 
clustered cell colonies compared to highly scattered colonies in control cells, 
reflecting an epithelial-like phenotype. Cell morphologies of the two invasive 
models of breast cancer changed to look more like epithelial-like. These results 
led us to investigate whether MnSOD could be a possible regulator of EMT in the 
last part of our study.  
 
Based on an EMT scoring system developed in a collaborating laboratory that 
estimates the degree of epithelial or mesenchymal phenotypes, a database of 
breast cancer patient samples was scored for degree of EMT. When a correlation 
test was computed for EMT score and MnSOD gene expression, MnSOD was 
shown to be strongly and positively correlated with EMT score (Supp.Fig.7A). 
This is consistent with the analysis of breast cancer subtypes where the basal-like 
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and claudin-low subtypes, which are mesenchymal in nature, express high levels 
of MnSOD. In addition, in a panel of breast cell lines scored for EMT, cell lines 
that are more mesenchymal in nature are also found to have higher levels of 
MnSOD expressions compared to cell lines that are more epithelial-like and have 
lower levels of MnSOD expressions (Supp.Fig.7B). This not only supports the 
correlation between MnSOD and EMT score, but also the categorization of the 
basal-like breast cancer cell lines such as MDA-MB-231 and BT549 to be more 
mesenchymal in nature while the luminal cell lines MCF7 and T47D are more 
epithelial-like, as suggested in previous studies [341].  
 
We set out to validate the role that MnSOD plays in regulating EMT by 
manipulation of MnSOD via siRNA silencing and plasmid overexpression studies. 
When MnSOD was suppressed in mesenchymal cell line MDA-MB-231, RT-PCR 
revealed a downregulation in mRNA levels of mesenchymal markers compared to 
control cells. Transcription factors that mediate the repression of epithelial marker 
E-Cadherin were also significantly downregulated upon silencing of MnSOD. 
Snail has been reported to inhibit E-Cadherin expression through interaction with 
proximal E-boxes on the E-Cadherin promoter [342]. Slug is able to form 
complexes with known co-repressors of transcription NCoR and Ctbp1 (C 
terminal binding protein 1) at the E-Cadherin promoter, thus downregulating its 
expression [343]. Zeb1 was found to recruit histone deacetylases HDAC1 and 
HDAC2 to the E-Cadherin promoter, repressing E-Cadherin levels [344]. Besides 
acting as a transcriptional repressor of E-Cadherin, Zeb2 was reported to activate 
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integrin α5 and vimentin transcription via Sp1 recruitment [345]. Increased levels 
of E-Cadherin mRNA were not detected in MDA-MB-231, possibly due to a key 
inhibitory repressor such as TCF3, TCF4 or FOXC2 that has yet to be removed 
[346]. When western blot analysis and immunofluorescence staining were 
conducted in MDA-MB-231 and BT549, expression levels of EMT-related genes 
corresponded to their changes in mRNA levels. In addition, protein levels of 
active β-catenin, involved in forming adherens junctions between cells and a key 
player in the Wnt signaling pathway to promote EMT, were also lowered. β-
catenin was demonstrated to form a complex with Snail via ERK1/2 signaling 
pathway, to activate Wnt and thus lead to progression of EMT [347].   
 
Corresponding to decreases in mesenchymal gene expressions upon MnSOD 
silencing, functional assays portrayed a reduction in migration and invasion 
abilities in mesechymal cells MDA-MB-231 and BT549. Several studies across 
different cancer types have shown that MnSOD is a regulator of tumor migration 
and invasion. Chen et al. reported the upregulation of FoxM1-MMP2 axis by 
MnSOD, thus promoting lung tumor invasion [92]. Another study showed 
overexpression of MnSOD in glioma cells elevated MMP1 and MMP9 proteins, 
contributing to migration and invasion [348]. Stimulation of MnSOD expression 
via progestin has led to activation of MAPK pathway and increased migration and 
invasion of breast cancer cells [349]. Therefore, these studies provide support for 
our data showing that MnSOD levels could induce changes in the EMT program, 
migration and invasion of tumor cells and possibly affect tumor metastasis. 
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4.12 MnSOD overexpression is associated with promotion of EMT in breast 
carcinoma 
Conversely, we observed that overexpression of MnSOD in MCF7 cells induced 
morphological changes in cells to become more fibroblastic and elongated 
compared to the control epithelial-like MCF7 cells, reflecting an induction of 
mesenchymal phenotype upon MnSOD overexpression. Correspondingly, there 
was downregulation of epithelial marker E-Cadherin, upregulation of 
mesenchymal markers and also increased levels of EMT transcription factors 
Snail, Zeb1 and Zeb2. Immunoflurorescence staining showed reduced levels of E-
Cadherin, increased expressions of mesenchymal genes N-Cadherin and Vimentin, 
and of note, an increased nuclear localization of active β-catenin, a signal of 
activated Wnt signaling and induction of the EMT process [350, 351].  
 
Functional assays showed increased invasion ability upon overexpression of 
MnSOD and formation of scattered colonies in cell scattering assay. This is in line 
with previous studies performed in breast and other tumor cell types that showed 
increased invasion upon MnSOD overexpression [92, 348, 349]. A previous study 
demonstrated that overexpression of MnSOD increased the invasiveness of breast 
cancer cells via upregulation of MMP-2 activity required for cell migration and 
remodeling of extracellular matrix [93]. Interestingly, in MDA-MB-231 cells 
rendered resistant to DOX and have upregulated basal MnSOD levels, 
	   196	  
mesenchymal markers and transcription factors were further enhanced. DOX-R 
cells were also more migratory and invasive than their parental cells.  
 
Taken together, these data provide evidence for the role that MnSOD plays in 
regulating MET and EMT and thus the process of metastasis and tumor 
progression (Fig.82). This is the first time that MnSOD is being implicated in 
EMT regulation in breast cancer, besides a recent publication that demonstrated in 
colorectal cancer that manipulation of miR-212 altered levels of MnSOD and 
hence affected EMT traits [235]. Manipulation of MnSOD levels leading to 
changes in epithelial and mesenchymal phenotypes in breast cancer cell lines also 
signify the interchangeable and dynamic nature of the EMT program. Tumor cells 
can then switch from an epithelial phenotype to a mesenchymal phenotype and 
vice versa, which could facilitate metastasis and tumor formation at secondary 
sites. This places the targeting of MnSOD as a strategy of regulating EMT and 
reducing tumor metastasis in good light.  
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Figure 82. Model of EMT regulation via changes in MnSOD levels in breast 
cancer. Lowering of MnSOD via siMnSOD RNA would drive cells towards MET 
to acquire an epithelial-like phenotype. Epithelial-like cells have lower levels of 
MnSOD that correspond to reduced migration, invasion and scattering properties. 
Increasing levels of MnSOD via overexpression would promote EMT and 
promote acquisition of mesenchymal traits such as cell elongation, increased 
migration, invasion and scattering.  
 
 
4.13 Mechanism of MnSOD-induced regulation of EMT involves ROS 
We next went on to hypothesize on the possible mechanism of MnSOD-induced 
EMT. Previous studies have identified a role of oxidative stress within the tumor 
microenvironment, in the induction of EMT and development of an invasive 
phenotype during metastasis [352, 353]. A direct cross talk between ROS and 
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TGF-β signaling was one of the earliest studies establishing a connection between 
ROS and EMT. Rhyu et al. reported that TGF-β-dependent ROS induction was 
responsible for phosphorylating Smad2, MAPK and ERK, upregulation of 
fibronectin and repression of E-cadherin [217]. H2O2 treatment reproduced the 
same EMT-related molecular effects, supporting the involvement of ROS. ROS-
induced activation of transcription factor NF-kB signals macrophages to secrete 
TNFα, which increases Snail and Vimentin expression and decreases E-cadherin 
levels [354]. In agreement with the previous study, H2O2 treatment was also 
reported to induce Snail-mediated hypermethylation of the E-cadherin promoter 
by recruitment of histone deacetylase 1 and DNA methyltransferase 1 [355]. 
 
The involvement of ROS as key mediators of EMT is further demonstrated by 
induction of MMP3, which is associated with Snail upregulation, E-cadherin 
repression, nuclear translocation of β-catenin and increased motility and invasion. 
These molecular alterations are prevented by antioxidant treatment and are 
conversely reproduced by exposure to H2O2. [356, 357]. In addition, a ROS-
dependent activation of tyrosine kinase c-Src leading to cell-cell disengagement 
through the Rho kinase pathway has been proposed, thus promoting the 
acquisition of a mesenchymal phenotype [239].  
 
The inverse has also been reported, where the activation of SNAIL led to 
induction of oxidative flux that culminated in ERK1/2 activation, thus promoting 
EMT [358]. Therefore, it remains elusive if activation of mesenchymal genes is 
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dependent on oxidative stress or the reverse scenario where the induction of 
mesenchymal genes plays a mandatory role in ROS production holds true, in 
order to activate the EMT program.  
 
Since MnSOD is a key regulator of mitochondrial ROS, there is strong evidence 
to link MnSOD-induced changes in oxidative levels in cells to regulation of the 
EMT process. Suggested mechanisms for MnSOD driving the EMT process could 
involve an increase in H2O2 flux upon MnSOD overexpression. Meng et al. 
reported that high levels of H2O2 activated the hypoxia inducible factor 1α, which 
enhanced the conferment of EMT traits on tumor cells [359]. Elevation of H2O2 
levels via MnSOD overexpression was also demonstrated to activate Akt, ERK 
and JNK kinases, leading to increased migration and invasion of glioma cells 
[348]. Since ERK1/2 has been reported to regulate EMT via the β-catenin/Wnt 
pathway, a link between MnSOD and EMT could thus be established via ERK1/2 
signaling (Fig.83) [347]. An increased level of ROS via MnSOD upregulation 
could also trigger the redox sensor LYN kinase, which has been identified as a 
mediator of EMT [360] and key driver of chemotaxis during wound recruitment 
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Figure 83. Proposed model of MnSOD-induced EMT via H2O2 and ERK1/2 
signaling. Overexpression of MnSOD would increase H2O2 flux which activates 
ERK1/2. ERK1/2 then activates β-catenin/Wnt pathway, increases Snail, 
Vimentin and Fibronectin, and decreases E-Cadherin. Snail acts as a repressor of 
E-Cadherin and also interacts with β-catenin to drive EMT via the Wnt pathway. 
(Adapted from Li et al., 2011 and Zucchini-Pascal et al., 2013 [347, 348]). 
 
 
 At the same time, suppression of MnSOD levels would translate to lower H2O2 
levels and accumulation of O2.-. As mentioned earlier in section 4.6, O2.- can 
combine with NO, which has been reported to be a strong inhibitor of EMT to 
form the RNS peroxynitrite [362].  We hence propose that since we have shown 
that the major species of free radicals generated during MnSOD suppression is 
ONOO-, the key species involved in inhibition of the EMT program would be 
peroxynitrite instead of the formerly reported nitric oxide [363, 364]. Mechanisms 
of NO-mediated inhibition of EMT include inhibition of Snail and induction of 
metastasis-suppressor Raf-1 kinase inhibitor protein (RKIP) [363]. Previous 
studies also demonstrated that NO donors inhibited NF-kB/Snail/Yin Yang 1 
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(YY1) circuitry, thus inhibiting EMT [364, 365]. These studies provide a basis for 
our hypothesis that ONOO- could be the key RNS species that inhibits EMT. 
Conversely, when MnSOD is overexpressed in tumor cells, there would be 
induction in H2O2 levels and a decrease in the production of ONOO-. Together, 
this would drive the EMT program in tumor cells towards acquiring of 
mesenchymal traits (Fig.84). 
 
Figure 84. Model of ROS-mediated regulation of EMT via changes in 
MnSOD levels. Decrease in MnSOD levels would promote accumulation of O2.- 
and thus formation of ONOO-, which promote MET, accompanied by decreased 
mesenchymal markers and increased epithelial markers. Increase in MnSOD 
levels would promote H2O2 formation, which promote EMT, accompanied by 
increased mesenchymal markers and decreased epithelial markers. 
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However, some key experiments are lacking for a full establishment of MnSOD 
as an EMT regulator.  An in vivo xenograft mouse model should be generated 
using stably transfected MnSOD-overexpressing MCF7 cells, where cells are 
injected into the mammary fat pads of mice and monitored for tumor growth, 
metastasis and formation of tumors in secondary organ sites. MCF7 tumor cells 
with ectopic overexpression of MnSOD are hypothesized to be more aggressive in 
engaging in EMT and are thus more likely to form metastatic tumors in the bone, 
lung and liver. This would provide stronger evidence for the positive correlation 
between MnSOD and EMT program. Further experiments have to be conducted to 
establish the involvement of ROS in MnSOD-induced EMT regulation. To 
determine the species of ROS involved in promoting the EMT program upon 
MnSOD overexpression in MCF7 cells or inhibiting EMT upon silencing of 
MnSOD in triple negative breast cancer cells, ROS measurements have to be 
carried out using different scavengers and contributors of ROS. Catalase can be 
used to remove H2O2, Tiron or DPI to scavenge O2.-, L-NMMA to inhibit NO and 
FeTPPS to eliminate ONOO-. DETA NONOate can be used to as a NO donor and 
SIN-1 can be used to drive ONOO- formation. As illustrated in the model (Fig.84), 
scavenging of H2O2 or increasing ONOO- concentrations during MnSOD 
overexpression in MCF7 cells should promote MET and block the EMT program. 
MCF7 cells should remain with an epithelial-like phenotype and not undergo 
changes in migratory and invasive properties. Conversely, scavenging ONOO- 
upon silencing of MnSOD in TNBC cells should promote the EMT program and 
cells would remain with a mesenchymal-like phenotype. These data would 
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confirm the involvement of ROS induced by manipulation of MnSOD levels in 
EMT regulation.  
 
In conclusion, levels of MnSOD indicate the phenotype of tumor cells to be 
epithelial- or mesenchymal- like and could reveal information on the metastatic 
potential of the tumor. As such this ignites the prospect of MnSOD to be a 
prognostic marker for metastasis and a potential target for cancer therapy. 
Therefore, this would propel the search towards more viable modes of targeting 
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CHAPTER 5 CONCLUSIONS  
 
Breast carcinoma is one of the most common malignancies among women 
worldwide as well as in Singapore and it is the highest cause of cancer-related 
deaths among Singaporean women. Among the molecular subtypes of breast 
carcinoma, basal-like and claudin-low subtypes, which are known to be more 
invasive and bear poorer prognosis, express higher levels of manganese 
superoxide dismutase (MnSOD) compared to the other molecular subtypes. In a 
Kaplan Meier analysis, basal-like breast cancer patients with MnSOD-high 
tumors have a lower survival rate compared to MnSOD-low patients, suggesting 
that MnSOD could be a prognostic marker for patient survival. 
 
MnSOD is an antioxidant enzyme that acts as a major regulator of cellular redox 
metabolism.  Whereas earlier reports highlighted a tumor suppressor role for 
MnSOD, recent evidence indicates increased expression in a variety of human 
cancers. To that end, our study highlights the association between increased 
MnSOD expression and an aggressive subtype of breast cancer. Upon suppression 
of MnSOD in triple negative breast cancer cell lines which resemble basal-like 
breast tumors, colony forming ability was significantly hindered and sensitivity to 
ROS-inducing chemotherapeutics was greatly enhanced, showing that targeting 
MnSOD is an effective strategy to improve chemo-sensitivity in TNBC. 
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We next provide evidence for the judicious use of PPARγ agonists as a 
pharmacological tool in TNBC as part of a ROS-mediated strategy that 
specifically downregulates MnSOD. A synthetic PPARγ agonist from the 
thiazolidinediones (TZDs) family, rosiglitazone, was also shown to decrease 
MnSOD expression levels in vivo in tumor tissues among a group of breast cancer 
patients. The use of PPARγ ligands induces intracellular oxidative stress in tumor 
cells, which culminates in an enhanced chemo-sensitivity to ROS-inducing drugs 
such as docetaxel and doxorubicin. This oxidative stress is shown to be a 
combination of superoxide and nitric oxide, which leads to the generation of a 
cytotoxic RNS peroxynitrite. Overexpression of MnSOD is able to attenuate the 
oxidative stress-mediated cell death, showing the importance of MnSOD in the 
chemo-sensitization process. Normal breast epithelial cells are refractory to this 
form of chemo-sensitization treatment, reflecting an antioxidant defense 
mechanism capable of coping with oxidative stress. This “oxidative stress therapy” 
is effective against triple negative breast carcinoma, which has limited treatment 
options and thus warrants serious consideration in the clinical settings.  
 
We went on to investigate the epigenetic regulation of PPARγ that influences its 
activity in breast tumor cells. Using a HDAC inhibitor LBH589, it increased 
PPARγ acetylation status, activity and expression levels in breast cancer cells. 
This prompted the use of HDACi to increase levels of PPARγ in tumor cells that 
express low levels of the receptor and hence enhance sensitivity to PPARγ ligands. 
Indeed, combination treatment of low concentrations of LBH589 and PPARγ 
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agonists in ERα cell lines induced therapeutic effects such as decreasing cell 
proliferation and angiogenesis, and increasing chemo-sensitivity and apoptosis of 
breast cancer cells. In the TNBC cell lines, effects of the PPARγ signaling 
pathway were further potentiated by the use of HDACi. This may prove to be a 
promising treatment strategy for breast cancer, avoiding potential problems such 
as PPARγ ligands being toxic at high concentrations and HDACi being 
ineffective as mono-therapy. Therefore, we conclude that a combination of 
HDACi and PPARγ agonists could be a feasible strategy that targets MnSOD and 
can potentially improve treatment of breast carcinoma.  
 
Lastly, when basal-like breast patient samples were scored for MnSOD 
expressions and EMT, MnSOD was positively correlated to EMT score. This 
trend was observed in a panel of breast carcinoma cell lines as well, where cell 
lines with higher expressions of MnSOD were more mesenchymal-like while cell 
lines with lower expressions of MnSOD were more epithelial-like. Therefore, this 
suggests that MnSOD could be a regulator of EMT and hence tumor metastasis. 
Thus, targeting of MnSOD could be a viable way of inhibiting the EMT program 
and possibly tumor metastasis.  
 
In an attempt to validate the positive correlation of MnSOD and EMT score in 
breast carcinoma cell lines, we manipulated MnSOD levels via silencing and 
overexpression studies. Suppression of MnSOD in mesenchymal-like breast 
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tumor cell lines significantly reduced levels of mesenchymal markers, migratory 
ability, invasiveness and cell scattering properties. Conversely, ectopic 
overexpression of MnSOD in epithelial-like breast tumor cells enhanced levels of 
mesenchymal markers, migration, invasion and cell scattering properties. 
Doxorubicin-resistant cell lines with a higher basal level of MnSOD than its 
parental cells also showed more mesenchymal traits. These data validate the 
association of MnSOD with EMT, with MnSOD possibly playing regulatory roles 
as well. Hence these reveal MnSOD to be a promising target for breast cancer 
therapy and provide basis for our ongoing search for feasible approaches of 
targeting MnSOD in the clinic.  
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APPENDIX 1: Materials and Methods from collaborators 
 
Mouse xenograft model using MDA-MB-231 cells 
All animal procedures and care were approved by the Institutional Animal Care 
and Usage Committee and carried out in Dong-A University. To determine the in 
vivo activity of 15d-PGJ2, viable MDA-MB-231 cells (1×107) resuspended in 100 
µl Matrigel and PBS were injected into the mammary fat pad of 6- week-old 
female Balb/c nude mice (Orient Bio Inc., Korea). When average subcutaneous 
tumor volume reached 50–70 mm3, mice were assigned into two treatment groups: 
(a) control (vehicle only) and (b) 15d-PGJ2 given at a dose of 5 mg/kg via tail 
vein every 3 days. Control groups were treated with vehicle. Tumor size was 
measured daily with a caliper (calculated volume=shortest diameter2 × longest 
diameter/2). Mice were followed for tumor size and body weight and were 
sacrificed on the 18th day. Tumors were resected, weighed, and frozen or fixed in 
formalin and paraffin embedded for immunohistochemical studies. Note that the 
xenograft model data were performed in Korea in Dr Joo In Park’s laboratory. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue block was cut into 5µm section and 
floated onto charged glass slides (Super-Frost Plus, Fisher Scientific, Pittsburgh, 
PA) and dried overnight at 60°C. A hemotoxylin and eosin (H&E) stained section 
was obtained from each tissue block. All sections for immunohistochemistry were 
deparaffinized in xylene and hydrated using graded concentrations of ethanol to 
deionized water. These were then quenched for endogenous peroxidise activity in 
3% (v/v) hydrogen peroxide, and processed for antigen retrieval by heating in 
10mM citrate buffer (pH6) at 90-100°C. Sections were incubated at 4°C overnight 
with MnSOD antibody (Cell Signaling, CA, USA). Immunostaining reactions 
were carried out using the Discovery XT TM automated immunostainer (VMS). 
All the slides were scanned and examined using the Nanozoomer virtual 
microscopy. Immunhistochemistry scoring was performed by measuring two 
parameters; Percentage of immunoreactive cells (0: absence of labelled cells, 1: 1-
10%, 2: 10-50%, 3: 50-70%, 4: 70-100%) and Staining intensity (0: no labelling, 
1: weak, 2: moderate, 3: strong). The final immunohistochemical score (IHS) was 
the product of quantity and staining intensity scores. The score could range from 0 
to 12. An IHS >3 was considered as positive expression. 
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Clinicopathological data  
The study cohort consisted of 98 breast cancer cases (invasive ductal carcinomas 
representing all grades and stages) treated by surgical resection at the National 
University Hospital of Singapore. The median age of patients was 52 years (range 
29–86). The distribution of patients according to the three most common ethnic 
groups in Singapore showed that they were of Chinese (81%), Malay (15%) or 
Indian (4%) descent. Histopathological staging was based on the TNM staging 
system and grading of tumours. This work was approved by the ethics committee 
of the National University of Singapore (DSRB Domain B/09/284). 
 
 
Tissue microarray construction 
Tissue microarray (TMA) blocks containing cores from 98 breast cancer patients 
were constructed as described previously [366, 367].  Briefly, a needle with 0.6 
mm diameter was used to punch a donor core from morphologically 
representative areas of a donor tissue block. The core was subsequently inserted 
into a recipient paraffin block using an ATA-100 tissue arrayer (Chemicon, USA). 
Three cores were taken from the center of tumour tissue and a single core was 
taken from histologically-normal colon epithelium of matched cases. Consecutive 
tissue microarray sections of 4µm thickness were cut and placed on slides for 
immunohistochemical analyses. The expression status of MnSOD is scored by 
immunohistochemistry following standard 4-tiered scoring practice, ranging from 
0 to +3. For statistical analyses, negative (0) and weak expression (+1) were 
grouped together and termed as ‘low expression’ of the proteins. Moderate (+2) 
and strong (+3) expression was termed as ‘high expression’.  Survival duration 
was measured from date of diagnosis till date of cancer-specific death, and 
censored for surviving cases. Survival curves were plotted using the Kaplan-
Meier method and compared using the log-rank test.  
 
 
Data preprocessing of TCGA and Affymetrix breast cancer data 
Invasive ductal breast cancer data was downloaded from The Cancer Genome 
Atlas (TCGA; http://cancergenome.nih.gov/). For this study, we included all 536 
available breast tumor gene expression data at the time that the analysis was 
initiated in October 2011.  The data is on Agilent custom gene expression 
microarray G4502A_07.  The data was imported to Partek ® Genomics Suite 6.6 
where the log ratio of gene expression value was quantile normalized for further 
analysis.   
	   235	  
Breast cancer data on Affymetrix U133A or U133Plus2 platforms were 
downloaded from Array Express and Gene Expression Omnibus (GEO). The 
panel of human breast cancer data utilized for analysis comprises 3,992 tumor 
samples from 26 cohorts [368].  Robust Multichip Average (RMA) normalization 
was performed on each dataset. The normalized data was combined and 
subsequently standardized using ComBat [369] to remove batch effect. 
Microarray gene expression data of breast cancer cell lines were downloaded 
from GSE15026 and E-TABM-157.  The data were first RMA-normalized using 
R® separately for each cohort, then combined and standardized with ComBat 
[369]. Subsequently, the standardized data were subjected to Epithelial-
Mensenchymal Transition (EMT) scoring [370].  
 
Single Sample Gene Set Enrichment Analysis 
Breast cancer subtype signature was obtained from Prat et al., 2010 [21].  
Subsequently, Single sample Gene Set Enrichment Analysis (ssGSEA) [371] was 
computed based on the breast cancer subtype signature for each sample.  Each 
sample was then assigned to be the subtype under which it has the maximum 
ssGSEA score. 
 
Estimation of Epithelial-Mesenchymal Transition (EMT) score 
The EMT scoring method was described in [370]. Briefly, an EMT signature 
comparing profiles of CDH1 with CDH2 expressing cell lines is obtained using 
Binary Regression method [372]. In the second step, the BinReg ovarian cancer 
EMT signature was applied to predict the EMT status of breast cancer cell lines.  
In the third step the top 25% (~20 samples) with the highest probabilities for 
epithelial or mesenchymal phenotype were used to obtain the epithelial or 
mesenchymal specific gene list for the breast cancer cell lines using Significance 
Analysis of Microarray (SAM), q-value =0 and ROC value of 0.85.  In the fourth 
step, Single Sample GSEA (ssGSEA; [373]) was employed to compute the 
enrichment score of a cell line based on the expression of the breast cancer cell 
line-specific epithelial or mesenchymal signature genes.  EMT score is defined as 
the normalized subtraction of the mesenchymal from epithelial enrichment score.  
The EMT score is a precise estimate for a cell line as having an epithelial or 
mesenchymal phenotype.  A higher or lower EMT score indicates that a cell line 
exhibits a more mesenchymal or epithelial phenotype (the detailed method is in 
Tan et al., manuscript under review) 
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Cellworks Tumor Cell Platform 
Predictive analysis was performed using the Virtual Tumor Cell technology 
(Cellworks Group Inc, CA, USA), which has been extensively validated and 
aligned with cancer physiology [374]. The Cellworks platform is implemented 
using a three-layered architecture.  The top layer is a TUI/GUI (Text user 
interface/graphic user interface) driven user interface.  The middle layer is the 
comprehensive representation of signaling and metabolic pathways covering all 
cancer phenotypes.  The bottom layer is a computational backplane that enables 
the system to be dynamic. The virtual Tumor Cell Platform is a dynamic and 
kinetic representation of the signaling pathways underlying tumor physiology at 
the bio-molecular level.  All the key relevant protein players and associated genes 
in tumor related signaling are comprehensively included in the system and their 
relationships quantitatively represented.  Signaling pathways for different cancer 
phenotypes including cross talks are represented, comprising an extensive 
coverage of the kinome, transcriptome and proteome components.  Examples of 
signaling pathways are EGFR, PDGFR, FGFR, c-MET, VEGFR and IGF-1R, cell 
cycle regulators, mTOR signaling, p53 signaling cascade, apoptotic machinery, 
DNA damage repair, cytokine pathways and lipid mediators.  The modeling of the 
time-dependent changes in the fluxes of the constituent pathways has been done 
utilizing modified ordinary differential equations (ODE) and mass action kinetics. 
Knockdowns or over-expressions of molecular genes can be done at the 
expression or activity levels.  When a drug is introduced into the system with a 
specific mechanism of action, the drug concentration in the virtual experiments is 
explicitly assumed to be post-ADME (Absorption, Distribution, Metabolism, 
Excretion).  
 
Predictive Study Experimental Protocol 
The virtual Tumor cell is simulated in the proprietary Cellworks computational 
backplane and initialized to a control state, following which the triggers are 
introduced into the system.  The virtual tumor cell technology allows the end user 
to align the system to a known cancer cell line with perturbations in known 
markers or mutations that can be used for further analysis [375]. In this kinetic 
based virtual tumor cell platform, there is no statistical variation in the outputs. 
The predictions have been validated against a large number of retrospective and 
prospective studies and possess high accuracy. 
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Statistical Analysis 
Statistical analysis was performed using paired Student’s t-test. A p-value of less 
than 0.05 was considered significant. Statistical significance evaluation by Mann-
Whitney test and Spearman correlation test were computed using Matlab®. Dot 
plot and Kaplan-Meier analysis were done using Graphpad Prism. 
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Supplementary Figure 1. MnSOD gene expressions among breast cancer 
patients. (A) MnSOD gene expression among 536 breast cancer patient data from 
The Cancer Genome Atlas (TCGA). Dot plot of MnSOD gene expression value 
(y-axis) for each breast cancer subtype, namely Basal, Claudin-low, Luminal-A, 
Luminal-B, ERBB2 (HER2+), and Normal-like. Maroon color represents basal 
subtype; yellow represents Claudin-low subtype; light blue represents Luminal-A, 
whereas dark blue represents Luminal-B tumors.  ERBB2 and Normal-like tumors 
are represented by orange, and green, respectively. (B) MnSOD gene expression 
among 3992 breast cancer patient data from Affymetrix platform.  Dot plot of 
MnSOD gene expression value (y-axis) for each breast cancer subtype, namely 
Basal, Claudin-low, Luminal-A, Luminal-B, ERBB2 (HER2+), and Normal-like. 
Maroon color represents basal subtype; yellow represents Claudin-low subtype; 
light blue represents Luminal-A, whereas dark blue represents Luminal-B tumors.  
ERBB2 and Normal-like tumors are represented by orange, and green, 
respectively. 
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Supplementary Figure 2. Lower expression of MnSOD correlates to lower 
patient survival. Kaplan-Meier plot of MnSOD-high and -low groups defined by 
median of MnSOD expression in patients within the basal subtype (n=72). Log-
rank test was used to compute the p-value.  Low expression of MnSOD is 
represented by blue color, whereas high expression of MnSOD is represented by 

























Supplementary Figure 3. PPARγ activation downregulates MnSOD 
expression in vivo. MDA-MB231 cells (1x107 cells/100 µl) were inoculated in 
the mammary fat pads of female Balb/c nude mice. Once the tumor volume 
reached 50 to 70 mm3, mice were randomized into 2 groups (n=3), and treatment 
was initiated. Mice were treated with vehicle control and 15d-PGJ2 (5 mg/kg). (A) 
Tumor size was measured daily with a caliper (calculated volume=shortest 
Control 15d-PGJ2 
Weight (g)	  
	   241	  
diameter2 x longest diameter/2). *P<0.05, significantly different from respective 
control. (B) Representative samples of tumors taken from the control group and 
15d-PGJ2group on day 0, day 9 and day 18 of treatment. (C) Tumors from the 
control group and 15d-PGJ2group were dissected on day 0, day 9 and day 18 of 
treatment and weighed. (D) Tumor tissues obtained from above experiment on 
day 18 were subjected to immunohistochemistry using antibodies against MnSOD. 
The sections were lightly counterstained with hematoxylin and photographed with 
a Scan Scope (Aperio Technologies, Inc., USA). 
 
 
Supplementary Figure 4. PPARγ activation via synthetic ligands 
downregulates MnSOD in breast cancer patients. Left panel: 
Immunohistochemical (IHC) MnSOD scoring results for breast cancer tissues and 
matched normal tissues from three different groups of patients: (Group I) diabetic 
breast cancer patients treated with rosiglitazone; (Group II) diabetic breast cancer 
patients treated with other anti-diabetic drugs and; (Group III) non-diabetic breast 
cancer patients. Right panel: IHC localization of MnSOD antigen done on 
formalin-fixed, paraffin-embedded tumor breast tissues. Tissue sections were 
incubated with rabbit monoclonal MnSOD antibody. Positively stained cells were 
evaluated using the following intensity categories: 0 (no staining), 1+ (weak but 
detectable staining), 2+ (moderately intense staining), and 3+ (very intense 
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Supplementary Figure 5. HDAC gene expression in breast cancer subtypes 
and correlation with PPARγ. Gene expressions of (A) HDAC1 (B) HDAC2 (C) 
HDAC3 (D) HDAC6 (E) HDAC8 in breast cancer subtypes. Color code: Basal, 
Maroon; Claudin-low, Yellow; Luminal-A, light blue; Luminal-B, dark blue; 
Normal-like, green. Correlation dot plots of PPARγ and expressions of (F) 
HDAC1 (G) HDAC2 (H) HDAC3 (I) HDAC6 (J) HDAC8. Spearman correlation 
test was performed and the corresponding Rho and p values are shown next to the 
dot plots.  In HDAC1, HDAC2, HDAC3, and HDAC6, n = 3,992, whereas for 
















Supplementary Figure 6. Predictive effects of combination therapy of 
LBH589 and PPARγ ligand. (A) Impact of two drugs Actos (PPARγ ligand) and 
Panobinostat (LBH589) individually and in combination on the tumor phenotypes: 
Tumor Volume, Proliferation, Viability and Angiogenesis. (B) Predictive in silico 
Tumor Cell platform generated results: Reduction in biomarkers-CCND1, ERK, 
STAT3, AKT, BCL2, VEGFA and survivin with Panobinostat and Actos tested 










Supplementary Figure 7.  Correlation of Epithelial-Mesenchymal Transition 
(EMT) status with MnSOD gene expression level in breast cancer cell lines. 
(A) MnSOD correlates with mesenchymal phenotype in breast cancer.  MnSOD 
gene expression value is positively correlated with breast cancer Epithelial-
Mesenchymal Transition (EMT) score (Spearman Rho = 0.6014, p-value < 1e-
128).  The red dotted line is linear regression curve.  MnSOD gene expression 
value is plotted on y-axis whereas EMT score is plotted on x-axis. (B) Breast 
cancer cell lines downloaded from GSE15026 and E-TABM-157 were aligned 
from the most epithelial to the most mesenchymal (upper panel), and the 
corresponding MnSOD gene expression level were shown in the lower panel. x-
axis = breast cancer cell lines; y-axis = EMT score. 
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